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RESUMO 
O crescente interesse por alimentos com propriedades nutracêuticas têm colocado a soja em 
posição de destaque na prevenção e tratamento dos sintomas menopausais. Esta ação é 
principalmente atribuída as isoflavonas da soja que possuem efeitos favoráveis sobre os 
sintomas vasomotores e urogenitais, atuando como possível alternativa à terapia hormonal 
(TH). O objetivo geral deste trabalho foi avaliar a ação de uma mistura comercial de isoflavonas 
de soja, na presença e ausência de probióticos, em parâmetros clínicos de mulheres 
menopausadas, buscando evidenciar possíveis alterações na produção de metabólitos das 
isoflavonas e na microbiota intestinal. Para tanto, foi conduzido um estudo prospectivo com 60 
mulheres, agrupadas de forma aleatória em três grupos, de acordo com as medicações via oral: 
Grupo A (isoflavonas), que utilizou cápsulas de isoflavonas (150 mg/dia); Grupo B 
(Isoflavonas+Probióticos), que utilizou cápsulas de isoflavonas (150 mg/dia), associadas a um 
produto probiótico (2 g/dia), e Grupo C (Terapia Hormonal), que utilizou estradiol (1 mg/dia) 
associado ao acetato de noretisterona (0,5 mg/dia), sendo estabelecidos como critérios de 
inclusão para o estudo mulheres de 40 a 60 anos de idade, com data da última menstruação 
espontânea há pelo menos 12 meses, valores de hormônio folículo estimulante (FSH) superior 
a 40 mUI/mL e presença atual de sintomas de privação estrogênica. No período de 4 meses 
foram avaliados a intensidade dos sintomas do climatério por meio do questionário MRS 
(Menopause Rating Scale), acompanhamento das alterações ginecológicas (espessura 
endometrial), além de parâmetros clínicos, nutricionais e antropométricos, com coleta de 
sangue para as análises bioquímicas, urina para pesquisa dos metabólitos equol e O-DMA, e 
fezes para análise da microbiota intestinal, com intuito de se identificar os filos predominantes 
existentes na microbiota dos produtores de equol. No estudo prospectivo de 16 semanas, 
isoflavonas e isoflavonas acrescidas de probióticos mostraram-se efetivos para serem usados 
no alívio de sintomas da menopausa e possíveis contribuidores na modulação da microbiota 
intestinal, ao promoverem crescimento de microrganismos associados ao metabolismo de 
isoflavonas e produtores de equol, podendo ser uma indicação de tratamento para pessoas que 
não poderiam beneficiar-se naturalmente das isoflavonas (não produtores de equol). 
Isoflavonas, associadas ou não a probióticos, podem auxiliar no alívio da sintomatologia 
climatérica, um dos fatores associados é a produção de metabólitos mais bioativos, como o 
equol, cuja produção é dependente de uma complexa relação bidirecional entre isoflavonas e as 
bactérias colonizadoras do trato gastrointestinal do indivíduo. A terapia hormonal também se 
mostrou capaz de modificar a microbiota intestinal, sugerindo uma importante relação entre 
estrógenos e microbiota intestinal. 
 
 
Palavras chave: menopausa, terapia hormonal, isoflavonas, probióticos, microbiota intestinal, 
sintomas vasomotores. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
The growing interest in foods with nutraceutical properties has placed soybeans in the 
prevention and treatment of menopausal symptoms, mainly due to the ability of their 
isoflavones to induce favorable effects on vasomotor and urogenital symptoms, acting as a 
possible alternative to hormonal therapy. The general objective of this study was to evaluate the 
action of a commercial mixture of soy isoflavones, in the presence and absence of probiotics, 
in clinical parameters of menopausal women, aiming at evidencing possible changes in the 
production of isoflavones metabolites and intestinal microbiota. A prospective study was 
conducted with 60 women, randomly grouped into three groups according to oral medications: 
Group A (isoflavones), which used isoflavone capsules (150 mg/day); Group B 
(Isoflavones+Probiotics), which used isoflavone capsules (150 mg/day), associated with a 
probiotic product (2 mg/day), and Group C (Hormonal Therapy), which used estradiol (1 
mg/day) to norethisterone acetate (0.5 mg/day), being established as inclusion criteria for the 
study women 40 to 60 years of age, with date of the last spontaneous menstruation for at least 
12 months, values of follicle stimulating hormone (FSH) greater than 40 mIU/mL and the 
presence of symptoms of estrogen deprivation. In the 4-month period, the intensity of 
climacteric symptoms was evaluated through the MRS (Menopause Rating Scale), 
gynecological changes (endometrial thickness), and clinical, nutritional and anthropometric 
parameters, with blood collection for biochemical analysis, urine for equol and O-DMA 
metabolites, and feces for analysis of the intestinal microbiota, in order to identify the prevailing 
phyla in the microbiota of equol producers. In the prospective study of 16-week, isoflavones 
and isoflavones plus probiotics have been shown to be effective in the relief of menopausal 
symptoms and possible contributors in modulating the intestinal microbiota by promoting 
growth of microorganisms associated with metabolism of isoflavones and equol producers, may 
be an indication of treatment for people who could not naturally benefit from isoflavones (equol 
non-producers). Isoflavones, associated or not with probiotics, may help relieve climacteric 
symptoms. One of the factors associated is the production of more bioactive metabolites, such 
as equol, whose production is dependent on a complex bidirectional relationship between 
isoflavones and the gut bacterial communities. Hormone therapy was also able to modify the 
intestinal microbiota, suggesting an important relationship between estrogens and gut 
microbiota. 
Keywords: menopause, hormone therapy, isoflavones, probiotics, gut microbiota, vasomotor 
symptoms. 
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1. INTRODUÇÃO GERAL 
O climatério é um período de transição natural, não patogênico, próprio do ciclo de 
vida feminino (1). Segundo o estudo STRAW (Stages  of  Reproductive  Aging  Workshop) (2) 
a transição do período reprodutivo para a permanente cessação menstrual, resultante da perda 
da atividade folicular ovariana, e denominada de menopausa, pode durar vários anos, passando 
pelos estágios de peri e pós-menopausa. O primeiro se subdivide em perimenopausa precoce, 
caracterizada por irregularidade no ciclo menstrual, e perimenopausa tardia, caracterizada por 
intervalos de amenorréia de ≥60 dias associado a algum fluxo menstrual, o qual evolui para a 
pós-menopausa inicial, caracterizada por 12 meses consecutivos de amenorreia (3). 
Sintomas climatéricos, como ansiedade, enxaqueca e insônia, podem estar 
presentes em mulheres transacionando pelo período da pré-menopausa, e se intensificarem na 
pós-menopausa, somando-se também aos sintomas físicos, como fogachos, atrofia urogenital, 
perda da elasticidade da pele e maior chance de fraturas osteoporóticas, devido à queda dos 
níveis de estradiol (4). A menopausa tem grande impacto na vida da mulher, uma vez que a 
interrupção da menstruação associada aos sintomas da privação estrogênica, além de trazerem 
a perda da capacidade fértil, afloram sentimentos de perda da feminilidade e sensação de 
senectude. Estas  alterações influenciam diretamente a libido e a sexualidade feminina, com 10 
a 40% das mulheres menopausadas apresentando dispareunia e ressecamento vaginal, além dos 
fogachos, sintoma mais representativo da síndrome, que são ondas de calores súbitas que 
atingem face e colo, e são geralmente acompanhadas de rubor, cefaléia e palpitações, sendo 
experimentadas por 60 a 80% das mulheres em algum ponto da transição, em variados graus de 
severidade (5–7). 
A expectativa de vida tem aumentado mundialmente de forma significativa. Dados 
da Organização Mundial de Saúde (OMS) indicam que em 2025 a expectativa de vida será de 
81 anos nos países desenvolvidos e de 78 nos países em desenvolvimento (8). Para a realidade 
brasileira, estima-se para as próximas décadas que mulheres poderão viver em média 80 anos 
(9), enquanto tendem a alcançar 85 anos em 2030 em países desenvolvidos, como Coréia do 
Sul, Austrália e Suécia (10), onde um terço dessa vida será vivenciada dentro do contexto da 
pós-menopausa, considerando-se 50 anos como idade média de entrada na menopausa. Este 
período de transição biológica coincide com o momento em que a mulher geralmente está em 
seu momento pessoal e profissional mais ativo. Assim, mudanças notáveis de humor, alterações 
no padrão de sono e na memória, bem como o início de sintomas urogenitais e vasomotores 
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podem afetar a qualidade de vida, na medida que diminuem o desempenho físico e psicológico 
(4). 
Embora as indesejáveis manifestações clínicas do hipoestrogenismo possam ser 
atenuadas ou revertidas pela terapia de reposição hormonal, muitas mulheres apresentam-se 
relutantes em seu uso. O estudo Women’s Health Initiative (WHI) intensificou a controvérsia 
sobre risco/benefício desse tipo de tratamento ao divulgar em um dos braços do ensaio clínico 
que o uso associado de estrogênio e progestagênio traria maior probabilidade no 
desenvolvimento de câncer de mama (RR 1.26; IC95%, 1.00-1.59) e doenças cardiovasculares 
(RR 1.29; CI95%, 1.02-1.63), o que levou a interrupção desse braço do estudo antes do previsto 
(5,2 anos de seguimento, ao invés de 8,5 anos) (11). O braço adicional do estudo que avaliou 
estrógeno isolado em mulheres histerectomizadas não observou aumento da incidência de 
câncer de mama durante os 7 anos de seguimento, embora corroborando o braço estrógeno + 
progestagêneo, tenha encontrado discreto aumento na incidência de derrame (8:10.000) (12).  
Dentre as principais críticas para os resultados do estudo WHI está a seleção da 
população estudada, composta por mulheres com idade média de 63,2 anos, com mais de 10 
anos de menopausa, sobrepeso indicado pelo índice de massa corpórea (IMC) médio de 28,5 
kg/m2, com uso prévio de hormônio em 26% da amostra, tabagismo atual ou pregresso em 50% 
dos casos avaliados, além de 35,7% serem portadoras de hipertensão arterial sistêmica (13). 
Tais fatores associados podem ter enviesado os resultados, e a falta de criticidade na 
interpretação dos dados fez com que o estudo, ao ganhar espaço na mídia leiga e na própria 
literatura científica, abrisse espaço para questionamentos e dúvidas entre pacientes e 
profissionais, o que resultou em expressiva queda das prescrições hormonais e aumento nas 
taxas de descontinuidade dos tratamentos, essas recomendações se deram inclusive com o aval 
de sociedades médicas da área que se pautaram nas primeiras comunicações de resultados 
prévios do WHI, que ainda estava em andamento no ano de 2001, impactando inclusive na 
continuidade de um estudo Europeu semelhante (Women’s International Study of long Duration 
Oestrogen after Menopause - WISDOM), que também esteve em andamento nesse período (14). 
A polêmica intensificou-se ainda mais com a relação estabelecida pelo estudo 
“Million women study”, coorte que avaliou 1.084.110 milhão de mulheres britânicas, na faixa 
etária de 50 a 64 anos, entre os anos de 1996 a 2001. Este estudo demonstrou que terapia  de  
reposição  hormonal  esteve  associada  ao aumento  do  risco  de  incidência  de  câncer de 
mama com  prognóstico  ruim,  sendo  o desfecho  de  morte  fortemente  associado  a  terapias  
que  combinavam  estrogênio e progesterona (2·00 [1·88–2·12], p<0.0001), enquanto usuárias 
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de estrogênio isolado (1·30 [1·21–1·40], p<0.0001) ou tibolona (1·45 [1·25–1·68], p<0.0001), 
em uso oral, transdérmico ou formulações implantadas, também apresentaram incidência 
significativamente aumentada da doença. O risco de câncer de mama aumentou 
proporcionalmente ao tempo total de uso da terapia hormonal (15). 
Em defesa da terapia hormonal, Pickar et al (16) destacaram que a implementação 
da terapia hormonal antes dos 60 anos e preferencialmente nos primeiros 10 anos de menopausa 
(janela de oportunidade) reduz riscos de mortalidade para doenças coronarianas e para todas as 
demais causas de mortalidade geralmente associadas a este tratamento. Entretanto, o início da 
terapia hormonal fora da janela de oportunidade pode trazer efeitos nulos ou adversos, 
ressaltando-se a importância de observar-se características da mulher a quem se prescreve a 
terapia hormonal, como idade, tempo de menopausa, sintomas climatéricos mais importantes, 
escolha da terapia adequada (estrógenos isolados ou associados a progesterona), além da dose 
e rota de administração mais eficiente para o alcance de benefícios a curto prazo (melhora 
vasomotora e dispareunia) e a longo prazo (manutenção da massa óssea, redução de risco 
cardiovascular) (17). 
Presença de útero, câncer de mama ativo ou histórico pessoal de câncer hormônio 
dependente são fatores determinantes na escolha e adequação do método para o alívio da 
sintomatologia climatérica (18). Atualmente o uso de terapia hormonal é contraindicado apenas 
em mulheres com câncer de mama ativo ou histórico pessoal de câncer hormônio dependente, 
sendo o histórico familiar importante para prevenção, mas não uma limitação ao uso de terapia 
hormonal, uma vez que a terapia hormonal estimula o desenvolvimento de lesões cancerígenas 
ocultas pré-existentes, não alterando a história natural da doença (18, 19). Demais situações, 
como tromboembolismo venoso, câncer endometrial e doenças cardiovasculares, não são 
contraindicações podendo-se utilizar formulações específicas, tais como progestagênio isolado 
(tibolona) ou estrogênio associado a progestagênio para mulheres com útero ou estrogênio 
isolado para histerectomizadas,  e vias de administração alternativas (vaginal, nasal, subdérmica 
ou transdérmica, utilizadas de forma cíclica ou continua), a fim de minimizar possíveis riscos, 
enquanto se promove alívio da sintomatologia climatérica e proteção da massa óssea (20,21). 
Embora a reposição hormonal seja a alternativa de primeira escolha, os 
fitoestrógenos passaram a ocupar um importante espaço terapêutico entre mulheres pós-
menopausadas com sintomatologia hipoestrogênica que não possuem indicação de reposição 
hormonal. Além disso, tem ganhado espaço ainda maior entre mulheres saudáveis, com 
indicação para uso de terapia hormonal, que ainda por receio das informações erroneamente 
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propagadas sobre o estudo WHI no início dos anos 2000, desejam realizar tratamentos naturais 
(18,22–24). 
Fitoestrógenos são compostos fenólicos, não esteroidais, com capacidade 
estrogênica, provenientes do metabolismo secundário de plantas, encontrados em ampla 
variedade de alimentos vegetais, como frutas, legumes e grãos integrais (25). Pertencentes a 
classe dos fitoestrógenos, as isoflavonas são encontradas em grande quantidade em vegetais 
como trevo vermelho (Trifolium pratense), kudzu (Pueraria lobata), cimicífuga (Cimicifuga 
racemosa), com destaque para a soja (Glycine max). As isoflavonas são compostos funcionais 
estruturalmente similares ao estrogênio de mamíferos, o 17β-estradiol (E2) e seus metabólitos 
ativos (Figura 1) (26,27).  
O 17β-estradiol (E2) é um hormônio esteróide derivado do metabolismo do 
colesterol que possui várias funções. Dentre as mais importantes estão a regulação dos órgãos 
reprodutivos feminino e masculino, além de atuar em tecidos não reprodutivos, tais como 
crescimento e remodelação óssea, diferenciação do sistema nervoso central, controle do 
mecanismo de vasodilatação e participação do metabolismo lipídico que ocorre no fígado (28). 
A similaridade química das isoflavonas com o E2 e seus metabólitos (Figura 1) permite a 
interação das isoflavonas com os receptores estrogênicos (ERα e ERβ), que possuem diferentes 
distribuições teciduais, mimetizando a estrutura conformacional do estradiol e promovendo 
funções agonistas e antagonistas sobre os mesmos, de forma alvo tecido específica (29,30). 
 
Figura 1. Estrutura química de 17β-estradiol e isoflavona (adaptado de Barnes et al) (31). 
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A nível celular, o estradiol liga-se aos receptores de estrógeno dos subtipos ERα e 
ERβ com afinidade equivalente. Por sua vez, as isoflavonas agliconas ativam preferencialmente 
o receptor β, enquanto equol, metabólito da daidzeína, é capaz de ativar ambos os receptores 
(32). Embora menos potente que o 17β-estradiol, em altas concentrações, as isoflavonas 
competem pelos receptores ER, bloqueando a ligação do estradiol ao receptor e 
consequentemente atuando como antiestrogênios em mulheres com níveis hormonais altos, ou 
como moduladores específicos dos receptores hormonais (SERMs) em casos de 
hipoestrogenismo (25,33). 
Estudos de padrões de expressão desses receptores de estrógeno (ERs) indicam que 
ERα apresenta ampla expressão tecidual existindo em tecidos como glândula mamária, útero, 
ovário (células tecais), osso, órgãos reprodutores masculinos (testículos e epidídimo), próstata 
(estroma), fígado e tecido adiposo. Já ERβ possui expressão focada, geralmente mais 
encontrado em próstata (epitélio), bexiga, ovário (células da granulosa), cólon, tecido adiposo 
e sistema imunológico. Ambos são marcadamente expressos no sistema cardiovascular e 
sistema nervoso central (28,34). 
O consumo de isoflavonas pode trazer diversos efeitos benéficos para a saúde da 
mulher no climatério (45), promovendo redução de 30% no risco de desenvolvimento de câncer 
de mama (46,47), não colaborando para hiperplasia uterina (48), possível prevenção da 
osteoporose, pois embora não possuam a potência da terapia hormonal, podem apresentar 
capacidade de preservação da densidade mineral óssea em mulheres pós-menopausadas (49–
51). Entretanto, apesar dos inúmeros estudos associando fitoestrógenos a saúde óssea, o 
tratamento da osteoporose por meio do uso de isoflavonas permanece controverso (52,53), 
provavelmente devido à variabilidade de doses, tempo de tratamento utilizados nos diferentes 
ensaios, além das diferenças individuais no metabolismo de isoflavonas, principalmente ligadas 
à capacidade de produção de equol, metabólito da daidzeína, capaz de ligar-se aos receptores 
estrogênicos mimetizando a ação do hormônio estrógeno (54–56). 
Menor incidência de doenças cardiovasculares também tem sido atribuída as 
isoflavonas e ao metabólito equol (57), com ação hipolipemiante controversa, onde alguns 
trabalhos demonstram redução do colesterol total e LDL-c, com aumento do HDL-c em 
contraposição a trabalhos que trazem reduções não significantes nas lipoproteínas plasmáticas 
(58,59) e diminuição de sintomas climatéricos, com especial redução de sintomas vasomotores, 
sugerindo uma relação direta entre capacidade de produção de equol e melhora da qualidade de 
vida durante a menopausa (60). 
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Após ingestão, as isoflavonas não estão biodisponíveis para absorção direta através 
dos enterócitos, pois são encontradas naturalmente nas formas de glucuronídeos conjugados à 
glicose por uma ligação β-glicosídica (Figura 2), realizada preferencialmente com o grupo 
hidroxila na posição C7 (7-O-glicosideos) (35). As formas das isoflavonas mais biodisponíveis 
para serem absorvidas e com maior afinidade pelos receptores de estrogênio são as agliconas 
(por ex.: genisteína, daidzeína e gliciteína, no caso da soja). Essas agliconas são liberadas de 
suas formas conjugadas através de hidrólise enzimática pela ação de glicosil hidrolases (da 
família das β-glicosidases) presentes na mucosa do intestino delgado e/ou na parede celular de 
bactérias da microbiota intestinal (36–38). 
 
 
 
Figura 2. Estrutura química das principais isoflavonas da soja, nas formas malonil-glicosídeo, 
acetil-glicosídeo, β glicosídicas e agliconas (adaptado de Popa and Rusu) (38). 
Após a metabolização inicial no intestino delgado, 1/3 das isoflavonas agliconas 
são diretamente absorvidas através do epitélio intestinal. O restante é submetido à nova 
metabolização pela ação de bactérias presentes no cólon (39). A porção não absorvida da 
daidzeína (t meia vida 21,1±4,8 horas) é hidrogenada e convertida à diidro daidzeína (DHD) (t 
meia vida 16,7±3,8 horas). A DHD pode então ser transformada em Ο-desmetilangolensina (Ο-
DMA), composto considerado inativo, ou em equol (t meia vida 8,8h). Por sua vez, a genisteína 
é convertida a -etilfenol e 5’-hidrox-equol (Figura 3), enquanto a gliciteína por ser uma 
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isoflavona metilada resulta em metabólitos com baixa bioacessibilidade (<10%), o que limita 
sua atividade estrogênica. Para que todas essas reações ocorram, a participação da microbiota 
intestinal se faz essencial (38,40,41). 
 
Figura 3. Metabolismo das principais agliconas: daidzeína (a) e genisteína (b) (Adaptado de 
Popa and Rusu) (38). 
A capacidade de biotransformação da daidzeína em metabólitos levou a proposição 
dos termos “equol producer” and “ODMA producer”, definidos como indivíduos que produzem 
equol e/ou ODMA em resposta ao consumo de isoflavonas, que embora derivados da mesma 
aglicona são fenótipos independentes, distribuído em 25-30% na população ocidental e entre 
50-60% entre a população oriental (japoneses, chineses e coreanos) e vegetariana (38,42). O 
metabólito Ο-desmetilangolensina possui tempo de meia-vida de 14,5±5,7 horas (43), e é 
estruturalmente diferente de seu precursor daidzeína e seu co-derivado equol, uma vez que estes 
são compostos difenólicos similares ao 17β-estradiol, o O-DMA se assemelha quimicamente a 
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um polifenol, possuindo um de seus anéis fenólicos clivados, o que pode justificar sua 
inatividade estrogênica, devido a ligação aos receptores ERα e ERβ prejudicada (44). 
O equol é um composto quiral apresentado nas formas -R e -S (Figura 4), sendo que 
apenas o enantiômero (-S) é sintetizado pela microbiota intestinal humana. Este composto 
possui atividade biológica em mamíferos, com potente afinidade pelos receptores ERβ, 
predominantemente encontrados em mama e útero. A principal limitação dos estudos com equol 
em humanos ou animais, é o uso de misturas racêmicas, que contém 50% de R-equol e 50% de 
S-equol, e que não possuem a mesma atividade biológica do S-equol isolado. Desta forma, os 
efeitos do metabólito in vivo podem ser sub ou superestimados, o que encoraja sobre o estimulo 
da produção natural de equol tendo em vista dificuldades sintéticas para obtenção do isômero 
S-equol puro (61). 
Estudos demonstram que valores plasmáticos de S-equol acima de 5 ng/mL podem 
trazer diminuição dos sintomas menopausais, ganho de densidade mineral óssea e melhora nos 
fatores de risco cardiovasculares (62–64).   
 
 
Figura 4. Estrutura das formas enantioméricas (R e S) do equol (Retirado de Richardson and 
Simpkins, 2012). 
A possibilidade de conversão de indivíduos não produtores em “equol producers” 
através da modulação da microbiota intestinal, por meio de bactérias ácido lácticas específicas, 
pode ser uma opção para populações não produtoras dessa substância alcançarem seus 
benefícios (65). 
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Os estudos que avaliam a eficácia da isoflavona no tratamento dos sintomas do 
climatério ainda apresentam grande diversidade nos resultados, porque a imensa maioria não 
avaliou a produção do metabólito ativo, S-equol, e nem mesmo considerou a interação da 
microbiota intestinal na capacidade de produção deste metabólito, sendo Ishiwata et al. (66) o 
primeiro ensaio clínico a avaliar os efeitos do S-equol na sintomatologia vasomotora em um 
estudo piloto de 12 semanas controlado com placebo, envolvendo 134 mulheres japonesas pós-
menopausadas, divididas em produtores de equol e não produtores. Salienta-se também que não 
há estudos em população latino-americana quanto a produção de equol em usuárias de 
isoflavonas. Diante destes fatos, realizou-se este estudo com critérios uniformes para avaliar os 
efeitos do uso da isoflavona associada ou não a probióticos, e a produção de S-equol em 
mulheres climatéricas sintomáticas, com o objetivo de implementar fitoestrógenos como uma 
possibilidade de uso em mulheres que apresentam contraindicação à terapia hormonal (padrão 
ouro) ou não desejam utilizá-la, melhorando a qualidade de vida destas. 
A presente tese foi elaborada na forma de artigos científicos, sendo dividida em 
quatro capítulos. O primeiro capítulo consiste de uma revisão bibliográfica que aborda aspectos 
relacionados ao metabolismo de isoflavonas, importância da microbiota intestinal, impacto do 
uso das isoflavonas e suas implicações clínicas. O segundo capítulo trata da associação de 
probióticos a isoflavonas como alternativa a terapia hormonal no alívio de sintomas 
climatéricos na mulher pós-menopausada. O terceiro capítulo analisa o perfil metabólico da 
mulher após a menopausa, e para finalização da tese o quarto capítulo estuda a produção de 
equol relacionada a microbiota intestinal entre mulheres menopausadas recebendo isoflavonas 
ou isoflavonas associadas à probióticos. 
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2. OBJETIVOS 
 
 
2.1 Objetivo geral 
Avaliar a influência da associação de probióticos a isoflavonas no tratamento de 
mulheres sintomáticas na pós-menopausa em relação a absorção e produção dos metabólitos de 
isoflavonas, sobre parâmetros clínicos e laboratoriais em comparação com a terapia hormonal. 
 
2.2 Objetivo específico 
Descrever a prevalência de mulheres produtoras de equol e O-DMA na população estudada; 
Avaliar a associação da produção de equol às alterações de parâmetros clínicos e melhora da 
sintomatologia do climatério; 
Avaliar a capacidade de produção de equol no perfil metabólico das mulheres em uso de 
isoflavonas em comparação a mulheres em uso de TH; 
Avaliar as mudanças da microbiota de mulheres produtoras e não produtoras de equol em 
função da sintomatologia climatérica 
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Abstract 
Menopause is a natural event that occurs in women around the age of 50 years, causing 
irregularities in the menstrual cycle until its complete end, due to the hormonal deficit, 
especially estrogen, that causes several unpleasant urogenital and vasomotor symptoms. 
Hormone replacement therapy has many benefits but should be prescribed with caution in 
women with a history of stroke, thromboembolic events, certain types of cancer, or increased 
risk (genetic predisposition) for these events, so many women seek alternatives to hormonal 
therapy. Phytoestrogens, especially isoflavones, have many benefits in the climacteric phase, 
due to the similarity of their chemical structure with the hormone estradiol (E2), reducing the 
rate of menopause side effects and resulting in symptom relief. Furthermore, the isoflavones 
may still have their effects potentiated by an intestinal microbiota modulated with probiotic 
strains, which act on metabolism and increase the bioavailability of these phytoestrogens, and 
can benefit menopausal women’s health. 
Key words: Menopause, Isoflavones, Gut microbiota, Probiotics, Equol 
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1. Introduction 
Menopause, a spontaneous physiological transition event, is characterized by 
permanent cessation of menstrual cycles and loss of ovarian function; it may be natural or 
iatrogenic (secondary menopause), which can be the result of surgery, illness, or use of 
medications. Characterized by progressive hypoestrogenism and clinically confirmed after 12 
full months of amenorrhea, menopause can begin between 35 and 40 years and extend until 
around the age of 65 years. This event brings a reduced production of estradiol, the more active 
form of estrogen, as well as increased levels of follicle stimulating hormone (FSH) and 
decreased levels of inhibin, a hormone that inhibits the release of FSH, and progesterone (Davis, 
2015; Sapre & Thakur, 2014; WHO, 1996). 
Considered a marker of biological aging, the worldwide median age of input at 
natural menopause (approximately 46 to 52 years) may be variable according to socioeconomic 
position and lifestyle factors, with an important association between a lower socioeconomic 
position (education and income) and later menopause, as well as smoking with earlier 
menopause. In general, women from developed countries enter menopause later in life than 
those living in developing countries (Schoenaker, Jackson, Rowlands, & Mishra, 2014). This 
later age in natural menopause has been associated with reduced risk of cardiovascular disease 
(CVD) and CVD death, maintenance of bone density with reduced risk of osteoporosis and 
fracture, increase in life expectancy, and improvement in overall survival. On the other hand, 
later menopause is associated with increased risk of cancer, mainly breast, endometrial, and 
ovarian (Gold, 2011). 
The decline in the secretion of sex hormones leads to the onset of menopause 
symptoms, being the vasomotor symptoms most commonly reported, followed by urogenital 
complaints. Hot flushes are the most common menopausal symptom, being reported by up to 
85% of women. According to the Melbourne Women’s Health Project, the most intense and 
31 
 
important vasomotor symptom, hot flushes, can last for an average duration of 5.2 years, 
beginning about 1 year before the final menstrual period (Santoro, Epperson, & Mathews, 
2015). 
The decline in the secretion of sex hormones converges with the appearance of 
vasomotor symptoms, including hot flushes and nocturnal sweating, in addition to other signs 
like insomnia, vaginal dryness, irregular menstrual bleeding, depressed mood, irritability, 
headache, forgetfulness, dizziness, irregular heartbeat, difficulty concentrating, memory loss, 
deterioration in postural balance, dry eyes, dry mouth, reduced skin elasticity, restless legs, 
muscle, joint pain, and general malaise (Davis, 2015; Moilanen et al., 2010; Santoro et al., 2015; 
Trimarco et al., 2016). 
These symptoms occur in 3 out of 4 menopausal women, which corresponds to 
approximately 72 million women in the world, with 2 million among the Brazilian population. 
The duration and severity are not uniform, as it may develop in the final menstrual period and 
persist for a few to many postmenopausal years (Kim, Kang, Chung, Kim, & Kim, 2015; 
Rapkin, 2007; Rozenfeld, 2007; Sarri, Pedder, Dias, Guo, & Lumsden, 2017). 
Besides the climacteric symptomatology, the hormonal fall predisposes women to 
accelerated bone loss, accumulation of central abdominal fat, and metabolic changes, such as 
increased blood pressure, which can cause cardiovascular disease and type 2 diabetes mellitus 
(Davis, 2015). 
Hormone replacement therapy is the first-line therapy for symptom relief and 
prevention of comorbidities, such as osteoporosis and coronary heart disease (NAMS, 2017). It 
is important to evaluate the route of administration of estrogen, the dosage, and type of 
progestin associated with estrogen to increase effectiveness of the therapy, and reduce adverse 
effects. Although the contraindications of hormonal therapy are few, oral estrogen therapy may 
not benefit women with a genetic predisposition to increased thromboembolic events; 
transdermal estrogen therapy in standard doses is better indicated for these postmenopausal 
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women (Level of evidence: 1A) (Mohammed et al., 2017). Moreover, women with no 
indication of hormone therapy may seek alternative therapies when there are potential health 
risks and uncertainty about the actual benefits they can provide (NAMS, 2012; Roussouw, 
2002; Taylor, 2015; Utian, Jones, & Setchell, 2015). 
Menopausal hormone replacement therapy was the mainstay of treatment for 
postmenopausal women until the publication of the Women’s Health Initiative (WHI) in 2002. 
This publication rekindled the discussion on the safety of menopausal hormone replacement 
due to a randomized clinical trial where researchers found more risks associated with continued 
administration of estrogen, and progesterone outweighed the benefits, leading to increased risk 
of breast cancer and cardiovascular events (Roussouw, 2002). 
Fifteen years later, the confusion prevails, with studies that support and others that 
refute the relationship of hormone replacement use with increased incidence of cancer (Beral, 
2003; Rozenberg, Vandromme, & Antoine, 2013). According to the (National Collaborating 
Centre for Women’s and Children’s Health, 2015) (Level of evidence: 1A), very few conditions 
are now considered as absolute contraindications: women with breast cancer or history of breast 
cancer should not make use of hormone replacement therapy (HRT), including tibolone and 
progestogens, which are being indicated as treatment options, as well as antidepressants or 
complementary therapies, such as isoflavones, which should be evaluated for drug interaction 
and safety. Evidence from this study shows that oral HRT increases the risk of venous 
thromboembolism, but transdermal HRT does not, where the therapy should be individualized 
based on clinical factors, patient preference, mode of delivery of estrogen, with the safety of 
hormone therapy depending on age and time since menopause (Baber, Panay, & Fenton, 2016; 
Marko & Simon, 2017; Sood, Faubion, Kuhle, Thielen, & Shuster, 2014; Stuenkel et al., 2015). 
Corroborating these findings, an observational follow-up of 27347 postmenopausal women, 
conducted by (Manson et al., 2017) (Level of evidence: 2C), with conjugated equine estrogens 
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(CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo 
(n = 8102) for 5.6 years (median) or CEE alone (n = 5310) vs placebo (n = 5429) for 7.2 years 
(median) noted that long-term hormone replacement therapy was not associated with a risk of 
all-cause (27.1% in the hormone therapy group vs 27.6% in the placebo group, p=0.60), 
cardiovascular (8.9 % with hormone therapy vs 9.0% with placebo, p=0.98), or total cancer 
mortality (8.2 % with hormone therapy vs 8.0% with placebo, p=0.50). The trials were not 
heterogeneously significant during a cumulative follow-up of 18 years, evidencing safety 
outcomes from this intervention.  
The drop-in prescription of hormone therapy was especially prevalent among 
women with a family history of cancer, cardiovascular disease, or bleeding disorders, and 
among those who, even having an indication, choose not to use hormone therapy. A family 
history of breast cancer (Colditz, Kaphingst, Hankinson, & Rosner, 2012) (Level of evidence: 
2A) is not a contraindication; individual history is more important, prepondering the view that 
HRT is a low-risk intervention that provides effective relief of menopausal symptoms and 
providing long-term protection against the major chronic diseases affecting women in their 
lifetime. Thus, for prescription, the risk/benefit assessment is the most important consideration 
for health care professionals (Baber et al., 2016; Chlebowski & Anderson, 2015; Currie, 
Abernethy, & Gray, 2017; Ko, 2014; Langer, 2017; Moreira, Silva, Santos, & Sardão, 2014; 
Nachtigall, 2001; Stuenkel et al., 2015). However, (NAMS, 2017) (Level of evidence: 1A) 
highlights that women aged younger than 60 years or who are within 10 years of menopause 
and have no contraindications for hormone replacement therapy have more benefits than risks 
when adhering to this treatment, as HT is probably the most appropriate bone-active therapy 
and most favorable for treatment of vasomotor symptoms. 
Many treatment options are available, both pharmacological and non-
pharmacological, to relieve menopausal symptoms, especially vasomotor symptoms. The 
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pharmacological possibilities are: 1) hormone replacement therapy, which commonly combines 
a progestogen with estrogen being used for most women; estrogen isolated is indicated for 
women with hysterectomies, or vaginal hormone creams, as local estrogen therapy, is suitable 
for treatment of genitourinary syndromes of menopause, chronic conditions that include genital 
symptoms (burning, itching, dryness or irritation), sexual symptoms (dyspareunia, lack of 
lubrication, pelvic discomfort and pain or impaired function), and also urinary symptoms 
(urgency, dysuria or recurrent urinary tract infections) (Kim, Kang, et al., 2015; NAMS, 2012); 
2-) tibolone, a synthetic steroid drug with estrogenic, progestogenic, and weak androgenic 
actions (Sarri et al., 2017); 3-) alternatives non-hormones for hot flushes including the selective 
serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitor (SNRI); 
these antidepressants are used off-label to treat menopausal hot flushes and sleep quality, 
improving only vasomotor symptoms by acting specifically in a thermoregulatory-neutral zone 
(Ensrud et al., 2012), and finally 4) phytoestrogens, which are phenolic compounds with 
estrogenic activity, due to their chemical structure similar to the endogenous estradiol (E2), and 
these compounds are found in vegetables, usually in the most common forms of lignans, 
coumestans, stilbenes, and isoflavones. The phytoestrogens are capable of binding to estrogen 
receptors (ER), with greater affinity for the β receptor than for α, promoting agonist and 
antagonist functions about them (Chlebowski & Anderson, 2015; Ko, 2014; Moreira et al., 
2014; Nachtigall, 2001).  
Phytoestrogens are phenolic compounds found in plants, such as flavonoids, 
isoflavones, and lignans, which possess estrogenic or antiestrogenic activities due to its 
similarity to mammalian estrogens (Cassidy, 2003; Frankenfeld, 2017). They belong to a huge 
family of secondary plant metabolites that are present in the diet, promoting several potentially 
health-benefits, like antioxidant, apoptotic, anti-inflammatory, anti-proliferative activities, 
cholesterol-lowering, and many other biological functions reported in the literature, in addition 
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to presumably inhibiting cancer cell proliferation and stimulating immune function (Burkard et 
al., 2017; Landete et al., 2016).  
Flavonoids, which are subdivided based on their chemical structure, into the 
subgroups flavonols, flavanols (or catechins), isoflavones, flavones, flavanones, and 
anthocyanidins, are found in plants often conjugated to sugar residues, known as flavonoid 
glycosides, creating a complex mixture with their respective aglycones (structure without the 
sugar residue) (Hollman, 2004). Some flavonoid glycosides are actively carried through the 
small intestinal epithelium by glucose transporters (Cermak, Landgraf, & Wolffram, 2003; 
Wolffram, Blöck, & Ader, 2002), while for other flavonoids, the hydrolysis of the sugar moiety 
may be required to facilitate their absorption (Németh et al., 2003). 
Isoflavones, one of the most important subgroups of flavonoids, are present almost 
exclusively in leguminous plants, and can be found in high amounts in soy and soy-derived 
products, and are present mainly as glycoside forms (Cao, Chen, Jassbi, & Xiao, 2015; Kim, 
Lee, & Han, 2015). The most effectively absorbed forms of isoflavones are the aglycones 
(genistein, daidzein and glycitein), which are partially hydrolyzed in the small intestine and are 
partially present in glycosidic forms (genistin, daidzin and glicitin, acetylidazid, acetylglycine, 
acetylglicitine, malonylgenistin, malonylidysin, and malonylglicitine) released from their 
conjugated form through the glycosyl hydrolases (enzymes of the family β-glycosidase), giving 
rise to compounds with higher biological activity, such as equol and 5-hydroxy equol, in 
addition to molecules considered inactive such as o-dimethylangolensin (O-DMA). This 
process has fundamental importance of intestinal microbiota involved in isoflavone 
bioavailability and metabolism (Guadamuro et al., 2015). 
The bioavailability and bioactivity of glycosidic forms of isoflavones are 
comparatively low as a result of their hydrophilicity and high molecular weight (Cremoux, This, 
Leclercq, & Jacquot, 2010; Guadamuro et al., 2015; Lopes, de Avila, de Queiros, Macedo, & 
Macedo, 2016). Aglycones, the bioactive forms, are absorbed more efficiently and in a higher 
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concentration than their glycosides forms in human intestine (Barnes et al., 2011; Hur, Lim, 
Decker, & McClements, 2011). This transformation is performed by enzymes of the gut 
microbiota, which are responsible for the hydrolysis of the conjugated isoflavones (Clavel & 
Mapesa, 2013; Kemperman, Bolca, Roger, & Vaughan, 2010). It is known that this 
transformation occurs in sequential steps involving several enzymes produced by several 
microbial types, but our knowledge about gut microbes, their enzymes, and the pathways 
involved in the metabolism of isoflavones is still limited (Clavel & Mapesa, 2013; Lopes et al., 
2016; Sánchez-Calvo, Rodríguez-Iglesias, Molinillo, & Macías, 2013). 
People with gut microbial environments capable of isoflavones biotransformation 
can result in health effects that diverge from individuals that do not have gut microbial 
environments with the same ability. The Asian population consumes considerably more 
isoflavones, compared to occidental population (e.g., Europeans and Americans). This fact 
promotes a favorable gut microbiota, which is associated to a better digestibility of these 
compounds (Chun, Chung, & Song, 2009; Frankenfeld, 2017). Modifications in the intestinal 
microbiota could also affect the hydrolysis of isoflavones, and thus affect the bioavailability of 
these phytoestrogens (Sánchez-Calvo et al., 2013). 
The predominant aglycone isoflavones are daidzein and genistein. Equol 
(C15H14O3) is a metabolite of the dietary isoflavone daidzein that is produced by the action of 
gut microbiota, and has a longer half-life and bioavailability than genistein and daidzein, 
besides possessing the highest antioxidant properties of the isoflavones. However, not all 
individuals are able to metabolize daidzein in equol due to differences in intestinal microbiota, 
which led to the creation of the term equol-producers to define those that could produce equol 
in response to consuming soy isoflavones and the hypothesis that the health benefits of soy-
based diets may be greater in equol producers than in equol nonproducers (Frankenfeld, 2017; 
Lopes et al., 2016; Setchell & Clerici, 2010). 
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For possess a chiral center, equol presents as a diastereoisomer and intestinal 
bacteria are enantiospecific in synthesizing exclusively the S-(-) equol enantiomer, which has 
selective affinity for the estrogen receptor-β. S-equol is the most important metabolite, however, 
both enantiomers are important from a pharmacological and clinical perception and are 
currently being developed as pharmacological and nutraceutical agents (NAMS, 2015; 
Sánchez-Calvo et al., 2013; Setchell & Clerici, 2010). 
The ability of an individual to convert isoflavones to equol and O-DMA, the 
metabolites with the highest biological activity, generated “producer” and “non-producer” 
terminology. After ingestion of soy isoflavones, about 20 to 30% of the western population 
metabolizes daidzein to equol, a low percentage compared to the frequency of approximately 
50% of the Asian population. The equol concentration in the non-producer serum is 
approximately ≤40 nmol/L, while the producers have at least double the compound in the blood 
(levels ≥83 nmol/L). In addition to the production of equol, the production of O-DMA occurs 
in 80-90% of the population (Liu et al., 2010; Setchell et al., 2002; Setchell et al., 2013). 
Several studies confirm the equol health benefits, mainly in women with 
menopausal disorders. A cross-sectional study by Yoshikata, Myint, & Ohta (2017) (Level of 
evidence: 1C) with 743 women showed that 236 women who were equol producers had 
significantly higher high-density lipoprotein cholesterol levels (p=0.038) and lower 
triglycerides (p=0.020) compared with nonproducers. This study also demonstrated that equol 
producer status was related with positive metabolic changes, as significantly lower body fat 
level (p=0.033), and visceral fat (p=0.001), significant decrease in uric acid (p= 0.031) and hs-
CRP (p=0.012), important biomarker associated with atherosclerotic conditions, mainly in 
menopausal transitional period where there is declining endogenous estrogen. They also found 
a relationship between urinary collagen type 1 cross-linked N-telopeptide (NTX), a bone 
resorption biomarker, showing that levels of this bone resorption marker tended to be lower in 
equol producers in women in their 60s (p<0.05). 
38 
 
In another study, Tousen et al. (2016) (Level of evidence: 5) studied the combined 
effects of a diet supplemented with soy isoflavones with or without the addition of resistant 
starch for 6 weeks on equol production, intestinal microbiota, bone mineral density, and 
inflammatory gene expression in the bone marrow of 28 female ddY strain ovariectomized 
mice, aged 8 weeks. They concluded that this combined treatment of isoflavones and resistant 
starch improved equol production (p<0.05) and prevented the ovariectomized-induced decline 
in trabecular bone mineral density and bone strength parameters in the distal femur (p<0.05), 
by modulating the enteric environment comprising a proliferation in Bifidobacterium spp., 
increased equol production in the intestine, which favored modifications in inflammation-
related gene expression in the bone marrow (p<0.05). They suggested that the arrangement of 
soy isoflavones and resistant starch may change the microbiota in the intestine and immune 
status in the bone marrow, resulting in attenuated bone loss in ovariectomized mice. 
Many other recent studies have shown the efficacy of equol considering several 
health benefits (Ahuja et al., 2017; Igase, Igase, Tabara, Ohyagi, & Kohara, 2017; Kladna, 
Berczynski, Kruk, Piechowska, & Aboul-Enein, 2016; Shimizu, 2017), and especially in 
menopause-related problems (Caruso et al., 2017; Davinelli et al., 2017; Guadamuro et al., 
2015; Lopes et al., 2016; Utian et al., 2015), which shows the importance of this compound in 
the individual diet. In addition to the hormonal effect that directly affects the relief of 
menopausal symptoms, isoflavones have been associated with beneficial effects on human 
health, mainly because of their antioxidant capacity, including reduction of the risk of 
cardiovascular disease, lower risk of cancer (Watanabe, Uesugi, & Kikuchi, 2002), and 
osteoporosis (Ma, Qin, Wang, & Katoh, 2008; Taku, Melby, Nishi, Omori, & Kurzer, 2011; 
Wei, Liu, Chen, & Chen, 2012). Though the maintenance of bone density by isoflavones does 
not possess the potency of a hormonal therapy, the isoflavones may improve bone preservation 
capacity in postmenopausal women according to Pawlowski et al. (2015) (Level of evidence: 
1A), making phytoestrogen therapy well accepted among women who cannot or do not wish to 
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use hormone therapy and provides scientific evidence that it can effectively be an alternative 
treatment. 
 
2. Methodology 
This study is a systematic review of the literature of relevant studies published from 1994 to 
2017. The search method used as reference for the research was the PRISMA “Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses” (Liberati et al., 2009). The 
literature review conducted based on the search for scientific articles on the subject “Use of soy 
isoflavones for the relief of climacteric symptoms in menopausal women as 
alternative/adjunctive therapy to hormone replacement therapy” on the PubMed and Science 
Direct databases, in the English language. The descriptors, words, and combinations for 
searching for data were “Menopausal symptoms” AND (Isoflavone* OR Hormone therapy* 
OR “Equol”). The criteria for inclusion of articles were: (A) Studies on the metabolism of 
isoflavones and the influence of the intestinal microbiota; (B) Peri or postmenopausal women; 
(C) Randomized controlled trials (RCTs) evaluating isoflavones and/or hormone replacement 
therapy; (D) Articles with the objective of verifying the influence or effects of isoflavones on 
additional health benefits in menopausal women; I Systematic reviews and meta-analyses; (F) 
Consensus/guidelines. Exclusion criteria applied were (G) women out of peri- or 
postmenopausal period, (H) some chronic associated illness, and (I) use of red clover 
isoflavones or another source of isoflavones other than soy. During the bibliographic search 
phase, the analysis of titles, reading of abstracts, exclusion of duplicates, complete reading of 
articles of interest, and inclusion of the data in the review were completed. The search strategy 
yielded 26,316 abstracts. Based on the review process, 180 Abstracts were reviewed, 30 
excluded and 150 unique trial reports were identified that met the study inclusion and exclusion 
criteria. Of these, 23 focused on RCTs, 16 on crossover studies, 69 on literature review, 
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systematic review or meta-analyses, and 42 in vitro reports or animal studies. 
 
 
3. Bioactivation of phytoestrogens through the gut microbiota and factors that affect the 
efficacy in climacteric syndrome 
 
The consumption of soybean and their derivatives has increased in recent years due 
to their nutritional value and numerous beneficial effects on human health, because isoflavones 
presumably promote a defense against chronic diseases, like cardiovascular disorders, 
osteoporosis, breast and prostate cancer, and alleviate menopause symptoms (Chen et al., 2012; 
Finley et al., 2013; Marazza, Nazareno, de Giori, & Garro, 2012; Sánchez-Calvo et al., 2013; 
Singh, Singh, Singh, & Nautiyal, 2010; Zhang et al., 2014). Although isoflavones consumption 
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is valid to improve general health, it is known that the compositions of each microbiota affect 
the bioavailability and absorption of these compounds and specific benefits can be influenced 
by several factors such as age, sex, ethnic race, chronic diseases, geographic distribution, and 
microbiota profile (Setchell & Clerici, 2010; Yuan, Wang, & Liu, 2007). 
Among the hydrolytic enzymes produced by the gut microbiota, the β-glucosidase 
is the enzyme responsible by metabolizing the isoflavones to produce absorbable aglycone 
forms (Setchell, Brown, & Lydeking-olsen, 2002; Setchell et al., 2002; Wang & Murphy, 1994). 
The β-glucosidase (b-D-glucoside glucohydrolases, EC 3.2.1.21) is produced by various 
microorganisms and is also naturally present in soybeans (Yeom, Kim, Kim, & Oh, 2012). This 
enzyme is responsible for catalyzing the hydrolysis of β -glucosidic linkages of 
oligosaccharides and glucosides to generate glucose and shorter oligosaccharides (Cairns & 
Esen, 2010; Xue, Yu, & Song, 2009). 
In non-fermented soy foods, the glycoside isoflavones are the predominant form, 
whereas, in fermented and processed foods such as miso, tempeh, and natto, the main forms are 
the aglycones isoflavones. This is due to the activity of the β-glucosidases produced by the 
bacteria during the soy fermentation process (Dimitri Tsangalis, Ashton, McGill, & Shah, 2003; 
Wang & Murphy, 1994). Therefore, the hydrolysis of glycoside isoflavones via the action of 
bacterial β-glucosidase has been the most often described method for increasing the 
concentration of bioactive isoflavones in soybeans, which consequently contributes to many 
advantageous properties of soy products (Chandrasekara & Shahidi, 2012; Juan & Chou, 2010). 
During soybean fermentation, the type of substrate, the growth medium, the 
bacterial characteristics, the microbial strain type, and the presence of isozymes can influence 
the degrees of β-glucosidase activity (Chien, Huang, & Chou, 2006; Tsangalis, Ashton, McGill, 
& Shah, 2002). Several studies have been performed to select microbial cultures that are able 
to metabolize the isoflavones. In general, the higher bioconversion rate of isoflavones is 
performed by the microorganism that presents the higher β-glucosidase activity (Donkor & 
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Shah, 2008; Hati, Vij, Singh, & Mandal, 2015; Lee et al., 2015). These enzymes are also critical 
to the biochemical process that occurs in the human body when isoflavones are being 
metabolized. 
Several microorganisms have been implicated in the metabolism of isoflavone 
aglycones. Among those, the lactic acid bacteria and Bifidobacterium are the strains that have 
strong β-glucosidase activity (Yeo & Liong, 2010). Species such as Lactobacillus acidophilus, 
Lactobacillus casei, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus 
plantarum, Lactobacillus bulgaricus, Bifidobacterium breve, and Bifidobacterium bifidum have 
proven to be excellent strains to use on soy fermentation because they are able to improve the 
bioavailability and conversion rate of isoflavones by the action of the β-glucosidase (Hati et al., 
2015; Marazza et al., 2012; Rekha & Vijayalakshmi, 2011; Rodríguez-Roque, Rojas-Graü, 
Elez-Martínez, & Martín-Belloso, 2013). 
In an in vitro study, (de Queirós, Macedo, & Macedo, 2016) (Level of evidence: 5) 
studied the capacity of three in vitro processes to increase the bioactive properties of soymilk. 
The authors evaluated the changes in the profile of isoflavones, the soymilk antioxidant activity, 
and the production of equol. The results showed that one of the processes based on the 
fermentation of soymilk using, simultaneously, Streptococcus ssp. Thermophilus (YF-L811), 
Lactobacillus delbrueckii ssp. Bulgaricus (LB-340), Bifidobacterium animalis ssp. Lactis (Bb-
12), and Lactobacillus acidophillus (LA-05) led to a significant increase in the content of 
bioactive isoflavone aglycones (daidzein and genistein) (p<0.05). Besides this, the total 
phenolic content and antioxidant capacity of soymilk significantly increased after the 
fermentation process, compared with the standard (p<0.05). The reduction of the concentrations 
of glycosides daidzin and genistin and increase of aglycones daidzein and genistein after the 
fermentation process can confirm the β-glucosidase activity inherent in the microorganisms 
used in this study.  
(Hati et al., 2015) (Level of evidence: 5), studied six strains of lactobacilli to 
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ferment the soymilk and showed a variable β-glucosidase activity between the strains L. 
rhamnosus C2 and C6, L. rhamnosus NCDC24 and NCDC19, and L. casei NCDC297 and 
NCDC17. All strains were significantly capable of producing the β-glucosidase enzyme 
(p<0.05) and were able to bioconvert the glucoside into their respective aglycones isoflavones 
during the fermentation process, indicating that β-glucosidase-producing Lactobacillus cultures 
have great potential for application as a functional ingredient. (Lee et al., 2015) also described 
the relation between the increase of bioactive isoflavones and the production of β-glucosidase 
by the probiotic during the fermentation of soymilk. In this in vitro study, they used 
Lactobacillus acidophilus ATCC 4356, Lactobacillus plantarum P8, and Streptococcus 
thermophilus S10 as single and mixed cultures to ferment black soymilk. The β-glucosidase 
activity was used to compare the performance of these different cultures, and the authors 
identified the best culture to bioconvert the glycosides to aglycone isoflavone after soymilk 
fermentation. The Streptococcus thermophilus S10 single culture was the most efficient 
bacterial strain, showed the highest β-glucosidase activity than mixed cultures, resulting in the 
highest aglycone content and best antioxidant effect, compared with controls (p<0.05). 
Furthermore, the microbial biotransformation of isoflavone has been widely related 
according to the increase of the antioxidant capacity of soy products (Cheng, Wu, Lin, & Liu, 
2013; Marazza, Garro, & Giori, 2009; Xiao et al., 2015). The gut microbiota is able to 
biotransform the complex polyphenols, as the glycoside isoflavones, into smaller molecules 
that can be absorbed in the intestine (Manach, Williamson, Morand, Scalbert, & Rémésy, 2005; 
Selma, Espín, & Tomás-Barberán, 2009). Therefore, the β-glucosidase from microbiota showed 
great potential to enrich bioactive isoflavones once the aglycone isoflavones are converted to 
aglycones, considered to have a higher bioactive capacity. 
Isoflavone metabolism (Figure 2) starts with hydrolysis and uptake, followed by 
passive diffusion through the intestinal mucosa and incorporation of these phytoestrogens into 
the chylomicrons, which carry them to the lymphatic system before entering the circulatory 
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system. Once in plasma, isoflavones will exert their metabolic effects in all cells that contain 
estrogen receptors, in forming the glucuronides, isoflavone sulfates, and isoflavone glucosides 
after undergoing the process of glucuronidation, sulfatation, and glycosidation, respectively, 
with an average half-life of 7 or 8 hours and with differing half-lives for each isoflavone (Chang 
& Choue, 2013). When these molecules are secreted in the bile by the liver, part goes through 
new bacterial hydrolysis being reabsorbed by the enterohepatic circulation, and part is excreted 
by the feces (Anderson & Garner, 1997). Approximately 10-30% of isoflavone dietary intake 
is eliminated in urine (Setchell, 1998) (Level of evidence: 1A). 
 
 
 
Figure 2. Isoflavones metabolism. 
In summary, this high variability in isoflavone metabolism is mainly attributable to 
interindividual differences in the composition of the gut microbiota, which plays an important 
role in determining the magnitude and pattern of isoflavone bioavailability.  
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Isoflavones have, therefore, become an important alternative to synthetic hormone 
therapy, because they have estrogen agonist activity and are proposed as treatment for 
vasomotor symptoms; although its efficacy has been investigated in numerous clinical trials, 
the effectiveness of soy isoflavones in relieving menopausal symptoms remains controversial, 
mainly because of the paucity of long-term, randomized, double-blind, controlled studies 
(Wender, Pompei, & Fernandes, 2014). 
(Nedrow et al., 2006) (Level of evidence: 1A) questioned the use of this type of 
alternative therapy in a systematic review by which they aimed to evaluate the efficacy of 
complementary and alternative therapies for the management of menopausal symptoms. In this 
work, Nedrow et al. (2010) compared studies that used several approaches, such as 
phytoestrogens and mind-body approach or whole medical systems (i.e., relaxation and 
acupuncture exercises). Although some studies, when evaluated individually, conclude benefits 
and improvements in menopausal symptoms, the data evaluated in sets are insufficient to prove 
efficacy. According to the authors, many of these therapies require further studies and trials 
with rigorous scientific models to determine benefit and safety. 
The meta-analysis conducted by (Bolanos, Del Castillo, & Francia, 2010) (Level of 
evidence: 1A) analyzed 19 randomized, placebo-controlled clinical trials, and the minimal 
follow-up time for considering the final analysis was 12 weeks. The study aimed to determine 
if the intervention with soy in different forms (diet, extract, and isoflavones concentrate), in 
doses from 33.3 to 134.4 mg/day with protocol durations from 12 to 96 weeks, would be able 
to reduce the incidence of hot flushes in climacteric women compared to placebo. The overall 
results, and combined according to the type of supplement, concentrate (p<0.001), dietary 
supplement (p=0.124), and soy extract (p<0.001), showed that soy tended to significantly 
decrease the incidence of vasomotor symptoms in comparison with placebo (p=0.014), although 
the author affirms that obtaining conclusive results has been hampered by the heterogeneity of 
the studies evaluated in the meta-analysis. 
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An exploratory and descriptive cross-sectional, multiple logistic regression 
analyses of 2,118 women was performed by (Gold et al., 2007), based on the SWAN (Women’s 
Health Across the Nation) (Level of evidence: 1A). In this longitudinal epidemiological study, 
they evaluated the health of women during middle age, and demonstrated that more than half 
of the patients evaluated (52.7%) used some alternative treatment or complementary therapies, 
such as the use of vitamins, supplements, yoga, phytoestrogen-based diet, acupuncture, among 
other similar approaches to relieve menopausal symptomatology. The search for these 
alternative methods is high among women with vasomotor symptoms, in relation to women 
with urogenital and psychological symptoms (p<0.0001), with the use of soy-based supplements 
(isoflavones) being significantly higher among those who reported some vasomotor symptoms 
(p=0.0051). These vasomotor symptoms associated with the climacteric varied according to 
race/ethnicity and social status, and were more often present in women with lower education, 
lower financial stability, smokers, those with sedentary lifestyle, and those with a high body 
mass index (BMI). 
A randomized placebo controlled study conducted by (Villa et al., 2009) (Level of 
evidence: 1A) evaluated the effect of genistein administration on metabolic parameters in 50 
postmenopausal women: randomized to group A (n=30) to receive 54 mg/day genistein, or 
group B (n=20) that was treated with the placebo for 24 weeks. In group A, two subgroups were 
created: normoinsulinemic (n=14) and hyperinsulinemic (n=12) women. Biochemical 
parameters, such as glucose intolerance, insulin sensitivity, and lipid and hormonal profiles, 
were analyzed and demonstrated that 6 months of treatment with 54 mg of genistein/day 
significantly improved glycemic metabolism (p<0.02), fasting insulin (p<0.005) in 
normoinsulinemic and hyperinsulinemic women, and vascular function in postmenopausal 
women compared to the placebo group (p<0.01). There was no difference in basal total 
cholesterol, triglycerides, and LDL-cholesterol levels, whereas HDL-cholesterol levels were 
lower in hyperinsulinemic patients (p<0.005). Due to the potential benefits of isoflavones for 
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women’s health and well-being, the North American Menopause Treatment Society (NAMS) 
that has suggested to women with vasomotor symptoms not responsive to other interventions 
to consider phytoestrogen supplementation (Clarkson et al., 2004). 
Accordingly (NAMS, 2011) (Level of evidence: 1A), soy-based isoflavones are 
modestly effective in relieving menopausal symptoms while presenting a lower risk of breast 
and endometrial cancer in observational studies. The efficacy of isoflavones on bone has not 
been proven, and the clinical picture of whether soy has cardiovascular benefits is still evolving. 
The interrelations of other dietary components on soy isoflavones consumed as a part of diet or 
by supplement on equol production also require further study to understand the modes of use 
of soy isoflavone supplements in women. Greater standardization and documentation of clinical 
trial data are necessary to bringing conclusive evidence. (NAMS, 2015) (Level of evidence: 
1A) expanded its evidence-based position on nonhormonal management of menopause-
associated vasomotor symptoms (VMS) when hormone therapy is not an option, and brings to 
light the concern with using ineffective therapies in midlife women recommending with caution 
some therapies that may be beneficial for alleviating VMS, as weight loss, mindfulness-based 
stress reduction, and the S-equol derivatives of soy isoflavones. 
A quantitative analysis (Level of evidence: 2C) on the relationship between 
menopause symptoms of low or high intensity and urinary excretion of isoflavones from 
soybean and equol in 108 peri and postmenopausal Japanese women (40-60 years) showed that 
there was no significant difference in the urinary excretion of daidzein (mean 19.6 ± 15.1 
μmol/24 h) and genistein (mean 10.0 ± 8.9 μmol/24 h) among women with a high or low degree 
of vasomotor symptoms, regardless of symptom severity. However, the urinary equol levels in 
patients with menopausal symptoms (4.9 ± 9.1 μmol/24 h) were significantly lower than those 
in patients who had a lower incidence of menopausal symptoms (16.3 ± 19.4 μmol/24 h) 
(p<0.05), suggesting that equol may assist in the suppression of menopausal symptoms, when 
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interacting with the α and β tissue receptors, which leads to lower renal excretion (Uchiyama et 
al., 2007). 
This ability to produce equol has great interindividual variability due to the different 
profiles of the intestinal microbiota, which respond to isoflavones metabolism, where part of 
the aglycones and their metabolites are excreted in the feces and part is reabsorbed by 
enterohepatic circulation acting on cells with estrogenic receptors (Figure 2), consequently 
determining their bioavailability (Timan, Rojanasthien, Manorot, Sangdee, & 
Teekachunhatean, 2014). It is known that the profile of the intestinal microbiota is decisive for 
the metabolism and greater bioavailability of the isoflavones and their metabolites. Some 
studies have shown that the administration of isoflavones together with probiotics provide 
health benefits, either directly through interactions with host cells or indirectly through effects 
on other bacterial species, thus being able to optimize the performance of these phytoestrogens 
(Benvenuti & Setnikar, 2011; Brahe et al., 2015; McCabe, Britton, & Parameswaran, 2015; 
Palacios, Rojo, Cancelo, Neyro, & Castelo-Branco, 2008; Piazza et al., 2007). 
(Ishiwata, Melby, Mizuno, & Watanabe, 2009) (Level of evidence: 1A), performed 
a randomized, placebo-controlled trial that offered an S-equol supplement for 134 Japanese 
women between the ages of 40 and 59 years, with a habitual intake of isoflavones limited to 20 
mg/day, grouped as equol producers and non-producers. The test had a duration of 12 weeks 
and the S-equol supplement was offered at a dose of 10 mg/day and 30 mg/day compared to 
placebo. A questionnaire of menopausal symptoms and mood state profile was performed at 
the beginning and end of the study. The results demonstrated that in comparison to placebo, the 
30 mg/day dosage of equol provided lower levels of anxiety (p<0.05), depression (p<0.05), and 
fatigue (p<0.01), as well as increasing the sense of vigor (p<0.05), suggesting that S-equol 
supplementation may be an interesting alternative therapy for menopausal women, including 
non-producer women. The fact that not all women who use isoflavones benefit from its effects 
requires more representative studies and with uniform criteria, comparing producers and non-
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equol producers, to help elucidate the real benefits of equol and its relationship with the 
intestinal microbiota. 
Phenolics compounds and microbiota have a bidirectional association, acting 
against pathogens, with antimicrobial activity for some microorganisms, while promoting the 
growth of others (Duda-Chodak, Tarko, Satora, & Sroka, 2015; Valdés et al., 2015). Intestinal 
strains found in the human microbiota that metabolize phenolic compounds, such as soy 
isoflavones (daidzein, genistein and glycitein aglycones) in derivatives of higher biological 
activity, as equol (Lopes, Queiros, de Avila, Monteiro, & Macedo, 2017), are shown in Table 
1. 
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Table 1. Human gut microbiota that metabolizes isoflavone daidzein to S-equol, the bioactive 
form (adapted from Lopes, Queiros, de Avila, Monteiro, & Macedo, 2017). 
 
Bacterial strains References 
Adlercreutzia equolifaciens FJC-B9T (Maruo, Sakamoto, Ito, Toda, & Benno, 
2008) 
Eggerthella spp. YY7980 and YY7918 (Kawada, Yokoyama, Yanase, Niwa, & 
Suzuki, 2016; Shin-ichiro Yokoyama & 
Suzuki, 2008; Shin ichiro Yokoyama, 
Oshima, Nomura, Hattori, & Suzuki, 2011) 
Eggerthella spp. Julong 732 (Kim et al., 2009) 
Enterococcus faecium (Decroos, Vanhemmens, Cattoir, Boon, & 
Verstraete, 2005) 
Slackia equolifaciens a (Jin, Nishihata, Kakiuchi, & Hattori, 2008; 
Jin, Kitahara, Sakamoto, Hattori, & Benno, 
2010) 
Slackia isoflavoniconvertens HE8 a (Matthies, Blaut, & Braune, 2009) 
Lactococcus garvieae (Shimada et al., 2010) 
Bifidobacterium spp. (Raimondi et al., 2009; Tsangalis et al., 
2002) 
Bacteroides ovatus (Ueno & Uchiyama, 2002) 
a Strains able to produce 5-hydroxy equol from the isoflavone genistein. This metabolite has greater antioxidant 
activity than your precursor. 
 
The rate of metabolite formation is influenced by nutrients in food matrix; 
consumption and eating habits; gut microbiota profile and immune properties; capacity of 
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intestinal bacterial fermentation, which is directly related to the availability of nutrients, 
especially polysaccharides; intestinal transit time, and alterations to bacterial redox physiology 
(Duda-Chodak et al., 2015). 
Many studies have evaluated the effects of separate natural components of 
isoflavones on various human diseases and have presented that aglycones (daidzein, genistein, 
and glycitein) have great biological activity on diseases that may manifest in the menopausal 
period. Table 2 summarizes some of these studies that demonstrate the performance of specific 
target organ isoflavones. Isoflavones interact with estrogen receptors and may bring additional 
benefits to menopausal women’s health, suggesting that isoflavones can be used along with 
hormone replacement therapy, not as a substitute, but as adjunctive or complementary treatment 
for a small portion of women who have no indications for hormone replacement therapy, 
especially for those who wish to make use of alternative therapies. 
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Table 2. Human intervention studies that punctuate additional effects of isoflavones on health. 
Study Subjects Intervention Duration Target Results 
Meta-analysis of randomized controlled trials 
Ricci et al. 2010 794 Postmenopausal 
Women (38-74 years) 
Were identified 10 eligible 
RCTs published in English and 
indexed in Medline from 
January 1990 to 
December 2009. 
Was evaluated the effects 
of soy isoflavones aglycones 
mixtures or genistein isolated 
(54 to 120 mg), on fasting 
blood glucose levels and 
insulin levels. 
3 to 24 
months 
Glycemia Glycemia reduction was not 
significant (p=0.17) for 
isoflavones use, but significant 
and homogeneous effect on 
insulin and HOMA-IR was seen 
(p=0.009) 
Prospective comparative study 
Singhal and Shullai 
2016 
100 peri and 
postmenopausal women 
(40–65 years) 
The study was planned to 
compare the effects of 
gabapentin and isoflavones in 
menopausal vasomotor 
symptoms. 
Women are divided into two 
groups: 
Group I (n=50) Gabapentin 
(900 mg/day) 
Group II (n=50) Isoflavones 
(60 mg/day) 
3 months Vasomotor 
symptoms 
(VS) 
Both interventions are equally 
efficacious in the treatment of 
hot flashes at the end of 12 
weeks (82% Group I, 74% 
Group II; P = 0.076), but 
isoflavones have better response 
when there are depression 
associated (p=0.026), while 
Gabapentin is better for VS with 
sleep disturbance (p=0.011). 
Only isoflavone had significant 
improvement in cholesterol, 
high-density lipoprotein, low-
density lipoprotein, and 
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triglycerides profiles after 12 
weeks (p < 0.001, 0.009, 0.024 
and <0.001, respectively) as 
compared to gabapentin. 
Randomized, double-blind, placebo-controlled trial 
Khaodhiar et al. 2007 190 postmenopausal women 
(38-60 years) 
Women were randomized in 
three groups to receive a 
placebo, 40 or 60 mg/day of 
daidzein, with objective to 
determine the effect of 
aglycone daidzein on hot flash 
symptoms in menopausal 
women, being evaluated at the 
beginning of the study and after 
8 and 12 weeks of intervention. 
12 weeks Vasomotor 
symptoms 
(VS) 
The comparison of the two 
treatment groups with the 
placebo group demonstrate a 
significant reduction in mean 
daily hot flash frequency. The 
supplement (either 40 or 60 mg) 
reduced hot flash frequency by 
43% at 8 weeks (p = 0.1) and 
52% at 12 weeks (p = 0.048). 
Suggesting daidzein isolated as 
an effective alternative 
treatment for menopausal hot 
flashes. 
Double-blind, randomized placebo-controlled trial 
Carmignani et al. 
2014 
60 postmenopausal women 
(40-60 years) 
The purpose of study was to 
assess the effects of a soy 
dietary supplement on the main 
biomarkers of cardiovascular 
health in postmenopausal 
women compared with the 
effects of low-dose hormone 
therapy (HT) and placebo. The 
subjects were divided in: 
16-week Metabolic 
profile 
There was an increase in HDL-
cholesterol (10.2%, p=0.9) and a 
slight decrease in LDL (-1.9%, 
p<0.01) and total cholesterol (-
0.7%, p<0.01) in soy groups, but 
these differences compared to 
baseline values were not 
statistically significant. 
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Group I (n=20)- estradiol 1 mg 
+ noretisterone acetate 0.5 mg 
Group II (n=20) – 
90 mg of total isoflavones/day  
Group III (n=20) – placebo 
 Double-blind, randomized placebo-controlled trial 
Hodis et al. 2012 350 postmenopausal women 
(45 to 92 years) 
 
 
 
 
 
 
 
 
The women were randomized 
to 2 evenly divided daily doses 
of 25 g soy protein containing 
91 mg aglycones isoflavones in 
followed proportions: 
genistein 52 mg; daidzein 36 
mg and glycitein 3 mg or 
placebo (none isoflavones). 
Was determined whether 
isoflavone soy protein (ISP) 
reduces subclinical 
atherosclerosis assessed as 
carotid artery intima-media 
thickness (CIMT) progression 
2.7 years Cardiovascular 
health 
Although CIMT progression 
was reduced on average by 16% 
in the ISP group relative to the 
placebo group, this treatment 
effect was not statistically 
significant (p=0.36). Among the 
subgroup of women who were 
randomized within 5 years of 
menopause, ISP participants 
had on average a 68% lower 
CIMT progression rate than 
placebo participants (2.16 vs. 
6.79 μm/year, p=0.05). The 
analyses suggest a possible 
benefit of ISP supplementation 
among women in the first 5 
years of menopause and with 
low cardiovascular risk, with the 
goal of preventing progression 
and not reversing 
atherosclerosis. 
Multiethnic cohort study retrospective 
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Zhang et al. 2017 6235 women with breast 
cancer (41,2 to 62,4 years) 
Was examined association of 
dietary intake of isoflavone, the 
major phytoestrogen in soy, 
with all-cause mortality 
9.4 years Breast cancer A 21% decrease was observed 
in all-cause mortality for women 
who had the highest versus 
lowest quartile of dietary 
isoflavone intake (p=0.01). 
Lower mortality associated with 
higher intake was limited to 
women who had tumors that 
were negative for hormone 
receptors (p=0.005) 
A systematic review and Meta-analysis  
Lambert et al. 2017  2652 peri and 
postmenopausal women 
Twenty-six randomized 
controlled trials systematically 
searched EMBASE and 
PubMed were analysed to 
evaluate isoflavone therapies 
for treating bone mineral 
density (BMD) loss at the 
lumbar spine and femoral neck 
peri and postmenopausal 
women. In postmenopausal 
women treated with 
isoflavones, in aglycones 
forms, for at least 3 months. 
Interventions varied 
substantially in terms of dose 
(4.4–300 mg), form of 
isoflavones used (total 
isoflavones or aglycone 
equivalent) and associations 
with other components that 
3 months to 
2 years 
Bone When evaluating lumbar 
spine, isoflavone treatment was 
associated with a significantly 
(p<0.00001) higher weighted 
mean difference (WMD) of 
BMD change of 0.01 (95% CI: 
0.01, 0.02) than the control. For 
the femoral 
neck, isoflavone treatment 
showed a significantly (p< 0.01) 
higher WMD of BMD change of 
0.01 (95% CI: 0.00, 0.02) 
compared with the control. 
Isoflavone aglycones, in their 
treatment arm showing the 
average effect was further 
significantly increased at the 
spine to 0.04 (p<0.00001; 95% 
CI: 0.02, 0.05) and femoral neck 
to 0.03 (p< 0.05; 95% CI: 0.00, 
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may influence bone health such 
as exercise, micronutrient 
supplementation or addition of 
protein sources to diet (milk or 
soy proteins). 
0.06) compared with the control. 
The study concludes that 
isoflavone treatments, 
especially in the aglycone 
forms, can be effective in 
preserving BMD and 
attenuating accelerated bone 
resorption. 
Blinded randomized crossover intervention trial 
Pawlowski et al. 2015 24 postmenopausal 
women (50 – 68 years) 
tested for their ability to 
produce equol (n=8 equol-
producer versus n=16 non-
producer) 
Was offered 5 types of soy 
isoflavone oral supplements 
ranged from 52 to 220 mg total 
isoflavones/day (2 doses of a 
genistein-rich soy supplement 
and 3 doses of mixed 
isoflavones in various 
proportions) and a 
bisphosphonate (Risedronate 5 
mg/day) 
 
Each 
intervention 
was given 
sequentially 
for 50 d 
followed by a 
50-d washout 
period 
Bone All isoflavone interventions 
except for Genistein-high are 
significantly effective bone-
preserving, with Genistein-low, 
Soy-high, and Soy-genistein, 
which resulted in increased bone 
calcium retention by 3.4% (p= 
0.0263), 5.5% (p= 0.0232), and 
5.8% (p = 0.0096), respectively. 
Risedronate intervention 
compared with nonintervention 
resulted in an increase in bone 
calcium retention of 15.3% (p = 
0.0014). There was no 
difference (p= 0.5) in bone 
calcium retention between equol 
producers and nonproducers. 
Meta-analysis of randomized double-blind controlled trials 
Liu et al. 2016 2167 peri and post-
menopausal women (47 to 
73 years) 
A total of 23 trials were 
identified in a combined search 
of the PubMed, Embase, 
3 months to 3 
years 
Endometrial 
thickness 
The baseline endometrial 
thickness varied from 
0.4±2.3mm to 7.25±2.88mm. 
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Cochrane Library and web of 
science, CINAHL and WHO 
ICTRP databases from 1950 up 
to August 2015. 
The interventions consisted in 
isoflavone supplementation 
doses ranged from 5 to 154 
mg/day. Control groups 
received placebo and were 
advised to keep their usual diet. 
All studies are randomized 
controlled trials (RCT) with 
evaluation of the thickness 
made by 
transvaginal ultrasounds.  
 
 
The overall results from pooling 
the 23 studies did not show 
significant change in 
endometrial thickness in either 
treatment or placebo groups 
(p=0.6). Stratified analysis 
suggested that a daily dose of 
more than 54mg could decrease 
the endometrial thickness for 
0.26mm (p=0.007), with 
isoflavone supplementation 
significantly decrease the 
endometrial thickness for 
0.23mm in North American 
studies (p=0.04), but it 
suggested an increase for 
0.23mm in Asian studies 
(p=0.10), demonstrating 
different effects in different 
populations and at different 
daily doses. 
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4. Conclusion 
Experienced by millions of women around the world annually, menopause, despite 
being a natural event in the female life, often involves troublesome symptoms, including 
vasomotor symptoms, vaginal dryness, decreased libido, urinary incontinence, insomnia, 
fatigue, muscle and joint aches, changes in body contour, and increased skin wrinkling due to 
the hormonal sudden drop (Santoro et al., 2015). 
Hormone therapy has many advantages, such as 75% reduction in frequency and 
87% in the severity of vasomotor symptoms, improvement of urinary incontinence and vaginal 
lubrication, and the protective effect on bone mineral density (Maclennan, Broadbent, Lester, 
& Moore, 2004; Moehrer, Hextall, & Jackson, 2003). Although it is known that oral estrogen 
therapy increases the risk of thromboembolic events, cancer estrogen dependent (usually type 
I), endometrial hyperplasia, and breast density trough to the endometrial stimulus that isolated 
estrogen produces owing the tissue distribution of estrogen receptors, these events may be 
reduced when appropriate dose and regimens are prescribed, containing appropriate 
progestogen or progesterone, especially if therapy is predominantly focused on the estrogen 
component (Lobo, Pickar, Stevenson, Mack, & Hodis, 2016). Risks may still be avoided when 
efficient substitutions are indicated, such as in the case of oral estrogen replacement for the 
transdermal form in women predisposed to thromboembolism (Lobo, 2013; Mørch, Kjær, 
Keiding, Løkkegaard, & Lidegaard, 2016; Roussouw, 2002; Rozenberg et al., 2013; Sare, Gray, 
& Bath, 2008). 
Some women may still opt for alternative treatments, and the potential benefits of 
isoflavones in the health of menopausal women have attracted great attention, not only because 
they may be an alternative to hormonal therapy in the improvement of climacteric symptoms, 
but also because isoflavones can be helpful in preventing some diseases associated with the 
menopausal transition, when associated with a healthy lifestyle. To that end, effective doses of 
total isoflavones or their isolated aglycones to be used in different diseases should be better 
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defined through randomized clinical trials, which also considers the variable equol-producing 
capacity of individuals (Kucuk, 2017).  
Gut microbiota is essential for the metabolism and subsequent clinical effect of 
isoflavones. The functionality of isoflavones depends on their bioavailability and their 
conversion within the intestinal tract to metabolites more active than the aglycones forms, as 
equol (metabolite produced from daidzein), for this is important variability of the intestinal 
microorganisms. Therefore, providing specific probiotic strains capable of promoting the 
production of equol from isoflavones may potentiate the action of these phytoestrogens in the 
usual relief of climacteric symptoms and help promote complementary health improvements 
(Clavel et al., 2005; Guadamuro, Dohrmann, Tebbe, Mayo, & Delgado, 2017; Guadamuro et 
al., 2015). 
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Abstract 
Objective: This study aimed to compare the effects of a soy isoflavone phytoestrogen, and its 
association with a probiotic, on menopausal symptomatology in postmenopausal women in 
comparison to low-dose hormone therapy. 
Methods: A randomized controlled trial including 60 healthy postmenopausal women aged 40–
60 years was performed for 16 weeks. The women were randomized into three groups: 
isoflavones (150 mg/day), isoflavones plus probiotics (150 mg/day plus 2 g/day of probiotic), 
or hormone therapy (1 mg of estradiol plus 0.5 mg of norethisterone acetate). Vasomotor, 
urogenital, and psychological complaints were evaluated using the Menopause Rating Scale, 
and transvaginal sonography was performed to evaluate endometrial thickness and side effects 
associated with medications. All variables were evaluated before and after the study. 
Results: A total of 58 women (96.67%) completed the study. It was observed that 60 mg of 
total isoflavones improved somatic, urogenital, and psychological symptoms of 
postmenopausal women and the association with probiotics can optimize these results. Over 16 
weeks, menopausal complaints were evaluated by the total score of the Menopause Rating 
Scale, and delta of -10.94 (10.09) reduction was observed in the isoflavone group, followed by 
-12.95 (8.87) reduction in the isoflavone plus probiotic group, compared with the -16.42 (8.72) 
reductions in the hormone therapy group (p<0.001). The performance of isoflavones plus 
probiotic group was more favorable, possibly because of the higher bioavailability of aglycones 
achieved after biotransformation by probiotic microorganisms. 
Conclusion: This 16-week prospective study implies that isoflavones and mainly isoflavones 
plus probiotics could be used to relieve menopausal symptoms. 
 
Keywords: Menopause, Phytoestrogens, Soy isoflavones, Probiotics, Hormone therapy, 
Menopause Rating Scale 
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1. Introduction 
Menopause, a spontaneous physiological event characterized by permanent cessation of 
menstrual cycles and loss of ovarian function, typically occurs in women in their late 40s or 
early 50s.1 
Metabolic and endocrine changes occur during the menopausal period because of hormonal 
decreases and associations with aging and lifestyle.2 Hypoestrogenism causes a range of 
troublesome symptoms, such as those having vasomotor, psychological, and urogenital3 
characteristics. In menopause, decreasing secretions of the female sex hormones can predispose 
women to chronic degenerative diseases, such as osteoporosis, dyslipidemia, hypertension, and 
other cardiovascular diseases.4 Important clinical and psychic changes in the menopausal period 
cause many women to seek health services in this phase, with hot flushes being the primary 
reason for pursuing treatment during menopause.  
Although hormone replacement therapy (HT) be recommended as a first-line therapy for 
symptom relief for healthy post-menopausal women with an intact uterus, the benefits of HT 
are not risk-free for all women; and because menopausal hormone therapy failed to prevent 
clinical cardiovascular events, secondary prevention of comorbidities, as cardiovascular 
disease, is not recommended, according to results of the Women’s Health Initiative trial.5 
Adverse effects5 are associated with long-term replacement hormone therapy (HT), this 
promote phytoestrogens, like isoflavones, for alternative use in postmenopausal women to 
control and relieve climacteric symptoms, with lower incidence of adverse effects.6,7 Although 
some studies still report controversial results on the additional benefits of isoflavones for bone 
health and cardiovascular protection,8,9 these phytoestrogens have their beneficial effects on 
well-documented vasomotor symptoms. Isoflavones are chemicals similar to estrogen (17β-
estradiol) and can bind to estrogen receptors, with more affinity for a β receptor (ERβ) than an 
α receptor (ERα), promoting agonists and antagonists functions.10,11 
The flavonoids daidzin, genistin, and glycitin and their glucoconjugates are the predominant 
isoflavone forms in soybeans (Glycine max). After ingestion, glucosilated isoflavones are 
hydrolyzed by enzymes that release the aglycones daidzein, genistein, and glycitein. They may 
be absorbed or further metabolized by the gut microbiota to metabolites, such as equol and O-
desmethylangolensin (ODMA) from daidzein, and p-ethyl phenol and 5-hydroxy-equol from 
genistein. The benefits of isoflavones are associated with the biotransformation capacity of 
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these compounds by the intestinal microbiota with particular bacterial groups (e.g. lactic acid 
bacteria) involved in the metabolism of the isoflavone glycosides.12 
Therefore, the aim of the study was to compare the effects of isoflavone ingestion, associate or 
not to probiotics, to those observed for low-dose HT on the psychological, somatostatic, and 
urogenital symptoms in postmenopausal women. 
 
2. Methods 
2.1 Study design  
We conducted a single-center, prospective, 16-week, randomized controlled clinical trial 
involving postmenopausal women living around Campinas, São Paulo, Brazil. Recruitment 
started in September 2016, and follow-up began in January 2017, with the final visit completed 
in August 2017. The study was performed at the Prof. Dr. José Aristodemo Pinotti Women’s 
Hospital of the Center for Integral Women’s Health Care, CAISM/ UNICAMP, Brazil. This 
study received approval from the Human Research Ethic Committees of the Women’s Hospital 
(process number 11/2016), approval in the Research Ethics Committee (CEP, acronym in 
Portuguese) (CAAE/process number 56751216.7.0000.5404) and was registered on the 
Brazilian Clinical Trials Registry (ReBEC; RBR-83wwpx number). This  clinical  trial  was  
performed  in  accordance  with  the  Consolidated  Standards of Reporting  Trials  2010  
statement  (CONSORT).   
In total, 300 women responded to local advertisements of the study on social networks, email 
and phone. Among that, 176 accepted to participate in a screening visit for eligibility through 
exclusion and inclusion criteria, received clarification about the study, and provided informed 
consent (Figure 1). Inclusion criteria for the study consisted of women aged 40–60, without 
spontaneous menstruation for at least 12 months, follicle stimulating hormone values >40 
mUI/mL, and the symptoms of estrogenic deprivation referred to in Menopause Rating Scale 
(MRS), such as hot flashes, vaginal dryness, decreased libido, insomnia, fatigue and joint pain.3 
The age range was specified the 40 to 60 years of age to ensure that women were just entering 
menopause, extremely symptomatic, as well as those who had been through, with later 
manifestations such as urogenital signs and symptoms, it could be studied. Assuming a 
homogeneous group for climacteric symptomatology, we recruit a representative group of 
women in menopause experience. 
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The exclusion criteria consisted of a history of chronic diseases such as type 2 diabetes, 
cardiovascular, or gastrointestinal diseases; contraindication to the use of HT; intolerance to the 
use of probiotics; bariatric surgery; previous hysterectomy; use of medications such as oral 
contraceptives, HT, antibiotics, or lipid-lowering agents within the last 6 months, as well as 
those not in accordance with the Free and Informed Consent Form. Sixty women were selected 
to participate in the study and one-hundred and sixteen were excluded, because they do not fit 
in the profile, decline participation or other reasons. 
 
Figure 1. Flowchart of the study. 
 
 
2.2 Protocol 
After the screening visit and recruitment, participants were randomized by computer 
randomization into three groups assigned to receive: 1) isoflavones, Soyfemme, Aché 
pharmaceutical laboratory®, one capsule of 150 mg/day. The physical characteristics of the 
drugs were divergents (gelatinous capsules - Soyfemme®; powder - Simfort® and tablet - 
Suprelle®), therefore the study cannot be double blind. 
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This phytoestrogen is commercially available as capsules containing 150 mg dry extract of 
Glycine max, standardized to 60 mg of total isoflavones; 2) Isoflavones, one capsule of 150 
mg/day, associated with one sachet of probiotic product, Simfort, Vitafor®, product chosen by 
provide an high isoflavone biotransformation and equol-producing lactic acid bacteria-
containing composition, comprising Lactobacillus acidophilus, Lactobacillus casei, 
Lactococcus lactis, Bifidobacterium bifidum and Bifidobacterium lactis, commercially 
available at a dose 1.109 UFC/g of product, was offered 1 sachet  (2 g) to be mixed with 100 ml 
of water; or 3) Hormone therapy, Suprelle, Biolab Sanus®, one tablet daily of estradiol (1 
mg/day) associated with norethisterone acetate (0.5 mg/day).  
Medications was ingested once a day, at same time every day, and adherence were evaluated 
by collecting the empty packages of the products in T60 and T120 visits. At the first visit 
(baseline) and final visit (after 120 days) of the study, personal data (e.g.: age, time of 
menopause, parity, marital status, social class and ethnicity) were collected, and clinical and 
anthropometrical parameters were determined. Simultaneously, the Menopause Rating Scale 
(MRS) was determined, considering several menopausal complaints, was determined in all 
visits (T0, T60 and T120). In addition to outpatient consultations (visit 1-3), there were two 
reassessments through telephone contact, to obtain information about adherence to treatment, 
possible side effects that have arisen, clarification of doubts and appreciation of the participant's 
comments, according to the scheme in Figure 2: 
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Figure 2. Clinical trial timeline and activities completed at each visit.   
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Considering hormone therapy as the gold standard method for the treatment of vasomotor 
symptoms during menopause, this group was used as a control group over the use of the 
placebo group. 
 
2.3 Measurements 
2.3.1 Symptomatology of menopause and side effects 
Personal data and menopausal symptoms were collected through personal interviews 
conducted by authors NESM and AER. Composed of 11 items evaluating the menopause 
symptoms, divided into three subscales (somatic, psychological, and urogenital 
symptoms), the climacteric symptoms were evaluated using the MRS, a formally and 
validated instrument with a Portuguese version, developed in Brazil following 
international methodological recommendations, respecting the patient’s culture, 
language, and social status.13 Each item was graded by the participants at 0 (absent), 1 
(light), 2 (moderate), 3 (severe), and 4 (very severe). The total MRS scores range from 0 
to 44 and are composed of the sum of each item within the subscale. 
In the baseline and throughout the study the women were assessed using a trial data 
collection form prepared to investigate the side effects of the interventions. Side effects 
were analyzed according to the occurrence or exacerbation of an adverse event during the 
treatment period, in the cases where the event was already present prior to admission to 
the study, either persisted unchanged or improved within the treatment period, it was not 
considered side effect.22 Apart from the comparison of means, we calculated the relative 
improvement compared with the situation before and after therapy for the subdomains of 
the MRS scale, through the delta difference. 
 
2.3.2 Measured variables 
During the follow-up visits (Figure 2) was collected the ensuing information on medical 
history, demographic characteristics, and anthropometric parameters: Age, in full years, 
referred to in the first consultation; Time of menopause, in months, elapsed between the 
date of the last menstruation and the time of the interview; Body fat percentage, measured 
with dual energy x-ray absorptiometer (DEXA); Weight gain defined as weight increase 
of >3% of body weight; Clinical co-morbidities, defined as the co-occurrence of two or 
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more disorders in the same individual at the same point in time (not included in the 
screening checklist); Smoking defined as smoking vs. never smoker; Physical activity, 
defined as yes, when there was least 150 minutes of moderate-intensity aerobic physical 
activity throughout the week or do at least 75 minutes of vigorous-intensity aerobic 
physical activity throughout the week and defined as no, when these criteria have not been 
met. 
 
2.4 Phytoestrogen characterization: Chromatographic profiles and antioxidative capacity 
2.4.1 Chemicals and samples 
Standard reference compounds of the aglycone isoflavones daidzein, genistein, glycitein 
and the flavonoid quercetin, used as an internal standard; Codein-d3 used as a calibration 
curve; gallic acid, Folin–Ciocalteu reagent, and N,O-bis(trimethylsilyl) 
trifluoroacetamide with trimethylchlorosilane with 1% trimethylchlorosilane (BSTFA) 
were purchased from Sigma–Aldrich (St. Louis, MO, USA). Ethyl acetate, 
dimethylformamide (DMF) was purchased from Sinergia (Campinas, SP, Brazil). All 
chemicals used were of an analytical grade. Soyfemme® phytoestrogen and Suprelle® 
hormone therapy was a kindly donated by Aché and Biolab Sanus, pharmaceuticals 
laboratories, respectively (São Paulo, SP, Brazil). The Simfort® probiotic was purchased 
through project resources. 
 
2.4.2 Determination of main compounds in phytoestrogen by gas chromatography 
coupled with mass spectrometry 
A Shimadzu gas chromatography (GC) QP 2010S, equipped with a Restek® RTX-5 fused 
crossbond 5% diphenyl, 95% dimethyl polysiloxane column (30 m, 0.25 mmID, 0.25 
umdf). The injector was set at 275 ºC and the detector at 290 °C, in splitless mode. GC 
conditions were set with a programmed oven temperature of 80 °C, held here for 0.1 min, 
then ramped to 245°C at a rate of 25 °C/min, held for 25.5 min and then raised to 270°C 
by 60 °C/min and held for 8 min; with carrier gas (helium) flow rate at 0.5 mL/min. The 
split vent was set at 30 mL/min and the septum purge was set at 1 mL/min. Mass 
spectrometer identification was performed in the single-ion monitoring (SIM) mode to 
quantification, using the following ions: 398 m/z for daidzein, 471 m/z for genistein, 428 
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m/z for glycitein and 647 m/z for quercetin (internal standard; IS), according to Deng and 
Zito.14 
 
2.4.3 Sample preparation, derivatization and analysis 
Samples of commercial phytoestrogen (Soyfemme®), weight of a single dose from 3 
batches, were weighed in a 15 mL centrifuge tube and hydrolyzed with 5 mL of 1 N HCl 
in 20% of methanol. The solution was then sonicated for 15 min at ambient temperature 
and heated at 85°C for 1 h in a wet bath. Thereafter, 5 mL of ethyl acetate was added and 
vortexed for 1 min followed by sonicating for 5 min, and then centrifuged for 10 min at 
5000 rpm. In the next step, in a vial 50 µL of the organic phase (supernatant) was taken 
for derivatization using 250 µL DMF and 250 µL of BSTFA + 1% trimethylchlorosilane 
with 50 µL of the IS quercetin (0,1 mg/mL). The mixture was heated at 115°C for 45 min 
in a drying oven and 1 µL of the derivatized sample was injected with GC/MS 
quantification.14 Codein-d3 was used as a standard in the calibration curve, plotted in a 
concentration range of 100–1000 µg/mL, when R2 = 0.9992, and the isoflavones detected 
and quantified were the aglycone isoflavones daidzein, genistein, glycitein, and quercetin 
(IS), by plotting the values in the analytical curve, followed by adjusting the sample 
dilution by means of formula: Concentration (µg /mL) = value in the curve/10000) × 200. 
 
2.4.4 Total phenolic content 
The total phenolic content (TPC) of the extracts prepared according Deng and Zito14, was 
measured after hydrolysis using the Folin–Ciocalteu assay according to Singleton et al. 
(1998). Gallic acid was used as a standard, and a calibration curve was plotted in a 
concentration range of 16–300 µg/mL. All analyses were performed in triplicate, and the 
results were expressed as µg of gallic acid equivalents (GAE)/mL of extract.15,16 
 
2.5 Statistical analysis  
The description of categorical variables was performed by Chi square test, followed by 
Fisher test, when necessary. Numerical variables were compared with Kruskal-wallis test, 
followed by post hoc test of Dunn. In longitudinal comparisons of numerical variables, it 
was used ANOVA for repeated measurements, with variables transformed into ranks due 
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to non-normal distribution, followed by mix model. The level of significance adopted for 
this study was 5%, and statistical analysis were performed using software SAS 9.4. 
In order to calculate the sample size, 16 patients per group were considered to detect 90% 
confidence in the treatment of 3 hot flushes per 24 hours, assuming a standard deviation 
of 3.8 hot flushes per day17. The test was performed with significance level of α 0.05 and 
β 0.05 and based on the study of Albertazzi et al.18 and as described by Carmignani et 
al.19 
Table 1. Calculation for the sample size according to α and β. 
f (α e β) β = 0,20 β = 0,15 β = 0,10 β = 0,05 
α = 0,01 14 16 18 21 
α = 0,05 10 11 13 16 
α = 0,10 8 9 10 13 
Twenty percent were added to the total number of 16 patients, totaling 20 patients per 
group due to possible follow-up losses. 
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3. Results 
3.1 Phytoestrogen characterization 
3.1.1 Chromatographic profile of phytoestrogen after hydrolysis. 
Figure 3 shows the chromatographic analysis of phytoestrogen, in which it was identified 
and quantified as the aglycones daidzein, genistein, and glycitein, which are attributed to 
their ability to modulate vasomotor symptoms. 
 
 
Figure 3. Chromatogram (GC/MS) of phytoestrogen (Soyfemme - Ache®) per capsule 
offered to women (Peaks: 1- Daidzein; 2- Genistein; 3- Glycitein; 4- Quercetin (added as 
internal standard at concentration of 0,1 mg/ml). 
 
Linear calibration curves of codeine-d3 standard, prepared with six-point 
calibration, were obtained in the concentration range of 100–1000 µg/mL, with R2 = 
0.9992, equation of the line equal to y = 5162,5x-445387 and quercetin was added as an 
IS in a concentration of 0.1 mg/mL, to test recovery and extraction efficiency. Table 2 
contains information about the analysis of commercial phytoestrogen, that showed 
aglycone isoflavones in a range of 46.10–51.40 mg, with glycosylated isoflavones in a 
range of 8.6–13.90 mg, estimated by difference in relation to total isoflavones that is 
presented in the product monograph. The isoflavone daidzein was found to be in major 
quantity, ranging from 24.61 to 31.61 mg, whereas the other aglycones genistein and 
95 
 
glycitein were found in smaller amounts, ranging from 9.60 to 14.38 mg and 7.10 to 10.19 
mg, respectively. The quantification agrees with the manufacturer requirements, that 
mentions 60 mg of total isoflavones in the product label (150 mg dry extract of Glycine 
max), analyzed by high performance liquid chromatography (HPLC). 
Table 2. Content of aglycones isoflavones in commercial product phytoestrogen after 
hydrolysis. 
Isoflavone m/z Mean variation (mg) 
Daidzein 398.00 24.61 -  31.61 
Genistein 471.00 9.60 - 14.38 
Glycitein 428.00 7.10 - 10.19 
Total aglycone isoflavone (mg/capsule)  46.10 – 51.40 
 
3.1.2 Total Phenolic Content 
The total phenolic content (TPC) of phytoestrogen Soyfemme® are presented in Table 3. 
The extracts analyzed were prepared with a hydrolysis step14. 
Table 3. In vitro antioxidant capacity of different capsules of phytoestrogen. 
Sample Absorbance 1 Absorbance 2 Absorbance 3 Absorbance 
Mean (SD) 
µgGAE/mL 
(p=0.9113) 
1 0.51947 0.52128 0.52285 0.52 (0.0017) 122.34 
2 0.52931 0.53225 0.53225 0.53 (0.0017) 124.73 
3 0.51905 0.52315 0.5249 0.52 (0.0030) 122.75 
4 0.54644 0.55362 0.55513 0.55 (0.0046) 129.37 
5 0.56583 0.56676 0.56877 0.56 (0.0015) 132.23 
6 0.53317 0.53379 0.53594 0.53 (0.0015) 125.06 
Values are expressed as mean ± SD (n = 6). Values no differ at p<0.05 by ANOVA test. 
 
The commercial phytoestrogen presented the TPC from 122.34 to 132.23 µgGAE/mL 
was determined by Folin-Ciocalteu assay. All analyses were performed in triplicate and 
the results were expressed as means of µg of gallic acid equivalents (GAE)/mL of extract, 
from the same batches offered to the participants. The total detectable phenolic average 
content of the samples were of 126.08±3.91 µg of GAE/mL. 
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3.2 Characterization of the population 
The baseline characteristics of the participants are presented in Table 4, based on the 
intervention group. No significant differences were observed between the groups. The 
average age was 52.4 (±3.3) years. Women were on average 46.6 (±44.0) months 
postmenopause, and the mean age at menopause was 48.6 (±3.8) years.  
The study population was homogeneous in relation to the age, age at menopause and time 
after menopause. The three groups were homogeneous for most population 
characteristics, except by HT group participants that had a higher social class (p = 0.03) 
and the majority were non-smokers (p = 0.04), providing greater reliability of intragroup 
and intergroup comparisons. The groups were similar at baseline in relation to total MRS 
and subscales (Table 4). 
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Table 4. Distribution and characterization of the study population regarding socio-
demographic reproductive variables, health conditions and baseline climacteric 
symptomatology. 
  Groups   
 ISO 
 (n=19) 
ISO+PROB 
 (n=20) 
HT 
 (n=19) 
p-value 
Age (years) Mean (SD) 53.05 (3.39) 52.00 (3.04) 52.21 (3.41) 0.55α 
Menopause age (years) 
Mean (SD) 
49.42 (3.67) 48.40 (2.84) 47.89 (4.81) 0.47α 
Time of menopause 
(months) Mean (SD) 
44.68 (35.81) 43.25 (25.58) 51.89 (70.68) 0.30α 
Numbers of pregnancies 
Mean (SD) 
2.47 (1.65) 2.75 (1.29) 2.21 (1.23) 0.55α 
Body fat (%) 38.52 (3.88) 37.34 (6.13) 38.72 (4.84) 0.61α 
Educational level (%)    0.68b 
<4 years of study 15.79 35.00 21.06  
>4 years of study 84.21 65.00 78.94  
Ethnicity (%)    0.16c 
    White 57.89 50.00 78.95  
    Not white 42.11 50.00 21.05  
Social class (%)    0.03c 
A 47.37 40.00 78.95  
B/C 52.63 60.00 21.05  
Marital status (%)    0.42c 
With partner 36.84 45.00 57.89  
Without partner 63.16 55.00 42.11  
Clinical co-morbidities (%)     
None 63.16 60.00 73.68 0.64c 
Yes 36.84 40.00 26.32  
Smoker (%)    0.04c 
Smoking 52.63 45.00 15.79  
Never Smoked 47.37 55.00 84.21  
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Physical activity (%)    0.14c 
Yes 47.37 45.00 73.68  
No 52.63 55.00 26.32  
MRS somatic subscale  
at baseline (mean±SD) 
8.42 (3.66) 9.65 (4.08) 8.47 (2.80) 0.59a 
MRS psychologic subscale 
at baseline (mean±SD) 
8.84 (4.63) 8.10 (4.01) 9.63 (4.69) 0.54a 
MRS urogenital subscale 
at baseline (mean±SD) 
3.00 (3.04) 4.70 (3.48) 4.95 (3.54) 0.14a 
Total MRS subscale  
at baseline (mean±SD) 
20.26 (8.54) 22.45 (8.69) 23.05 (9.72) 0.70a 
ISO:Isoflavone; ISO+PROB:Isoflavone plus probiotic; HT: Hormone therapy. Data were 
expressed as means ± SD or percentage (%). α Kruskal-Wallis non-parametric test; b Chi 
square test; c Fisher’s exact test (p<0.05). 
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3.3 Menopause Rating Scale 
The mean score of menopausal symptoms as assessed by the MRS are shown in Table 5. Isoflavones caused a progressive decrease in somatic 
symptoms (8.42±3.66 at baseline to 3.00±3.82 after 120 days, p=0.046), although not comparable to the control (8.47±2.80 at baseline to 2.16±2.17 
after 120 days of study). When compared to the other groups, hormonal therapy was more effective to urogenital symptoms control (p=0.001). 
 
Table 5. Means (Standard Deviation) score of Menopause Rating Scale and delta variation according to the treatment group. 
 Groups  
 ISO (n=19) ISO+PROB (n=20) HT (n=19) ¥ ANOVA 
Days T0 
Mean 
(SD) 
T60 
Mean 
(SD) 
 
T120 
Mean 
(SD) 
Delta 
(Δ) 
T0 
Mean 
(SD) 
T60 
Mean 
(SD) 
T120 
Mean 
(SD) 
Delta 
(Δ) 
T0 
Mean 
(SD) 
T60 
Mean 
(SD) 
T120 
Mean 
(SD) 
Delta 
(Δ) 
p# 
 
p$ p& 
Somatic 
subscale 
8.42 
(3.66) 
4.63 
(4.28) 
3.00 
(3.82) 
-5.41 
(3.18) 
9.65 
(4.08) 
4.50 
(2.96) 
3.63 
(2.71) 
-6.21 
(3.75) 
8.47 
(2.80) 
2.16 
(2.12) 
2.16 
(2.17) 
-6.32 
(3.42) 
0.18 <0.001 0.06 
Psychological 
subscale 
8.84 
(4.63) 
4.21 
(3.52) 
4.18 
(4.60) 
-4.88 
(5.96) 
8.10 
(4.01) 
4.70 
(3.11) 
3.11 
(2.56) 
-5.11 
(4.29) 
9.63 
(4.69) 
3.16 
(3.86) 
2.21 
(2.74) 
-7.42 
(4.57) 
0.55 <0.001 0.17 
Urogenital 
subscale 
3.00 
(3.04) 
3.21 
(2.80) 
2.24 
(2.54) 
-0.65 
(2.76) 
4.70 
(3.48) 
3.10 
(2.81) 
3.05 
(2.20) 
-1.63 
(3.52) 
4.95 
(3.54) 
2.58 
(2.93) 
2.26 
(2.45) 
-2.68 
(2.87) 
0.57 <0.001 0.04 
Total score 20.26 
(8.54) 
12.05 
(8.55) 
9.41 
(9.36) 
-10.94 
(10.09) 
22.45 
(8.69) 
12.30 
(7.12) 
9.79 
(5.73) 
-12.95 
(8.87) 
23.05 
(9.72) 
7.89 
(7.77) 
6.63 
(6.05) 
-16.42 
(8.72) 
0.38 <0.001 0.09 
¥Repeated measures ANOVA. Variables transformed into ranks in the analyzes due to the absence of normal distribution. # Comparison between groups, $ 
Comparison between time-points (T0, T60 and T120/days), & Group-time interaction. 
Delta (Δ): difference between baseline and final time intervention (T120-T0). 
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3.4 Side effects 
Statistically significant differences in the adverse effects evaluated were observed for mastalgia and bleeding, only for post-intervention analysis 
in the HT group. Mastalgia, bleeding and nausea were more frequent at time T60 in the studied population. Other side effects did not demonstrate 
statistical differences among the three treatment groups before or after intervention. 
 
Table 6. Percentage distribution of side effects during the treatment period, according to n of women available for analyses (Chi square test or 
*Fisher’s test, p<0.05). 
 ISO ISO+PROB HT p-value 
 n % n % n %  
Mastalgia (n=54) 3 18.75 3 15.79 12 63.16 0.0028 
Bleeding (n=55) 0.0 0.0 0.0 0.0 9 47.37 <.0001 
Skin allergy (n=55) 1 5.88 3 15.79 3 15.79 *0.68 
Headache (n=56) 2 11.11 3 15.79 4 21.05 *0.89 
Nausea (n=56) 1 5.56 1 5.26 7 36.84 *0.01 
Flatulence (n=56) 7 41.18 4 20.00 6 31.58 0.37 
Diarrhea (n=55) 3 17.65 1 5.26 2 10.53 0.49 
Intestinal constipation (n=55) 4 23.53 3 15.79 7 36.84 *0.34 
Weigh gain (n=55) 5 27.78 1 5.56 4 21.05 *0.23 
Edema (n=57) 4 22.22 3 15.00 4 21.05 *0.84 
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Figure 4. Endometrial thickness (ET) (mm) evaluation in uterus of menopausal women 
before (T0) and after intervention (T120). Graphic subtitle: white bar= Isoflavone (n=19); 
gray bar= Isoflavone with probiotics (n=20), black bar= Hormone therapy (n=19). Data 
expressed as Mean ± SD, Mann-whitney test, p<0.05.  
Endometrial thickness (Figure 4) was used as a safety criterion, and no statistically 
significant differences in endometrial thickness were found between the three groups at 
baseline or after 16 weeks of treatment. Comparative analyzes between groups 
(p=0.3048), time points (p=0.4786) and group-time interaction (p=0.1707) demonstrated 
non-significant variations. 
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4. Discussion 
This study compared the effects of isoflavones, their association with  
probiotics and HT for the relief of menopausal symptoms. Although HT has been 
considered the most effective treatment for relief climacteric symptoms, our findings 
show that isoflavones plus probiotics and isoflavones alone were also effective in 
improving climacteric symptoms, for all subscales of MRS, with different magnitude 
effect among treatment. The total, psychological, somatic, and urogenital scores were 
significantly different (p<0.001) over time, with a delta difference and percent of change 
before and after intervention that demonstrated the effectiveness of the three treatments 
in relieving climacteric symptoms.  
The association of specific probiotics strains with isoflavones may reduce the incidence 
of somatic, psychological, and urogenital symptoms, more prominently than 
phytoestrogen alone; being an interesting alternative to hormone therapy. These results 
are attributed to the ability of lactic acid bacteria to modulate the intestinal microbiota 
increasing the bioavailability and bioactivity of these isoflavones.20,21 
Moreover, an adequate profile of aglycone isoflavones was offered to participants as 
shown in Figure 3, which shows a separation of the aglycones daidzein; genistein; 
glycitein; and quercetin, an internal standard (IS) added at the beginning of the analysis 
to monitor the extraction process. These compounds were identified by comparing their 
retention times and mass spectra with those of purchased standards. The phytoestrogen 
used in this study, as well as most products of this class, had its concentration of 
isoflavones expressed as total isoflavones per dosage in the label form, without 
specifications related to the aglycone profile. A chromatographic analysis of this 
phytoestrogen showed a profile characterized by a small amount of glycitein and high 
levels of daidzein and genistein, in addition to a plot of glycosides that required 
deconjugation to release the bioactive aglycones, as also reported by Uifalean et al.22 
Several studies on climacteric symptoms, in which isoflavones had inconclusive results 
or insufficient evidence on the effectiveness, mainly in vasomotor symptoms, do not 
demonstrate the chromatographic profile of the phytoestrogen used, and the low 
concentration of aglycones may be a limiting factor for these studies. This was also 
discussed by Li et al,23 which may lead to inconclusive or unsatisfactory results for 
isoflavones in relieving menopausal symptoms.9,24,25 
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Although soy isoflavones may require more time to achieve their maximum effects 
compared with HT,23 it is known that most significant effects on the relief of menopausal 
symptomatology occurred within the initial short period of isoflavone exposure, typically 
within 12 weeks of treatment19,26,27. With shorter effective times already reported,28,29 it 
is important to consider the isoflavone dose used, for adequate efficacy and safety. In our 
study, the 16-week period of intervention was satisfactory to observe the climacteric 
symptoms relief. 
Isoflavones are recognized by their antioxidant capacity, and the phytoestrogen analyzed 
in this study had an important total phenolic content (TPC). Table 3 shows levels of 
122.34–132.23 µg GAE/mL of extract prepared according Deng and Zito14. The TPC was 
similar to that found in soy milk, as illustrated by Queirós et al,30 who reported a 
considerable increase in the content of phenolics and the antioxidative capacity of soy 
extracts after the biotransformation process with probiotic lactic bacteria, starting from 
101 µg of catechin/mL in soymilk to 254 µg of catechin/mL in fermented soymilk. This 
demonstrates that isoflavones have some antioxidative capacity, but possibly may 
become better when biotransformation by probiotics, basing our hypothesis of association 
between probiotics and isoflavones. 
Isoflavones aglycones daidzein and genistein have important estrogenic and 
antiestrogenic properties. Both isoflavones have molecular structures, resembling that of 
17β–estradiol and binds to the same estrogen-receptors (ERα and ERβ) in a dose-
dependent manner. Daidzein is more bioavailable than genistein, and the longer half-life 
in the intestine favors gut microbial bioconversion to bioactive metabolites, such as equol, 
while genistein degrades about twice as fast and is less absorbed.31 Jou et al32 reiterated 
the importance of biotransformation of isoflavones with a 6-month intervention study that 
used 135 mg/day isoflavones (65.4 mg/day daidzein aglycone equivalents, 17.1 mg/day 
genistein aglycone equivalents) and only in the equol producers, the treatment improved 
menopausal symptoms. Possibly the optimal performance of the ISO+PROB group in the 
improvement of the clinical symptoms can be attributable to the modulation of the gut 
microbiota promoted by probiotics. 
The use of aglycone forms and their adequate dosages are fundamental for consistent 
results. Hirose et al33 conducted a study to verify the effects of ultra-low (12.5 mg/day) 
and low dose (25 mg/day) of isoflavone aglycones, derived from soybeans, on the 
menopausal symptoms of middle-aged women, compared with a placebo. The most 
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remarkable results were the significant improvements in psychological symptoms, such 
as depression and insomnia with the use of the low dose isoflavone, but there was no 
significant improvement in vasomotor symptoms. The isoflavones were administered 
only in aglycone forms, which is absorbed faster and in greater amounts than the 
glucoside form, and was rich in genistein, which has higher estrogenic activity than 
daidzein and other phytoestrogens. Other studies have also suggested that isoflavones 
alleviate and control psychological symptoms associated with menopause.34,35 In contrast, 
Crawford et al7 who tested a high isoflavone dose (100 and 200 mg/day) found a greater 
percentage of reduction in vasomotor symptoms. In our study, aglycone isoflavones were 
administered, with a median total dose (60 mg/day) and supplement rich in daidzein, 
which is more bioavailable than genistein, and produces metabolites with a higher 
estrogenic potency, which may have contributed to improvement in all MRS subscales. 
Significant declines in the mean scores were observed after treatment, being indicative of 
improvement. In this study, the comparison of isoflavone, isoflavone with probiotic and 
hormone therapy allowed to observe that for the somatic, psychological and urogenital 
symptoms, isoflavone have improved symptoms over time, but still lower than hormone 
therapy. Considering that clinical improvement with a placebo is nearly 30% and that an 
improvement of ≥50% classifies an individual as a responder to treatment,36 it can be 
considered that in this study, there was a significant improvement in all groups. An 
important decrease was observed on vasomotor symptoms (somatic subscale) in 
participants who used isoflavones, indicated by delta -5.41 (±3.18), but association of 
probiotics to isoflavone increased the effectiveness of this phytoestrogen for this subscale 
(difference of the delta -6.21 (±3.75), demonstrating that ISO+PROB group presented 
lower score of vasomotor symptoms. In somatic symptoms, hormone therapy, with a delta 
of -6.32 (±3.42), was effective as phytoestrogens associated to probiotics.  
The literature supports these findings, as Cheng et al4 rated 51 healthy postmenopausal 
women who received 60 mg isoflavones or placebo daily for 3 months. The results 
demonstrated that hot flashes and night sweats were reduced by 57% and 43%, 
respectively. Similarly, a dietary supplementation of isolated daidzein (40–60 mg/day) 
significantly decreased the hot flash frequency in the study by Khaodhiar et al,37 with hot 
flashes frequency reduced by 43%–52% from the 8  to 10 weeks, compared with a 32%–
39% change in the placebo group.  
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In psychological subscale, which addresses mood swing and insomnia complaints, 
significant improvement was observed in isoflavone with delta of -4.88 (±5.96), and 
isoflavone with probiotics with delta of -5.11 (±4.29) from baseline. Although hormone 
therapy with a delta of -7.42 (±4.57), still achieves superior improvement, it can be seen 
that the addition of probiotics also brought benefits for these symptoms. Psychological 
symptoms may originate from vasomotor symptoms, through so-called domino effect, 
but it is also known that ERβ mediate estrogen-anxiolytic function in the central nervous 
system; isoflavones are anxiolytic compound and have higher affinity to ERβ, which 
justifies the effectiveness of these phytoestrogens for psychological symptoms.38 
Urogenital symptoms, such as vaginal dryness, urinary complaints, and sexual problems, 
are common during the menopausal period. Mittal et al39 evaluated the effect of soy 
isoflavones (75 mg/day for 12 weeks) using the Menopause Symptom Score with 
significant decreases from baseline (12.47 ± 8.15) to 9 and 12 weeks (9.35 ± 5.23 and 
9±5.14, respectively; p=0.004), with significant improvement in urogenital symptoms 
compared with the placebo. In accordance with these evidences, a systematic review 
conducted by Hanson et al,40 determined the efficacy of probiotics (Lactobacillus ssp.) 
for the prevention and treatment of urogenital infections in adult women, including 
menopausal women, demonstrating probiotic intervention as effective in the treatment 
and prevention of bacterial vaginosis, recurrences of candidiasis and urinary tract 
infections, which are frequent in postmenopausal women. 
Similarly, in our study, the isoflavones and isoflavones with probiotics exerted an 
estrogenic action on the urogenital tract, attenuating urogenital symptoms (difference 
delta before and after treatment was -0.65 ± 2.76 and -1.63 ± 3.52, p=0.048 for group-
time interaction, respectively), demonstrating the benefits of probiotics when added to 
phytoestrogens and their possible use for the prevention or co-treatment in menopausal 
urogenital complaints. Another study previously conducted by our group41 demonstrated 
that dietary soy supplement, containing soy protein and isoflavones, used for 16 weeks 
fails to exert an estrogenic action on the urogenital tract but improved vaginal dryness. 
The best results achieved in the actual study may be attributed to the use of isoflavone 
aglycones, not complexed with proteins, and the association with probiotics.42 
The adverse effects were more frequent in the hormone therapy group. Usually 
isoflavones possess satisfactory acceptability and are associated with few side effects; 
they are beneficial in the gastrointestinal system, while HT includes bleeding, mastalgia 
106 
 
and nausea as the main adverse effects. Thus, these findings were in accordance with the 
literature.19,43 
Endometrial thickness did not change in all three groups. Quaas et al44 attributes the 
endometrial safety of isoflavones to the differentiation of estrogen receptors because in 
the uterus, the main receptor is ERα, and isoflavones action is predominantly on ERβ. 
The duration of the intervention and follow-up of 16 weeks were effective and consistent 
with previous studies and recommendations41,45. To date, this is the first study to evaluate 
the relief of climacteric symptomatology in Latin American women comparing HT to 
isoflavones, independently of their association with probiotics, for modulating the 
intestinal microbiota to biotransform isoflavones and increase their bioavailability. 
However, future studies that evaluate the association of isoflavones with probiotics, 
correlating equol production and vasomotor symptoms, may contribute to the data found. 
 
5. Conclusion 
In the 16 weeks of treatment with isoflavones, isoflavones associated with probiotics, and 
HT, it was observed that all three treatments were effective to improve menopausal 
symptoms (somatic, psychological and urogenital), but with differences with respect to 
the magnitude of efficacy. For women who choose not to take HT, the isoflavone and 
isoflavones plus probiotics may be an effective treatment, including fewer side effects. 
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Abstract 
Objective: Evaluate the influence of isoflavone associated or no to probiotics on the 
improvement of metabolic profile in postmenopausal women compared to hormone 
therapy, on habitual dietary intake. 
Study design: A randomized, controlled trial with sixty healthy postmenopausal women 
of 40-60 years of age was performed. The women were allocated to use phytoestrogen 
(ISO) (containing 60 mg of isoflavone/capsule), phytoestrogen associated to probiotics 
(ISO+PROB) (2 g of probiotics product containing Lactobacillus and Bifidobacterium 
strains or hormone therapy (HT) (1 mg estradiol and 0.5 mg norethisterone acetate). 
Biochemical tests of glycemia, insulin, total cholesterol, HDL, LDL, triglycerides, 
estradiol and FSH were assessed at baseline and after 16 weeks of treatment, as well as 
the production status of urinary equol. Over the study, dietary assessment was performed 
by a mean of three-day food records in allowing the estimation of energy, carbohydrate, 
total fiber, protein, cholesterol, total fat, saturated fatty acids (SFA), monounsaturated 
fatty acid (MUFA) and polyunsaturated fatty acids (PUFA) intake. Food consumption 
frequency questionnaire (FFQ) was used to access average phenolic intake. Statistical 
analyses were carried out using the chi-square test, Fisher’s exact test, the Kruskal–Wallis 
non-parametric test and analysis of variance (ANOVA). 
Results: No statistically significant differences were found between the groups with 
respect to baseline clinical and sociodemographic characteristics. Comparison between 
groups revealed a non-statistically significant improvement in glucose, insulin, total 
cholesterol, HDL-c, LDL-c and triglycerides when isoflavone or isoflavone plus probiotic 
are used, but an important decrease in total cholesterol (p=0.0077) and LDL-c (p=0.0102) 
was observed in HT group. The average consumption of total polyphenols/portion (mg) 
was 43.23 mg in ISO group, 100.75 mg in ISO+PROB group and 57.52 mg in HT group 
participants. The concentrations of equol (ug/mL) among groups over time were 7.69 
µg/ml in ISO group, 7.39 µg/ml in ISO+PROB group and 2.46 µg/ml in HT intervention 
(p=0.005). 
Conclusion: Hormone therapy may constitute a good therapeutic approach in 
postmenopausal women with dyslipidemia, in detriment to the use of phytoestrogens. 
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1.Introduction 
Hormone replacement therapy is often prescribed to relieve the symptoms 
associated with menopause.  However, it causes some unwanted side effects, leading to 
low adherence.  Phytoestrogens may be an alternative treatment that leads to fewer 
unwanted symptoms, and association with probiotics (i.e. live micro-organisms) may 
positively modulate the gut microbiota to prevent or treat some diseases and to potentiate 
isoflavones benefits in menopausal women [1,2]. The climacteric is an endocrinological 
transition that occurs naturally in women during their late 40s or early 50s, and the 
menopause marks the end of phenomenon and of female reproductive life. Menopause is 
confirmed after 12 months of amenorrhea, which occurs after a significant drop in the 
levels of estrogen and progesterone [3-5]. 
More than a third of woman’s life occurs after climacteric period.  This stage 
of life is also frequently associated with vasomotor, urogenital and psychological 
symptoms that can compromise the quality of life of the woman and the people around 
her [6]. In addition to these symptoms, other serious medical concerns related to 
menopause may adversely affect the postmenopausal women, leading to increases in 
weight, blood pressure, cholesterol and glycose levels. In the climacteric phase, women 
are also more predisposed to comorbidities, such as osteoporosis and cardiovascular 
disease, all of which can significantly compromise her health during this time [7,8]. 
Hormone replacement therapy (HRT) is recommended for the relief of climacteric 
symptoms, with approximately 50% of women initiating HRT because of 
symptomatic hot flashes [9].  Hormone replacement is also important for preventing or 
treating menopause-related comorbidities [10,11]. Despite its advantages, there is often a 
low long-term adherence to hormone therapy, with 70% of women discontinuing 
treatment after the first year [12]. 
There are several reasons for this lack of long-term adherence, including 
vaginal bleeding, mastalgia, recurrent headaches, water retention, and even fear of breast 
cancer.  Support from healthcare professionals influences the average duration of HRT 
and extensive medical care promotes better compliance, so that women overestimate the 
risks and contraindications, and underestimate the impact of menopausal symptoms on a 
woman’s quality of life [13]. For women who have no indication for or interest in taking 
hormone therapy, phytoestrogens may be an alternative treatment. 
114 
 
Phytoestrogens are non-steroidal estrogenic compounds-groups found in a 
wide variety of vegetables foods, of which isoflavones are one of the most widely 
researched categories. Isoflavones are diphenolic compounds with estrogenic activity, 
chemically similar to endogenous estradiol (E2), able to bind to both estrogen receptors 
(ER), with greater affinity for the β receptor than for the α receptor, and normally found 
in vegetables in esterified forms (i.e. malonyl glucoside, acetyl glucoside or glucoside). 
The polar form of these glycosides doesn’t cross cellular membrane by passive diffusion, 
so the biologically active aglycones can be made by hydrolytic enzymes, from probiotic 
strains [14,15]. 
As well as hormone replacement therapy, isoflavones also are associated with 
a reduced risk of menopause-related chronic diseases, by producing a significant 
reduction in insulin resistance, hyperinsulinemia and visceral fat and better management 
of weight, hypertension and diabetes mellitus [16-18]. 
In this context, the aim of the present study was to investigate the influence 
of isoflavones associated or not associated with probiotics on the improvement of 
metabolic profile in postmenopausal women, compared to standard hormone therapy, on 
daily dietary intake. 
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2.Methods 
2.1 Subjects 
This randomized controlled trial was carried out at the Women’s Integrated 
Healthcare Center of the University of Campinas, Campinas, São Paulo, Brazil, from 
January to August 2017. Postmenopausal women were recruited by advertisement in local 
media (social networking sites and local radio), followed by inclusion criteria: women 
with age between 40 and 60 years, menopause confirmed for 12 consecutive months of 
amenorrhea, values of follicle stimulating hormone (FSH) levels >40 IU/L, symptoms of 
estrogen deprivation, no use of hormone therapy or hypolipid drugs in the past 6 months. 
Hysterectomized women, history of chronic diseases such as type 2 diabetes, 
cardiovascular or gastrointestinal diseases; contraindication to the use of HT; intolerance 
to the use of probiotics; bariatric surgery; use of medications such as oral contraceptives, 
HT, antibiotics, or lipid-lowering agents within the last 6 months, as well as those not in 
accordance with the Free and Informed Consent Form were excluded. One hundred and 
seventy-six women were screened, but only sixty women were selected for the study, 
fulfilling the inclusion and exclusion criteria. The study protocol was approved by the 
university Research Ethics Committee (CAAE/process number 56751216.7.0000.5404) 
and registered on the Brazilian Clinical Trials Registry (ReBEC; RBR-83wwpx number) 
and a written informed consent was obtained from every participant. 
 
2.2 Design and randomization 
After the initial screening, sixty women were randomized to three different 
treatment, according a sequence determined by a computerized random-number 
generator. The protocol lasted 16 weeks, with three intervention visits: The first visit at 
time zero, the second after 60 days and the third after 120 days. The women were 
randomized into three intervention group: 1) Isoflavone group (n=20): One capsule of 
phytoestrogen per day. This phytoestrogen is commercially available as capsules 
containing 150 mg dry extract of Glycine max, of which 60 mg are relative to total 
isoflavones (Soyfemme®; Aché Pharmaceuticals, São Paulo, Brazil); 2) Isoflavone plus 
probiotics group (n=20): One capsule of phytoestrogen per day (Soyfemme®; Aché 
Pharmaceuticals, São Paulo, Brazil) associated with a probiotic product containing 
Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium 
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bifidum and Bifidobacterium lactis at a dose 109 cell-forming unit equivalent to 2 mg/day, 
to be mixed with 100 ml of water (Simfort®; Vitafor, São Paulo, Brazil); 3) Hormone 
therapy (n=20):  One tablet per day of Estradiol (1 mg/day) associated with norethisterone 
acetate (0.5 mg/day) (Suprelle®; Biolab Sanus, São Paulo, Brazil) (figure 1). 
 
 
Figure 1. Flowchart of study participants. 
 
At the randomization visit, the remaining 60 women were allocated in equal 
numbers to the three groups, but there was an initial loss of 2 participants for biochemical 
analysis as shown in Figure 1, while 3 participants did not provide the complete dietary 
assessment at the end of the study, the n available for each analysis is evidenced in the 
respective tables. The groups were followed-up for 16 weeks, although compliance was 
high (91,7% of adhesion), during follow-up there were 5 dropouts, completing the study 
with fifty-five participants. 
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2.3 Measurements 
At first visit, after are allocated to their respective group, the participants 
answered a standardized questionnaire through of one-to-one interviews on demographic 
and socioeconomic characteristics (e.g., age, education, marital status and physical 
activity practice) and medical history (e.g., chronic diseases, current medications or 
feelings about the medication of the study). 
The following data were collected at baseline and at 16 weeks of the study 
for the three groups: Body weight (in kilograms) verified on digital scale; Height (in 
meters) was evaluated standing without shoes; Body mass index (BMI) (kg/m2), 
calculated as body weight divided by the square of height; Blood pressure (mmHg), was 
measured at the left arm by standard mercury sphygmomanometer after at least 5 min of 
rest; Waist circumference (cm), was measured at first and final visit midway between the 
lowest rib and the iliac crest using an anthropometric tape; Hip (cm), measured at the 
level of the point of greatest circumference of the gluteal region, Waist-to-hip, calculated 
as waist divided by the hip circumference. 
Blood glucose (mg/dl), insulin (mUI/ml), total cholesterol (mg/dl), HDL 
(High density protein) (mg/dl), LDL (low density protein) (mg/dl), triglycerides (mg/dl), 
17β-estradiol (pg/ml), FSH (Follicle stimulating hormone) (mIU/ml) were measured to 
examine the effects of the treatments before and after intervention. Blood samples for 
serum analysis of biomarkers concentrations were obtained between 8 AM and 10 AM, 
in the fasting state (8h) and the assay performed by standard methods (kinetic colorimetric 
and enzymatic methods), run immediately after collection in certified private laboratory. 
HOMA-IR was used to evaluate insulin resistance (fasting serum insulin (μIU/ml) × 
fasting plasma glucose (mmol.L-1)/22.5) and HOMA-β was used to evaluated insulin 
secretion (20 × fasting serum insulin (μIU/ml) / (fasting serum glucose (mmol.L-1) – 3.5) 
[19]. For conversion of glucose from mg/dl to mmol/l, the value in mg/dl were multiplied 
by 0.0555. 
Urine samples were collected from each woman and equol production 
status was determined by gas chromatograph mass spectrometer (GC–MS), according to 
Ko et al. (2010) [20], with adaptations. For urine sample preparation, 1 mL of sample was 
mixed in vortex with 50 μL of 12 N HCl for 1 min. The mixture was heated at 100 °C for 
60 min. After cooling to room temperature, 1 mL of carbonate buffer solution (1.5 M, pH 
8.5) and 4 mL ethyl acetate (EA) were added and mixed for 10 min. Then, the EA layer 
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was removed and dried with nitrogen. The residue was dissolved in 100 μL EA and 40 
μL BSTFA reagent, followed by incubation at 80 °C for 60 min. The final reactant was 
analyzed by GC–MS. Analyses were carried out in a gas chromatograph mass 
spectrometer (GCMS-QP2010S Shimadzu), in selective ion monitoring (SIM) mode with 
demand of the mass-to-charge ratios (m/z) 192, 386, 371 for equol. The RTX-5 capillary 
column (Restek, 5% diphenyl, 95% dimethyl-polysiloxane) was used (30 m length × 0.25 
mm diameter inner × 0.25 µm film thickness). The operating conditions of the 
chromatograph were: injector temperature 250 °C; ion source 230 °C; quadrupole 150 
°C; injection volume 1 µL in splitless mode; carrier gas of helium at constant flow rate of 
1 mL/min; oven program temperature 160 °C maintained for 2 min and increased at 13 
°C/min to 290 °C and held an additional 2 min; and GC–MS interface temperature 290 
°C. 
Dietary assessment was performed using three non-consecutive validated 
food frequency questionnaires and 24HR recalls to access the participants usual diet, these 
questionnaires were calculated in the computer program Dietwin® professional. The food 
consumption of the participants was introduced in the software in grams or milliliters 
based on the home measurement table, used for food consumed in Brazil [21], and dietary 
quality indexes provided by macronutrients were calculated. 
The food consumption frequency questionnaire (FFQ) was developed with 
the following question: ‘During the last six months, what is the frequency with which you 
have consumed or consume the following foods?. The FFQ included 57 polyphenol-rich 
foods, classified as those with content of polyphenol substances above 
the 75th percentile, i.e. with at least 30 mg of polyphenol per 100 g of food, as established 
by the American database (United States Department of Agriculture 
2007) and based on a valid questionnaire in the study of Vian et al (2015) [22,23]. The 
median portion size of each food used in FFQ was established in interview with the help 
of a 24HR used previously and the most cited foods rich in polyphenols were selected 
from the food records. 
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2.4 Sample size determination and power calculation 
 
Sample size was initially calculated based on vasomotor symptoms as they 
are the most prevalent symptoms during the menopausal transition. An α error of 5% and 
a power of 90% were considered, and we found that 16 participants would be sufficient 
for the study. The total number of women per group was increased to 20 (an increase of 
>20%) to compensate for any possible loss to follow-up. The sample size was calculate 
the same way that described by Carmignani et al. [24]. 
The power of the sample and the sample size were evaluated for the purpose 
of comparing the mean of the difference between T0 and T120 of the LDL values between 
the 3 groups, with estimates obtained from the current sample, setting the level of 
significance at 5% and power of 80%. The results showed a 63.1% power for the LDL 
delta of the current sample, requiring a sample of n=28 patients in each group to obtain a 
power of 80%.  
 
2.5 Statistical analysis  
The description of categorical variables was performed by Chi square test, 
followed by Fisher test, when necessary. Numerical variables were compared with 
Kruskal-wallis test, followed by post hoc test of Dunn. In longitudinal comparisons of 
numerical variables, it was used ANOVA for repeated measurements, Mann-Whitney, 
for independent samples and for categorical variables generalized estimating equation 
was performed. The level of significance adopted for this study was 5% and the software 
program used to perform all the statistical analyses was SAS, version 9.4 (SAS Institute 
Inc.,Carey, NC, USA). 
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3. Results 
A total of 300 women demonstrated interest in the study, being 176 
interviewed in order to select 60 participants. Women were recruited through the local 
midia and invited to complete a check list to verify whether they met the admission 
criteria for the study.  
Of the 116 excluded women, some exclusions were because they did not meet 
the inclusion criteria (32.8%), but there were exclusions because they had no interest in 
participating in the study (10.3%) and for others reasons (56.9%). 
Table 1 summarize the baseline characteristics of the participants according 
to treatment group. There were no statistically significant differences in baseline for the 
main characteristics, although the variables social class (p=0.0356) and smoking 
(p=0.0468) presented a significant difference between the groups. Social class was 
defined according criteria of Associação Brasileira de Anunciantes (ABA) and 
Associação Brasileira dos Institutos de Pesquisa de Mercado (ABIPEME), classified by 
Almeida & Wickerhauser (1991). 
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Table 1. Prevalence (expressed as mean ±standard deviation in %) of baseline population 
characteristics  
 Groups  
 ISO ISO+PROB HT p-value 
Age (years) 53.05 (3.39) 52.00 (3.04) 52.21 (3.41) 0.55α 
Menopause age (years) 49.42 (3.67) 48.40 (2.84) 47.89 (4.81) 0.47 α 
Marital status    0.42c 
With partner 36.84 45.00 57.89  
Without partner 63.16 55.00 42.11  
Ethnicity (%)    0.16 c 
White 57.89 50.00 78.95  
Not white 42.11 50.00 21.05  
Education level (%)    0.68 b 
Primary or less 15.79 35.00 21.06  
Secondary or more 84.21 65.00 78.94  
Social class (%)    0.04 c 
High (A) 84.21 80.00 94.74  
Intermediate or low 
(B/C) 
15.79 20.00 5.26  
Physically active    0.14 c 
Yes 47.37 45.00 73.68  
No 52.63 55.00 26.32  
Chronic disease     
Yes 36.84 40.00 26.32 0.64 c 
None 63.16 60.00 73.68  
Smoking    0.05 c 
Smoker 52.63 45.00 15.79  
Never smoker 47.37 55.00 84.21  
ISO: isoflavones; ISO+PROB: isoflavones plus probiotics; HT: hormone therapy. α 
Kruskal-Wallis non-parametric test; b Chi square test; c Fisher’s exact test (p<0.05). 
In Table 2, it is observed that the groups were homogenous for the following variables: 
weight, body mass index, arterial blood pressure and anthropometric measurements as 
waist, hip and waist-hip ratio (WHR), in intra and intergroup comparisons, as the p-value 
indicates. The participants in the hormone therapy group presented higher values for 
HOMA-IR and β in the two evaluated times. 
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Table 2. Clinical and anthropometric parameters in menopausal woman at baseline and after a 16 week of treatment. 
 Before intervention Mean (SD) After intervention Mean (SD) ANOVA¥ 
 Isoflavone 
(n=19) 
ISO+PROB 
(n=20) 
HT 
(n=19) 
Isoflavone 
(n=19) 
ISO+PROB 
(n=20) 
HT 
(n=19) 
p# 
 
p$ p& 
Weight (kg) 71.98 (12.37) 75.51 (16.01) 71.36 (13.61) 73.21 (12.48) 77.14 (14.79) 71.02 (13.87) 0.51 0.07 0.09 
BMI (kg/m2) 29.01 (4.24) 30.05 (6.37) 28.72 (4.32) 29.22 (4.43) 30.61 (5.97) 28.58 (4.47) 0.67 0.73 0.06 
BPs (mmHg) 131.21 (21.27) 128.60 (19.38) 127.05 (14.07) 126.71 (20.76) 124.47 (14.95) 131.47 (15.55) 0.78 0.70 0.20 
BPd (mmHg) 80.47 (15.40) 77.40 (11.94) 79.84 (9.63) 76.24 (9.94) 74.58 (11.37) 80.53 (9.23) 0.40 0.54 0.67 
WC (cm) 92.55 (10.18) 93.75 (15.17) 91.53 (11.42) 92.76 (10.88) 95.18 (11.04) 90.26 (10.76) 0.66 0.79 0.16 
HC (cm) 106.11 (9.36) 106.75 (12.38) 105.21 (9.34) 106.18 (9.44) 108.97 (11.22) 104.26 (8.83) 0.64 0.65 0.13 
WHR 0.87 (0.07) 0.87 (0.06) 0.87 (0.06) 0.87 (0.09) 0.87 (0.05) 0.87 (0.06) 0.91 0.94 0.84 
HOMA-IR 1.59 (0.69) 1.61 (0.70) 2.06 (1.00) 2.06 (1.08) 1.95 (0.96) 2.19 (0.87) 0.63   
HOMA-β 101.44 (50.33) 101.91 (58.94) 135.91 (71.96) 110.37 (58.23) 101.31 (38.06) 124.01 (53.66) 0.74   
BMI: body mass index, BPs: systolic blood pressure, BPd: diastolic blood pressure, WC: waist circumference (cm), HC: hip circumference (cm), 
WHR:  waist-hip ratio, HOMA-IR: Insulin resistance index, HOMA-β: β-cell function. ¥Repeated measures ANOVA followed by Mann-whitney 
test. # Comparison between groups, $ Comparison between time-points, & Group-time interaction. HOMA-IR and HOMA-β: Kruskal-wallis test. 
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In figure 2, the comparison of the groups before and after the intervention 
demonstrated glucose and insulin in the fasting state remained within the normal range. 
Total cholesterol was above the reference value (˂190 mg/dL) in the basal evaluation for 
all the groups, after the intervention only the group taking hormone therapy showed a 
significant reduction (p=0.0077). HDL-c showed no significant change, while LDL-c 
significantly reduced in the HT group, when compared to the baseline (p=0.0102). The 
levels of triglycerides were adequate (˂150 mg/dL) for the all groups, at baseline and end 
of study. Our findings corroborate an improvement in the lipid profile among women who 
used hormone therapy. 
As expected, FSH decreased (p=0.0001) and 17β-estradiol increased 
(p=0.0142) only in the HT group, remaining the same for isoflavones and isoflavones 
with probiotics, in relation to baseline. 
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Figure 2. Effect of isoflavone, isoflavone with probiotics and hormone therapy on 
biochemical parameters of menopausal women. Serum concentration of: A) glucose 
(mg/dL); B) glucose (log10(mg/dL)) (p
#=0.8462, p$=0.0002, p&=0.5886); C) insulin 
(mUI/mL); D) insulin (log10(mUI/mL)) (p
#=0.3773, p$=0.0117, p&=0.6154); E) total 
cholesterol (mg/dL); F) total cholesterol (log10(mUI/mL)) (p
#=0.8949, p$=0.0584, 
p&=0.0045); G) HDL: high-density lipoproteins (mg/dL); H) HDL (log10(mg/dL)) 
(p#=0.6133, p$=0.4353 , p&=0.8634); I) LDL: low-density lipoproteins (mg/dL); J) LDL 
(log10(mg/dL)) (p
#=0.6527, p$=0.0186, p&=0.0185); K) triglycerides (mg/dL); L) 
triglycerides (log10(mg/dL)) (p
#=0.3971, p$=0.0566, p&=0.5617); M) FSH: follicle-
stimulating hormone (mIU/mL); N) FSH (log10(mIU/mL)) (p
#=0.0010, p$=0.0008, 
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p&=0.0001); O) Estradiol (pg/mL); P) Estradiol (log10(pg/mL)) (p
#=0.0142,p$=<0.05, 
p&=<0.05), where p-values signify: # Comparison between groups, $ Comparison between 
time-points and & Group-time interaction. Data are expressed as means ± SD (Mann-
whitney test, p<0.05). Graphic subtitle: white bar= Isoflavone (ISO); gray bar= 
Isoflavone with probiotics (ISO+PROB), black bar= Hormone therapy (HT). 
 
Table 3 shows the comparison of the sum of equol and equol intermediates between the 
groups isoflavone (ISO), isoflavone plus probiotic (ISO+PROB) and hormone therapy 
(HT). 
Table 3. Concentration of total urinary equol (ug/mL) from the sum of equol and 
intermediates, expressed by median (quartile 1- quartile 3) among groups. 
Equol (ug/mL) ISO ISO+PROB HT pvalue* 
T0 3.29 (2.51-4.11) 4.29 (1.78-5.91) 3.36 (0.00-3.89) 0.20 
T60 7.69 (4.75-55.00) 7.39 (5.26-16.83) 2.46 (0.00-7.89) 0.005 
T120 7.96 (4.36-9.51) 5.56 (4.51-7.26) 1.82 (1.42-5.97) 0.28 
*p-value for the Kruskal-Wallis test 
 
In an additional longitudinal and comparative analysis between group and time, there was 
a significative increase after 60 and 120 days for total urinary equol in ISO and 
ISO+PROB groups (p<0.001). This information was obtained through analysis of 
variance for repeated measures (ANOVA for repeated measures), with the variables 
transformed into ranks due to the absence of normal distribution. 
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The results of total polyphenols found in dietary questionnaires were described in milligrams in Table 4. The average consumption/day of total 
polyphenols/portion (mg) was 109.00 mg in ISO group, 186.96 mg in ISO+PROB group and 165.89 mg in HT group participants (p=0.75). 
 
Table 4. Total amount of polyphenols of food consumed reported in a FFQ and R24h applied in menopause women. 
  ISO ISO+PROB HT 
Food Total 
polyphenols 
(mg/100g) ** 
Median of 
consumption (g or 
mL) 
Total 
polyphenols/ 
portion (mg) 
Median of 
consumption 
(g or mL) 
Total 
polyphenols/ 
portion (mg) 
Median of 
consumption 
(g or mL) 
Total 
polyphenols/ 
portion (mg) 
Orange 278.6 135.0 376.11 270.0 752.2 378.0 1053.11 
Apple with peel 201.5 91.0 183.37 182.0 366.7 169.0 340.54 
Raw cabbage 176.7 24.0 42.40 51.0 90.1 28.0 49.47 
Black tea 104.5 180.0 188.06 224.0 234.0 120.0 125.38 
Tomato with skin 45.1 51.0 22.98 66.5 29.9 65.0 29.29 
Banana 154.7 77.0 119.12 137.5 212.7 71.5 110.61 
Papaya 57.6 76.5 44.06 117.0 67.4 85.0 48.96 
Pineapple 147.9 23.0 34.02 180.0 266.2 198.0 292.86 
Raw with onion 45.5 44.0 20.02 24.5 11.1 31.0 14.11 
Garlic 40.8 2.6 1.06 2.6 1.06 3.3 1.35 
Olive oil 55.1 16.3 8.99 9.8 5.4 10.2 5.62 
Natural orange juice 48.9 164.5 80.41 228.0 111.4 120.0 58.66 
Raw strawberry  289.2 12.6 36.44 11.9 34.4 19.5 56.39 
Green spice 89.3 13.5 12.05 13.0 11.6 19.0 16.96 
Raw red grape 184.9 99.7 184.42 159.5 295.0 93.0 172.02 
Bitter black chocolate 1859.9 21.0 390.57 27.0 502.2 15.0 278.98 
**Database on polyphenol content in foods, Phenol Explorer (2009). P-value according Kruskal-Wallis test. 
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Throughout the study, women in three groups presented adequate consumption of energy, carbohydrate, fiber, protein, cholesterol and total lipids, 
with an unbalance in the amount of saturated fat consumed (Table 5). The dietary information were obtained from a mean of three R24h applied 
on visits T0, T60 and T120. 
Table 5. Mean ± standard deviation of energy intake, macronutrients, nutritional recommendations and percentage of adequacy in relation to 
nutritional recommendations (DRIs), after analysis of the Dietary Reminder (R24H) of women. 
 Groups Mean (SD)  Percentage of suitability (%)  
 ISO (n=18) ISO+PROB 
(n=19) 
HT (n=19) Reference ISO ISO+PRO
B 
HT p-value 
Energy intake (kcal/day) 1842.44 (488.93) 1959.19 (506.49) 1678.55 (467.42) 2000 kcal 92,12% 97,96% 83,93% 0.21 
Carbohydrate (g/day) 234.95 (71.74) 223.58 (57.78) 200.90 (51.28) 45-65% 51,01 45,65 47,87 0.20 
Total fiber (g/day) 20.98 (8.36) 19.34 (6.21) 20.87 (7.95) 21 g/day - - - 0.79 
Protein (g/day) 75.16 (18.21) 88.80 (28.49) 72.32 (23.47) 10-35% 16,32 18,13 17,23 0.14 
Cholesterol (mg/day) 260.74 (99.56) 296.20 (90.72) 241.48 (94.90) ˂300 mg/day - - - 0.25 
Total lipids (g/day) 66.43 (21.55) 76.18 (41.84) 65.64 (26.94) 20-35% 32,45 35,00 35,19 0.86 
Saturated fat (g/day) 23.21 (9.29) 24.34 (13.42) 22.39 (9.87) ˂10% 11,34 11,18 12,01 0.98 
Monounsaturated fat (g/day) 21.02 (6.91) 24.12 (16.40) 20.73(9.33) ≤20% 10,27 11,08 11,11 0.89 
Polyunsaturated fat (g/day) 11.18 (3.68) 14.48 (9.20) 14.21 (7.38) ≤10% 5,46 6,65 7,62 0.43 
129 
 
4. Discussion 
The population of this study (table 1) is characterized by have more than 3 
years of postmenopausal, being composed of 65.52% overweight (BMI above 25 kg/m2) 
and prevalence of 34.48% of obesity I. Our results are comparable to the results of 
Brazilian population-based studies at this stage of women's life [25–28], confirming the 
premise that during the menopausal transition and in postmenopausal period weight gain 
may occur, due the drops in hormone levels. According Park et al. [29] increase in the 
percentage of total body fat and changes in body fat distribution happen independently 
and are significantly higher in postmenopausal women. 
Koning et al. [30], suggested in a meta-regression analysis, an important 
correlation between waist circumference (WC) and waist-hip ratio (WHR), these 
parameters brought up similar risk of cardiovascular diseases (CVD) in men and women, 
with an average age of 57 year, being 1 cm increase in WC related with a 2% increase in 
chance of cardiovascular incident, while a 0.01 increase in WHR promote a 5% increase 
of relative risk in future cardiovascular events. The participants of this study have a WC 
>90 cm, demonstrating central obesity and risk for metabolic disease in the total sample 
(p=0.9651) (table 2), once high waist circumference is associated with an increased 
risk for type 2 diabetes, dyslipidemia, hypertension, and cardiovascular diseases in 
women with WC >88 cm. WHR, a good predictor of CVD risk, was 0.87 (SD 0.6- 0.9; 
p=0.9898) for all participants of this study, being greater than the ideal cut-off point, 
standardized as 0.85 for women. This marker is more strongly associated with CVD than 
WC. 
In relation to blood pressure, the results showed a mean decrease of 4.5 
mmHg for systolic blood pressure (SBP) and 4.26 mmHg for diastolic blood pressure 
(DBP) in the soy isoflavones-treated group, while that for isoflavone plus probiotics the 
reduction of mean blood pressure (BP) was less, being 4.13 mmHg and 2.82 mmHg for 
systolic and diastolic pressure, respectively (Table 2). In the hormone therapy treatment 
there was an increase of 4.42 mmHg in SBP and 0.69 mm Hg in DBP, although not 
statistically significant, it’s possible to observe that soy isoflavones did not affect SBP 
and DBP negatively. After menopause, risk of high blood pressure jumps drastically, 
inversely proportional to the levels of the hormones estrogen and progesterone, which fall 
progressively, in this study blood pressure levels have been normal values [31]. 
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Although the benefits of soy isoflavones on blood pressure be controversial 
[18], the cohort performed in middle-aged adults (45.2±3.63 years) by Richardson et al. 
[32], similarly to our study, demonstrated that SBP decrease 4.3 mm Hg (p<0.0001) 
among subjects consumers of high amounts of isoflavones (2.51 – 222.27 mg/day) 
compared with low dietary intake (0.0 – 0.33 mg/day), suggesting that usual soy 
isoflavone intake get a significant BP lowering effects, probably in a dose-dependent 
manner. 
Hyperinsulinemic-euglycemic clamp and the hyperglycemic clamp are the 
gold standard for the laboratory characterization of insulin resistance, however in clinical 
practice insulin resistance and insulin secretion are usually calculated with HOMA-IR 
and HOMA-β (The Homeostasis Model Assessment), a validated method that predicts 
efficiently the insulin sensitivity and beta cell function in fasted conditions [33,34]. In the 
baseline study, the HOMA-IR was 1.59 (0.69), 1.61 (0.70) and 2.06 (1.00) for the women 
randomized in isoflavone, isoflavone plus probiotics and hormone therapy groups, 
respectively. 
After the intervention these values became 2.06 (1.08), 1.95 (0.96) and 2.19 
(0.87) for the same groups (p=0.6312), although they are within the appropriate value for 
the index (HOMA-IR: ≤ 2.8), even if there was an increase for all groups, the isoflavone 
plus probiotic exhibited less insulin resistance. Similarly, the HOMA-β score was 101.44 
(50.33), 101.91 (58.94) and 135.91 (71.96) for isoflavone, isoflavone plus probiotics and 
hormone therapy, respectively, and after the treatment the following values were found: 
110.37 (58.23), 101.31 (38.06) and 124.01 (53.66) for the respective groups (p=0.7451), 
being possible to look the discreet beta-cell protection provided by probiotics. Our 
findings are corroborated by Zhang et. al. [35] and Ruan et. al. [36] that demonstrated the 
potential benefits of probiotic strains in glucose metabolism. 
In figure 2, the comparison of the groups before and after the intervention 
demonstrated glycemic levels within normal limits, although there has been a slight 
increase in a mean glycemia for all groups, and an increase insulin in soy groups, being 
these findings according to the meta-analysis of Liu et. al. [16], that observed no favorable 
effects on decrease of fasting glucose and insulin levels when purified isoflavones or 
isolated soy protein were consumed, but positive outcomes on glucose-insulin was found 
in trials that used whole soy, with benefits being attributed to compounds other than 
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isolated isoflavones (e.g. isoflavone-soy protein interaction, soy fiber, phytosterol and 
unsaturated fatty acid). 
Chinese women (n=165), aged 30-70 years, with impaired glucose regulation 
were evaluated by Ye et. al. [37] as regard insulin sensitivity and glucose metabolism, 
receiving for 24 weeks a daily dose of 10 g of soy protein alone or added of 50 mg of 
daidzein or 50 mg of genistein. Consistent with our finding, no significant reductions 
were found in evaluated women as for fasting glucose, 2h-glucose, HbA1c, fasting and 
2-h insulin between the three treatment groups at 12 or 24 weeks. 
In this study, there was an important improvement in the lipid profile only 
among women who used HT, with a decrease in total cholesterol (p=0.0077), and LDL-c 
(p=0.0102) for the group that used hormone therapy, as also observed by Ki et. al. [38], 
and a non-significant decrease in LDL levels for those women who used isoflavones 
(p=0.4422), comparing initial and final time. A meta-analysis of Zhuo et. al. [17], 
reported a significant reduction in serum LDL-c in normocholesterolemic (decreases in 
0.14 mmol/L or 3.87 mg/dL, p=0.0008) and hypercholesterolemic (decreases in 0.18 
mmol/L or 6.96 mg/dL, p=0.03) participants who made use soy protein isolate with high 
isoflavone content, mean 96 mg/day over 1-3 months. These results were not found in 
subjects who ingested the same amounts of soy protein (mean 50 mg/day) with low 
isoflavones content (mean 6 mg/day). No significant changes were observed in 
triglyceride levels for any groups over time. Contradicting our findings, Kim et. al. [39] 
conducted a randomized clinical trial in one hundred thirteen Korean postmenopausal 
women (53.6 years ± 2.9-3.8) that received 70 mg isoflavone or placebo capsules daily 
for 12 weeks, had their triglyceride levels significantly reduced (111.9 ± 62.8 to 95.7 
±58.3, p=0.0215). 
Tokede et al. [40], in a meta-analysis that evaluated intake of soy products 
treatment duration from 4 weeks to 1 year, found that soy products, but not isoflavone 
supplements, significantly improved serum lipids, resulting in a significant reduction of 
total cholesterol (-5.33 mg/dl, p<0.01), LDL-cholesterol (-4.83 mg/dl, p=0.01), 
triglycerides (-4.92 mg/dl, p<0.01), beyond a non-significant increase in HDL-cholesterol 
(1.40 mg/dl, p=0.74) in relation to baseline. Our findings agree with the literature, 
reaffirm the need for synergistic interaction between isoflavones and protein to get it 
hypolipidemic effect of soy, suggesting that the beneficial effects of isoflavones alone, 
when in aglycones forms, are not attributed to the reduction of lipoproteins in  serum, but 
132 
 
the ability of these phenols to protect lipoproteins against oxidation and initiation of the 
inflammatory cascade which leads to increases the risk of cardiovascular diseases [41]. 
In hormone therapy group FSH decrease (p<0.0001), while a significant increase of serum 
17β-estradiol was observed between groups over time (p=0.0142). These same 
biomarkers remained constant in the other groups, as expected and observed in similar 
work [24]. 
The equol production was higher in the group with probiotic addition after 60 
days of intervention, demonstrating that a diet rich in bioactive compounds and a 
modulated microbiota favors the induction of equol producing profile (table 3). In table 
4, it was possible to observe that the mean phenolic consumption was higher in the 
isoflavone group with probiotics, indicating that dietary polyphenols also are relevant in 
the modulation of gut microbiota [42].  
In relation to food consumption (table 5), although the population is mostly 
of overweight women, it was observed that the mean of energy intake (kcal/day), 
percentage of carbohydrates and proteins were within the Acceptable Macronutrient 
Distribution Range (AMDR) recommended by the Dietary Reference Intakes (DRIs), 
being in agreement with average energy consumption (1710 kcal/day) for Brazilian 
women in the age group of 19-59 years demonstrated by the Pesquisa de Orçamentos 
Familiares (POF) 2008/09 [43,44]. This vies can be attributed to specific characteristics 
of the population, who made a sub relate of food intake, also which may require different 
proportions of macronutrients to  maintain a reduced weight with less effort, or a greater 
number of days of analysis may be necessary to obtain reliable food intake data, to 
minimize within and between-individual variances [45,46]. 
The dietary intake found in this study are according with Duval et al. [47], 
that when investigating the dietary intake and appetite across the menopausal transition 
for 5 years, and observed the followed percentage of macronutrients: protein (%) 
17.7±3.1, carbohydrate (%) 49.6±8.0, fat (%) 32.7±4.1 and dietary fiber 26.8±7.9 g/day. 
Total fiber intake was near to that recommended for all groups (20.98±8.36 
for isoflavone, 19.34±6.21 for isoflavone plus probiotics and 20.87±7.95 to hormone 
therapy, p=0.7984) and was similar to that found by Duval et al. [47]. Recommendation 
for women diverges in the case of fiber consumption, being 25 g/day for women aged 31-
50 years and 21 g/day for women aged 51-70 years, as this study contemplates both age 
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groups we use the recommendation of 21 g/day, due to the average age of our population 
being 52.42 years. 
Although still within the adequacy range (20-35%), it was observed high 
consumption of total lipids for the groups ISO, ISO+PROB and HT, with consumption of 
66.43±21.55 mg/day (32.45%); 76.18±41.84 mg/day (35.00%) and 65.64 ±26.94 mg/day 
(35.19%) (p=0.8570), respectively. The cholesterol intake agreed with the 
recommendations for all groups. 
Ratio intake of saturated fatty acid (SFA), mono unsaturated fatty acid 
(MUFA) and poly unsaturated fatty acid (PUFA) were 11.34%:10.27%:5.46% for 
isoflavone, 11.18%:11.08%:6.65% for isoflavone plus probiotic and 
12.01%:11.11%:7.62% to hormone therapy, being possible to observe a misaligned ratio 
consumption in relation the reference ratio 10%:20%:10% to health subjects, with 
excessive consumption of saturated fat and low intake of MUFA and PUFA. Beneficial 
effects on plasma glucose, insulin and HOMA-IR score are obtained when SFA are 
replaced with MUFA or PUFA, whereas high-saturated-fat and high-carbohydrate diets 
have similar effects on insulin sensitivity and risk of development of type 2 diabetes. 
Beside that an ideal dietary fat composition decreases cardiovascular risk through 
reduction of total cholesterol, triacylglycerols and adequacy of LDL/HDL ratio [48,49]. 
 
5.Conclusions 
In a 16-week intervention, isoflavone or isoflavone plus probiotic they were 
not able to improvement of metabolic profile in postmenopausal women compared to 
hormone therapy, demonstrating the superiority of hormone therapy over phytoestrogen 
associate or no to probiotic in lipid profile, when associated with a usual healthy diet. 
However, a diet rich in phenolic compounds when associated with lactic acid bacteria 
may favor the production of equol. 
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Abstract 
Consumption of an isoflavone-rich daily supplement added or not to probiotics was 
compared to hormone therapy on the equol producer status, menopause symptoms and 
composition and diversity of the gut microbiota. Sequencing of 16S rDNA amplicons was 
performed on faecal samples taken at baseline and after 120 days of treatment. Members 
of the family Coriobacteriaceae were found in greater proportions in isoflavone alone 
supplementation, while was observed an increase of anti-inflammatory bacterium 
Faecalibacterium prausnitzii, butyrate-producing Roseburia faecis, beside that equol-
producing Alkaliphilus crotonatoxidans and Blautia coccoide in women of the 
ISO+PROB group. The production of equol in the studied population coincides with the 
current data of the literature, being greater than 50% in the groups that used isoflavones 
plus probiotics and remaining in 32% among individuals who used hormone therapy. No 
relation of equol with MRS subscales and total score was found, only over time, that is, 
reduction of the scores at times T60 and T120. The modulation of the intestinal microbiota 
by lactic acid bacteria associated with isoflavones contributes to the identification of 
microorganisms producing isoflavone-desirable metabolites, such as equol, which could 
ultimately be used as probiotics by people who cannot naturally benefit from isoflavones. 
 
Key-words: Women's health, Hormone therapy, Menopause, Gut microbiota, 
Isoflavones, Equol 
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1. Introduction 
Menopause is a normal and natural event in the aging process, defined as the final 
menstrual period, confirmed after 12 full months of amenorrhea [1]. The permanent 
cessation of menses resulting from ovarian hormone deficiency, can occur spontaneously 
on average around age 50, or be the result of surgical or drug intervention (iatrogenic 
menopause) [2,3]. 
Menopausal hormone therapy using estrogen or, in a woman with a uterus, a combination 
of estrogen and progestin, is considered an effective and first-line therapy for relieving 
menopause-related symptoms, as vasomotor, psychological and genitourinary order, and 
to prevent bone loss and fractures [4]. In the post-Women’s Health Initiative era, 
symptom management has become more complex, due the association of hormone 
therapy with an increased risk of breast cancer and cardiovascular events reported in study 
participants randomized to receive hormone therapy compared to women randomized to 
placebo [5]. 
Risks of hormone therapy replacement differ between women, to maximize benefits and 
minimize risks the treatment should be individualized to consider features such as type, 
dose, duration of use, route of administration and timing of initiation of therapy, as well 
as the actual absolute contraindications, that are limited to breast cancer or history of 
breast cancer [4,6]. Women employ a range of symptom management, designated as 
Complementary and Alternative Medicine (CAM) therapies, including prescription 
drugs, lifestyle modifications, as weight loss and stress reduction, or soy isoflavones use 
[7]. 
Non-hormonal therapies based on majoritary soy isoflavones (daidzein, genistein and 
glycitein) are proposed because the phytoestrogen, which are phenolic compounds with 
estrogenic activity, possess similar structures to 17 β-estradiol hormone, and isoflavone 
affinity towards estrogen receptors, ERα and ERβ, with higher predilection for oestrogen 
β receptors; the heterogeneous receptors tissue distributions exert organ-specific 
oestrogenic or anti-oestrogenic activity [8]. Isoflavones can be indicate for women who 
cannot or do not wish to use hormone therapy and it can effectively be an alternative 
treatment, mainly if stimulated the production of equol, metabolite of daidzein isoflavone, 
a higher estrogenic compound. 
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In a placebo-controlled clinical trial, Khaodiar et al. [9] observed that in postmenopausal 
women with hot flashes, dietary supplementation with 40 to 60 mg of aglycone daidzein 
per day significantly decreased hot flash frequency by up to 52% before 12 weeks, 
compared with 39% change in placebo group; demonstrating that the supplement 
potential efficacy was mediated by conversion of daidzein to active metabolite equol. 
The benefits of isoflavones depend of the intensity of the symptoms, the amount ingested, 
the level of isoflavone absorption of each woman, but mainly the isoflavone metabolism, 
catalyzed by gut bacteria [10]. Equol is a specific metabolite from daidzein, formed 
exclusively by gut microbiota, with higher affinity for binding to ERβ, than other 
isoflavones. The term equol-producer defines those adults that could make equol in 
response to consuming soy isoflavones, because which have a converting microbiota with 
high activity of β-glucosidase enzymes [11]. The prevalence of equol producers has been 
reported to be 25% to 30% in adult Western population when they consume soy foods 
containing isoflavones, while than 50% to 55% in population of Asiatic countries or 
among vegetarian adults [12]. 
The gut microbiota has hydrolytic enzymes capable of metabolizing the glycoside 
isoflavones (daidzin, genistin, and glycitin) in aglycones forms (daidzein, genistein and 
glycitein) to metabolites equol and O-desmesthylangolensin (ODMA), with has a 
significant effect on their bioavailability and absorption. The compositions of each gut 
microbiota affect the bioavailability and absorption of these compounds. Species such as 
Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus 
rhamnosus, Lactobacillus plantarum, Lactobacillus bulgaricus, Bifidobacterium breve 
and Bifidobacterium bifidum have proven to be excellent strains to use on the isoflavone 
biotransformation, since they are able to improve the bioavailability and conversion rate 
of isoflavones by the action of their β-glucosidase enzymes [11]. 
In Brazil, no studies have reported the prevalence of equol producers in postmenopausal 
women. We therefore conducted an epidemiological study in Campinas, São Paulo, 
Brazil, from January to August 2017 to compare the equol production profile to gut 
microbiota of menopausal women who received isoflavones (150 mg/day), isoflavones 
plus probiotics (150 mg/day plus 2 mg/day of probiotic), or hormone therapy (1 mg of 
estradiol plus 0.5 mg of norethisterone acetate). The main objectives of the study were 
find out if there is a similar microbiota composition profile among women producing 
equol; observe whether administering probiotics along with isoflavones increases chance 
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to produce equol; know the percentage of Brazilian women from the São Paulo region 
that can be considered equol producers. 
 
2. Materials and methods 
2.1 Study characteristics 
The study is a randomized controlled clinical trial with 16 weeks of follow-up, conducted 
in postmenopausal women. The trial was registered on the Brazilian Clinical Trials 
Registry (ReBEC; RBR-83wwpx number), the institutional Research Ethics Committee 
(CAAE/process number 56751216.7.0000.5404) and the institutional review board of the 
Women’s Hospital of the Center for Integral Women’s Health Care, University of 
Campinas, Brazil, approved the study protocol in November 2016. Executed informed 
written consent was obtained from all study participants 
 
2.2 Study population 
Eligible participants were community-living women aged 40-60 years, with the last 
spontaneous menstruation for at least 12 months, follicle stimulating hormone (FSH) 
values greater than 40 mIU/mL and levels of estradiol less than 30 pg/mL, presence of 
symptoms of estrogen deprivation such as hot flashes, depression, anxiety, fatigue, joint 
stiffness, back pain, vaginal discharge, frequent urination, headaches and palpitations. 
Participants with a history of chronic diseases, such as type 2 diabetes, cardiovascular or 
gastrointestinal illness, contraindication to the use of hormonal therapy, intolerance to the 
use of probiotics, bariatric surgery, previous hysterectomy, use of drugs as oral 
contraceptives, hormone replacement therapy, antibiotics or lipid-lowering agents in the 
last 6 months, as well as those women who did not accept the free and informed consent 
form were excluded. 
 
2.3 Study design 
After disclosure of the study in the media, 300 women responded to local advertisements 
of the study, of which 120 accepted to participate in a screening visit for eligibility and 
only 60 met inclusion and exclusion criteria, being integrated into the study. All subjects 
provided written informed consent prior to the initiation of any study-related procedures. 
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Women who met the inclusion criteria were randomly assigned to one of the three 
different intervention-groups using a computer-generated random-number table, with 
daily oral intakes as follows: 1) Isoflavones (n=20): One capsule per day of Soyfemme, 
Aché pharmaceutical laboratory® (150 mg/day); 2) Isoflavones associated with a 
probiotic product (n=20): One capsule per day of Soyfemme, Aché pharmaceutical 
laboratory® (150 mg/day) plus one sachet of probiotic Simfort, Vitafor® (2 g/day) 
containing Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, 
Bifidobacterium bifidum and Bifidobacterium lactis at a dose of 109 cell-forming unit 
equivalent; or 3) Hormone therapy (HT) (n=20): One capsule per day of Suprelle, Biolab 
Sanus®, hormone therapy composed of estradiol (1 mg/day) associated with 
norethisterone acetate (0.5 mg/day), used as control in this study. Medication adherence 
was evaluated by collecting the empty packages of the products. 
During the 4 months of study, the participants performed 3 visits, that happened at the 
baseline, after 60 days and at the end of study, after 120 days. At each visit of follow up, 
data on medical history, urine and feces samples were collected to chromatographic and 
metagenomic analyzes, respectively. All volunteers were requested to avoid soy-foods 
and isoflavones supplements during the trial. First urine-morning samples were collected 
after 10 to 12 h of the last ingestion of medication and stored at -20 ºC until GC-MS 
analysis, feces were collected the day before the visit and stored at -80 ºC until 
metagenomic analysis. 
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Figure 1. Flowchart of the study design. 
 
2.4 Chemicals 
Codeine d3 (7,8-didehydro-4,5-epoxy-3-methoxy-17-trideuteromethylmorphinan-6-ol) 
was obtained from Cerilliant Co. (Austin, Tex., U.S.A), N O-bis (trimethylsilyl) 
trifluoroacetamide (BSTFA), daidzein, genistein, glycitein, O-desmetilangolensin, and 
equol standards were obtained from Sigma-Aldrich Co. (Dorset, UK). The used gases 
(nitrogen and helium) were GC grade. 
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2.5 Detection and quantification of aglycones and metabolite 
Daidzein, genistein, glycitein, intermediate compounds, equol and O-DMA were 
measured using a GC-MS procedure based on a method for equol determination in urine, 
according Ko et al. [13]. Briefly, in a glass tube 1 mL of urine was incubated with 50 µL 
of 12 N HCl and 50 µL of internal standard codeine d3 (1 µg/mL), the mixture was 
homogenized in vortex for 1 min and heated at 100 ºC for 60 min. After reaching room 
temperature, each tube was replenished with 1 mL of carbonate buffer solution (1.5 M, 
pH 8.5) and 4 mL ethyl acetate (EA), followed by shaking for 10 min. After separation 
of the phases the EA layer was withdrawn and flushed with nitrogen to dryness, being the 
residue resuspended in 100 µL of EA and 40 µL of BSTFA, followed by heating (80 ºC, 
60 min) for enhance trimethylsilyl derivative formation and GC-MS quantification. 
The samples were analyzed using the GC-MS instrument (Model GCMS-QP2010S 
Ultra, Shimadzu Co., Japan), with a chromatographic separation performed by a RTX-5 
column, 5% diphenyl, 95% dimethyl-polysiloxane, 30 m × 0.25 mm i.d. and 0.25 μm film 
thickness, fused-silica capillary column (Restek, Bellefonte, PA, USA). The operating 
conditions are: injector port temperature 250ºC, interface temperature 290ºC, solvent cut 
time after 6 min, injection volume of 1 μL in splitless mode; carrier gas of helium at 
constant flow rate of 1 mL/min. The oven program temperature starts at 160 ºC its held 
for 2 min and increased at 13 ºC/min to 290 ºC, being held for an additional 2 min, with 
total running time of 14 min [13]. The MS operating conditions was positive electron 
ionization mode (EI) with an electron energy of -70 eV, the ion source temperature was 
230ºC. Identification was performed in a Scan mode for the standards, to building the 
authentic reference, while the samples were analyzed in Selected Ion Monitoring (SIM), 
with monitoring of the following ions (m/z) 192, 386, 371 for equol, 398, 383 for 
daidzein, 471, 327 for genistein, 428, 413 for glycitein, 281, 73 for O-DMA and 302, 237 
for Codeine d3, where the first ion was based in application for quantification and the 
others ions was used for confirmation [14]. 
The concentrations of isoflavones and their metabolites in urine samples were determined 
by a calibration curve plotted for concentrations of 16.00, 25.00, 50.00, 75.00, 100.00 
ug/ml of codeine-d3 standard solution. The concentration range of 16–100 µg/mL was 
represented by the following analytical curve: y=85,324x+519,42 with coefficient of 
determination R2=0.9991. Were conducted triplicate pretreatments and GC-MS 
quantifications for each urine sample and means of 3 determinations with standard 
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deviation are reported in the results, after plotting the values in the analytical curve, 
followed by adjusting the sample dilution by means of formula:  
Concentration (µg /mL) = (value in the curve/1000)*200 
 
2.5.1 Prevalence of the equol-producer phenotype and its relationship 
with menopause rating scale (MRS) 
 
Interviews on menopausal symptom were conducted by using the questionnaire 
menopause rating scale (MRS). The Menopause Rating Scale (MRS) was used to evaluate 
menopausal symptoms at baseline, after 60 days and 120 days of treatment. The MRS is 
composed of 11 items assessing menopausal symptoms and is divided into three 
subscales: somatic symptoms (hot flashes, heart discomfort, sleeping problems and 
muscle and joint problems in the items 1-3 and 11); psychological symptoms (depressive 
mood, irritability, anxiety, physical and mental exhaustion, in the items 4-7); urogenital 
symptoms (sexual problems, bladder problems and vaginal dryness in the items 8-10) 
[15]. The urine test is also processed by using gas chromatography mass 
spectrophotometry (GCMS) [13]. Then the results of the questionnaire were compared to 
the results of the GCMS to evaluate the symptoms of menopause, through statistical 
analysis, considering non-producers women with median <2.128 and producers those 
with median ≥2.128. 
 
2.6 Faecal sample collection and microbial community analysis 
Forty-eight faecal samples were collected using universal sterile polystyrene containers 
in baseline and final protocol and remained stored at -80ºC until analyze. Total bacterial 
DNA was extracted and amplified from the faecal samples with the Stool DNA Isolation 
Kit (Cat. 27600) (Norgen Biotek Corp.,Thorold, Canada) by MiSeq platform, with MiSeq 
v3 2x300 cycles. The library construction and sequencing were performed as 
recommended by the manufacturer (Illumina, San Diego, CA, USA). The protocol 
included the primer pair sequences for the V3 and V4 region that create a single amplicon 
of approximately ~460 bp. The forward primer (515F) GTGYCAGCMGCCGCGGTAA 
was taken from Caporaso et al. [16] and reverse prime (805R) according Herlemann et 
al. [17]. The protocol also includes overhang adapter sequences that must be appended to 
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the primer pair sequences for compatibility with Illumina index and sequencing adapters, 
according the adapter Nextera®. Sequencing was performed on an Illumina MiSeq 
sequencer at the Helixxa Genomic Services (Paulínia, São Paulo, Brazil). 
 
2.7 Statistical analyses 
For all GC-MS quantifications of urinary isoflavones, intermediates and metabolites 
mean of 3 determinations with standard deviation are expressed; stool samples 
sequencing were done at the beginning and end of the study. Numerical variables were 
compared between groups through Kruskal-Wallis test. Simultaneous evaluations were 
performed with ANOVA repeated measures, followed by Tukey test (intergroup 
comparison) and contrast (intragroup comparison). Variables with a non-normal 
distribution were transformed in posts/ranks, considering a significance of 5% (p<0.05) 
and data were acquired and analyzed using SAS System for Windows, version 9.2. 
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3. Results 
3.1 Isoflavones aglycones and metabolites analysis. 
In this randomized clinical trial, forty women received isoflavones capsules containing 
on average 57% of daidzein, 24% of genistein and 18% of glycitein, while twenty women 
received estradiol associated to norethisterone acetate. 
The first morning urine sample collection after supplements and hormone therapy intake 
was received from each participant at baseline, after 2 months (T60) and 4 months (T120) 
of study. In table 1 the urinary excretion of aglycones, intermediates and their metabolites 
were expressed as the direct proportion to those of respective consumed from 
phytoestrogen product, associated or no to probiotics, and the control (HT). 
Chromatographic analysis of urinary aglycones, performed from the medians and 
quartiles 1 and 3, demonstrated a significant increase of daidzein in the ISO+PROB 
group, after 2 months of treatment (T60), followed by an important decrease in the final 
evaluation of urine (T120) (p<0.001), justified by increase in equol and equol 
intermediates production. Genistein (p = 0.066), Glycitein (p = 0.009) and ODMA (p = 
0.021) showed a significant increase over time for the group that consumed probiotics. 
The isoflavone-probiotic association was also able to increase equol intermediates in T60 
and T120, compared from the baseline values (p <0.001). Aglycones, intermediates and 
equol do not showed statistically significant difference over time to ISO and HT groups. 
However, significant differences were observed in the interaction effect of time of 
isoflavone with probiotic use compared to equol urinary concentration after 12 weeks of 
intervention, its possible to observe natural equol producers, defined as women who 
produced equol at initial time (T0). 
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Table 1. Urinary content of aglycones, intermediates compounds, equol and ODMA in postmenopausal women over 4 months. 
 ISO – Median (Q1-Q3)  ISO+PROB - Median (Q1-Q3)  HT - Median (Q1-Q3)  
Urinary 
content 
(ug/mL) 
Baseline 
(n=19) 
2 months 
(n=18) 
4 months 
(n=17) 
p-
value* 
Baseline 
(n=19) 
2 months 
(n=19) 
4 
months 
(n=19) 
p-
value* 
Baseline 
(n=19) 
2 
months 
(n=19) 
4 
months 
(n=19) 
p-
value* 
Daidzein 0.0 (0-0) 2.98 (0- 
27.74) 
14.72 (2.19-
71.20) 
0.16 0.0 (0-0) 9.23 (0-
20.38) 
3.61 
(1.49-
8.93) 
<0.001 0.0 (0-0) 0.0 (0-
0) 
2.48 (0-
6.03) 
0.003 
Genistein 1.82 (0-
2.98) 
2.13 (0-
4.00) 
5.37 (3.57-
9.41) 
0.87 2.01 (0-
3.20) 
2.06 (0-
3.33) 
7.50 
(5.74-
9.86) 
0.07 2.18 (0-
3.32) 
0.0 (0-
1.96) 
5.28 
(3.59-
7.23) 
0.19 
Genistein 
intermediary 
0.0 (0-
2.26) 
0.0 (0-
4.25) 
0.0 (0-1.88) 0.41 1.89 (0-
2.39) 
1.38 (0-
1.92) 
0.0 (0-
2.02) 
0.54 2.00 (0-
2.42) 
0.0 (0-
1.67) 
0.0 (0-
1.97) 
0.88 
Glycitein 0.0 (0-0) 0.0 (0-0) 1.66 (0-2.96) 1.00 0.0 (0-0) 0.0 (0-
2.31) 
2.41 
(1.78-
3.19) 
0.01 0.0 (0-0) 0.0 (0-
0) 
2.09 (0-
2.97) 
0.39 
Equol 1.90 (0-
2.64) 
3.44 (1.65-
7.21) 
2.32 (0-4.57) 0.15 2.08 (1.78-
3.45) 
2.24 (0.0-
3.95) 
2.74 
(2.09-
3.49) 
0.15 1.67 (0-
2.22) 
1.32 (0-
3.16) 
1.78 (0-
3.24) 
0.27 
Equol 
intermediary 
1.58 (0-
2.22) 
2.51 (2.01-
51.61) 
2.97 (2.50-
4.35) 
0.76 0.0 (0-2.22) 3.34 
(1.74-
11.64) 
3.01 (0-
3.97) 
<0.001 1.59 (0-
1.89) 
0.0 (0-
1.76) 
2.28 (0-
2.92) 
0.15 
ODMA 0.0 (0-0) 0.0 (0-0) 0.0 (0-1.30) 1.00 0.0 (0-0) 0.0 (0-
5.71) 
1.76 (0-
4.48) 
0.02 0.0 (0-0) 0.0 (0-
0) 
0.0 (0-
3.36) 
0.07 
*p-value referring to Kruskal-Wallis test. Q1: first quartile; Q3: third quartile.
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The compounds identification was performed by ions comparation and time retention, as 
shown in figure 2. After hydrolysis and derivatization reactions the compounds are 
introduced into the GC-column as trimethylsilyl (TMS) ethers or N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA). 
 
 
Figure 2. Typical chromatogram of urine samples showing retention times of equol (m/z 
192), daidzein (m/z 398), genistein (m/z 471) and glycitein (m/z 428). 
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The structures of the isoflavones isolated were confirmed by using authentic reference 
compounds. The figure 3 highlights the equol reference spectrum compared to compound 
identified in urine, pointing base and secondary ions (192 – 386). The molecular ion (m/z 
192, 100%) and the respective trimethylsilyl derivate ion (m/z 386, 90%). 
 
Figure 3. Mass spectrum of trimethylsilyl derivates of gas-chromatographic-separetd 
equol. A: urinary equol; B= authentic equol (analytical standard). 
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The figure 4 shows the equol producers and non-producers at baseline of study T0, T60 
and T120 times, considering as non-producing those with equol <2.70 ug/ml, women that 
did not present the compound in the urine were not part of the median. Producers were 
defined as every woman with urinary presence of the metabolite above 2.70 ug/ml, the 
equol production median over time. The equol-producers percentage was 21%, 56% and 
47% for ISO group, 26%, 47%, 53% for ISO+PROB group and 11%, 32% and 32% to 
HT group, considering T0, T60 and T120 times. Women with equol production in T0 was 
named natural equol-producers. 
 
 
Figure 4. Distribution of equol producer and non-producer number in each group over 
time. Data comparisons were non significant (p=0.98 for group, p=0.99 for time, p=0.99 
for group x time). 
 
The ODMA producer percentage observed at time T60 was 47%, 47% and 11% for ISO, 
ISO+PROB and HT, respectively. For both production profiles (equol and ODMA), the 
cut-off was established from the data found in this study. 
 
3.2 Metabolic profile of isoflavones and their metabolites throughout treatment 
The isoflavone aglycones were effectively absorbed, and the biotransformation in equol 
intermediates and ODMA was significantly more expressive in the group that used 
isoflavone associated with probiotics, as can be seen in the graphs (Figure 5). The p-
values in bold are referring to the group ISO+PROB. 
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As can be seen in figure 5, there was a significant decrease in daidzein and in parallel a 
significant increase of the equol and ODMA intermediate in the ISO+PROB group, 
evidencing an intense metabolization. 
 
 
Figure 5. Concentrations of major urinary isoflavones and metabolites evaluated 
throughout the study. A) Daidzein; B) Genistein; C) Glycitein; D) Equol intermediates; 
E) O-DMA. Data are means ± SD and different letters represent statistical diferences, 
where a represents the comparison between groups, b comparison between time points and 
c interaction betwenn group-time. Statistically significant differences (p value <0.05) are 
show above the charts for the identified comparisons. 
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3.2.1 Comparative Analysis between Equol producer status and MRS 
 
Table 2 shows a descriptive statistics of subscale items of Menopause Rating Scale, from 
somatovegetative, psychological and urogenital areas, in relation to the production or no 
production of equol at baseline, T60 and T120. The time it takes to decrease the 
symptomatology, but not the equol production.  
Table 2. Descriptive analysis of Menopause Rating Scale (MRS) items by time and equol 
production relation. 
Subscales e Total MRS Equol producer Equol Nonproducer 
 Mean±SD (Median) Mean±SD (Median) 
Somatic   
T0 (n=57) 8.43 ± 3.69 (9.00) 9.24 ± 3.48 (9.00) 
T60 (n=56) 4.59 ± 3.74 (5.00) 3.04 ± 2.86 (3.00) 
T120 (n=55) 3.41 ± 3.16 (3.00) 2.26 ± 2.56 (2.00) 
Psychological   
T0 9.09 ± 4.52 (9.00) 8.76 ± 4.45 (9.00) 
T60 4.24 ± 3.32 (4.00) 3.59 ± 3.49 (2.00) 
T120 3.59 ± 3.18 (3.50) 2.48 ± 3.67 (2.00) 
Urogenital   
T0 3.30 ± 2.93 (3.00) 4.82 ± 3.66 (5.50) 
T60 2.90 ± 2.87 (2.00) 2.93 ± 2.84 (2.00) 
T120 2.81 ± 2.38 (3.00) 2.13 ± 2.28 (2.00) 
Total score   
T0 20.83 ± 8.91 (20.00) 22.82 ± 9.05 (22.00) 
T60 11.72 ± 8.25 (12.00) 9.56 ± 7.52 (7.00) 
T120 9.81 ± 7.30 (8.00) 6.87 ± 6.73 (5.00) 
Values expressed as mean ± SD and median. 
 
In Table 3, are presented the results of the comparative analysis of MRS items according 
to group (ISO, ISO + PROB and HT), producer Equol status (classified by the median in 
<2.128 (No) and ≥2.128 (Yes)) and time (T0, T60 and T120), through the analysis of 
Generalized Estimating Equations (GEE). Due to the absence of normal distribution of 
the MRS scores, the transformation by ranks was used in the analyzes. Regarding the 
median value of equol used for association with MRS, the value of 2.128 ug/ml was used 
as a cut-off point for equol production. Women with equol equal to zero, considered non 
equol-producer, were included due to also present menopausal symptoms. Comparisons 
based on the reference variables. 
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Table 3. Results of GEE analysis for comparison of MRS subscale (somatic, 
psychological and urogenital) and total score, between intervention groups, equol 
production status and times in comparison to references: isoflavone (group), baseline 
(time) and non-producer (metabolic status). 
 Estimate SE 95% CL p-value 
Somatic     
Equol producer 0.05 0.06  -0.07 to 0.16  0.44 
Equol Nonproducer (ref.) -- -- -- -- 
HT 0.13 0.09 -0.04 to 0.31 0.14 
ISO+PROB 0.11 0.09 -0.07 to 0.28 0.24 
ISO (ref.) -- -- -- -- 
T0 (ref.) -- -- -- -- 
T60 -0.62 0.07 -0.75 to -0.49 <0.0001 
T120 -0.78 0.08 -0.94 to -0.63 <0.0001 
Psychological     
Equol producer 0.05 0.06 -0.07 to 0.17 0.44 
Equol Nonproducer (ref.) -- -- -- -- 
HT 0.004 0.10 -0.20 to 0.21 0.97 
ISO+PROB -0.05 0.09 -0.24 to 0.14 0.58 
ISO (ref.) -- -- -- -- 
T0 (ref.) -- -- -- -- 
T60 -0.54 0.08 -0.69 to -0.39 <0.0001 
T120 -0.71 0.09 -0.90 to -0.53 <0.0001 
Urogenital     
Equol producer -0.01 0.07 -0.15 to 0.11 0.84 
Equol Nonproducer (ref.) -- -- -- -- 
HT 0.18 0.16 -0.14 to 0.50 0.26 
ISO+PROB 0.21 0.16 -0.09 to 0.51  0.18 
ISO (ref.) -- -- -- -- 
T0 (ref.) -- -- -- -- 
T60 -0.22 0.06 -0.35 to -0.09 0.0007 
T120 -0.27 0.07 -0.40 to -0.13 0.0001 
Total score     
Equol producer -0.01 0.07 -0.15 to 0.14 0.91 
Equol Nonproducer (ref.) -- -- -- -- 
HT 0.21 0.13 -0.06 to 0.47 0.12 
ISO+PROB 0.15 0.14 -0.12 to 0.41 0.28 
ISO (ref.) -- -- -- -- 
T0 (ref.) -- -- -- -- 
T60 -0.75 0.08 -0.91 to -0.58 <0.0001 
T120 -0.95 0.10 -1.15 to -0.75 <0.0001 
SE: Standard error; 95% CI: 95% confidence interval; ref.: reference; statistically 
significant differences: p-value <0.05. 
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3.3 Gut microbiota profile  
In phyla (Figure 6A), significant differences were observed in Firmicutes that increased 
55.32% to 67.11% (413.1±295.7 to 580.8±664.5) for ISO; 59.72% to 71.40% 
(587.3±488.8 to 473.1±345.5) for ISO+PROB and 63.97% to 66.17% (121.8±547.3 to 
746.8±258.9) for HT (p#=0.0012, p$=0.06; p&=0.05). The Bacteroidetes phyla decrease 
35.82% to 21.42% (267.5±209.2 to 185.4±23.6) for ISO; 32.88% to 20.67% (323.4±329.2 
to 136.9±186.9) for ISO+PROB and increase 63.97 to 66.17% (315.1±24.9 to 
527.7±265.4) for HT (p#=0.01, p$=0.71; p&=0.01), showing significant differences 
between the groups where the ISO and ISO+PROB groups had a lower prevalence of this 
phyla, which has an important role on gut microbiome homeostasis. The data were 
expressed as percentage changes and comparison of the mean ± SD relative abundances 
of taxonomies at the phylum and genus level for each dataset were enclosed in 
parentheses. 
 
In genera (B), Faecalibacterium increase 18.83% to 19.77% (827.9±674.7 to 
852.1±898.2) for ISO; 14.42% to 19.59% (882.1±71.8 to 732.9±535.7) for ISO+PROB; 
17.67% to 24.93% (115.6±929.2 to 294.2±149.6) for HT (p<0.01 for all comparisons). 
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Flavobacterium decrease 10.47% to 5.37% (46.0±546.3 to 231.3±214.2) for ISO; 9.33% 
to 8.24% (570.7±555.4 to 308.5±43.5) for ISO+PROB and 9.23% to 11.78% 
(603.8±645.5 to 139.1±732.9) for HT (p# < 0.01, p$=0.37; p& <0.01) 
Prevotella decrease 13.70% to 3.15% (602.1±111.7 to 135.9±165.9) for ISO; 7.43% to 
4.86% (454.4±642.4 to 181.7±446.4) for ISO+PROB and increase 3.59% to 6.19% 
(235.1±372.2 to 731.6±411.4) for HT (p#=0.65, p$=0.53; p&=0.01) 
Ruminococcus increase 7.90% to 12.71% (347.5±323.8 to 547.9±630.5) for ISO; 11.63% 
to 13.99% (711.3±775.5 to 523.4±621.7) for ISO+PROB and decrease 10.03% to 9.91% 
(656.7±37.8 to 117.1±617.3) for HT (p#=0.02 p$=0.15; p&=0.08) 
 
 
In species (C), Alkaliphilus crotonatoxidans increase 3.46% to 4.63% (519.7 ± 636.5 to 
462.3±922.1) for ISO (p=0.786); 7.49% to 21.39% (118.1±954.3 to 196.2±197.5) for 
ISO+PROB (p=0.157) and decrease 10.96% to 4.58% (204.1±383.3 to 163.4±140.1) for 
HT (p=0.748). 
Faecalibacterium prausnitzii increase 22.44% to 33.98% (337.2±307.4 to 339.4±369.1) 
for ISO (p=0.978); 20.31% to 23.47% (215.3±213.4 to 320.1±294.9) for ISO+PROB 
(p=0.204) and 20.00 to 29.61% (372.4±429.0 to 105.6±593.4) for HT (p=0.003) 
Blautia coccoide increase 5.29% to 14.45% (144.4±182.3 to 794.4±566.3) for ISO 
(p=0.129); 5.58% to 9.60% (879.6±658.2 to 880.5±762.8) for ISO+PROB (p=0.997) and 
decrease 10.59% to 10.10% (197.1±107.9 to 160.2±161.1) for HT (p=0.026) 
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Roseburia faecis decrease 9.52% to 8.42% (943.1±164.0 to 840.7±121.6) for ISO 
(p=0.148); increase 5.93 to 9.80% (899.5±12.4 to 934.0±112.3) for ISO+PROB 
(p=0.927) and also decrease 15.06% to 7.75% (280.5±234.1 to 276.3±151.9) to HT 
(p=0.951). 
 
 
 
Figure 6. Fecal microbiota composition (% reads basis) of each group over time 
according to (A) phyla, (B) genera and (C) species. Statistical analysis performed with 
repeated measures ANOVA, where: p#: p-value comparison between groups, p$: p-value 
comparison between time-points, p&: p-value group-time interaction. 
 
 
In order to visualize distances or clusters among the different groups the data 
were submitted to Principal component analysis (PCA). In Figure 7, it is observed PCA 
plots of the gut microbiota in phyla level for isoflavone, isoflavone with probiotics and 
hormone therapy groups. Points that are close together have concordant relative 
abundance across all samples. The increase in the proportion of Firmicutes showed a 
positive association with microbial diversity.
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Figure 7. Principal coordinate plots by phyla. 
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In table 4, the sequencing of faecal samples detected wide variations in bacterial 
population sizes among subjects, and between samples from the same subject at both 
sampling points, with an important population formed by Bacteroides sp. and Clostridium 
sp.  
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Table 4. Gut microbiota composition as number of reads (Mean ± SD) in all menopausal woman before and after intervention.
Species ISO - Mean (SD) ISO+PROB - Mean (SD) HT - Mean (SD) ¥ ANOVA 
 T0 T120 T0 T120 T0 T120 p# p$ p& 
Akkermansia muciniphila 59.60 (435.31) 1015.76 (0.11) 126.09 (261.50) 364.39 (0.12) 782.25 (216.00) 131.56 (0.27) <0.05 <0.05 <0.05 
Slackia piriformis 14.41 (26.79) 28.54 (0.11) 85.70 (21.06) 25.17 (0.31) 65.42 (72.54) 65.06 (0.35) 0.0201 0.5985 0.2084 
Adlercreutzia equolifaciens 49.32 (40.10) 77.77 (0.75) 46.53 (24.38) 32.13 (0.38) 111.81 (181.09) 121.06 (0.08) <0.001 0.0634 0.0270 
Bacteroides stercoris  1655.37 (1392.79) 4958.21 (0.74) 1146.46 (469.78) 671.01 (0.12) 2429.50 (960.0) 591.43 (0.61) <0.0001 <0.0001 0.2198 
Faecalibacterium prausnitzii  3556 (3054) 3819 (3842) 3509 (3070) 2273 (2138) 5481 (4547) 10561 (5934) <0.0001 0.1111 0.0088 
Roseburia faecis  2281 (1885) 1375 (1551) 1745 (1251) 2262 (1879) 4349 (1897) 3206 (1722) 0.0093 0.3504 0.4068 
Alkaliphilus crotonatoxidans  1541 (0) 4000 (0) 2056 (798) 2691 (1858) 5657 (6618) 5073 (0) 0.3481 0.6424 0.7819 
Prevotella copri  7763 (10756) 1683 (1806) 6422 (6645) 2841 (4066) 5915 (4587) 7051 (3106) 0.7040 0.1675 0.3446 
Bacteroides dorei  680.37 (558.89) 1431.34 (0.61) 445.36 (420.05) 1069.45 (0.42) 935.00 (252.72) 181.69 (0.15) <0.0001 0.0046 0.0737 
Slackia isoflavoniconvertens 31.99 (48.21) 113.09 (0.39) 39.76 (9.44) 16.58 (0.12) 33.14 (110.18) 105.80 (0.02) 0.0401 0.0296 0.0198 
Lactobacillus delbrueckii 0.23 (0.37) 0.95 (0.19) 1.42 (0.77) 3.06 (0.64) 2.36 (0.00) 5.41 (0.18) 0.3096 0.0480 0.2335 
Clostridium cadaveris  3220 (2579) 868 (516) 3069 (2353) 953 (515) 8377 (0) 5708 (2911) 0.0005 0.0305 0.9766 
Bacteroides vulgatus  2427 (1286) 3097 (3725) 3794 (4828) 2246 (1558) 5654 (2748) 4181 (1961) 0.1012 0.3762 0.5081 
Rikenella microfusus  1066 (880) 972 (1253) 666 (0) 616 (21) 3956 (0) 2784 (2139) 0.0429 0.5967 0.8141 
Slackia heliotrinireducens 0.3153 (0.31) 0.5824 (0.16) 0.4714 (0.38) 0.6978 (0.13) 0.3015 (0.27) 0.4671 (0.34) 0.8692 0.0473 0.9343 
Bifidobacterium adolescentis  363.70 (1433.84) 3478.53 (0.1043) 620.64 (746.38) 1068.16 (0.1341) 491.13 (728.81) 1338.80 (0.1269) 0.7452 0.0316 0.4906 
Bacteroides uniformis  1567 (862) 940 (735) 11783 (0) 637 (331) 3761 (2608) 5143 (0) 0.0062 0.0054 0.0007 
Parabacteroides merdae  1768 (2217) 894 (0) 7561 (4629) 0 (0) 0 (0) 0 (0) >0.05 >0.05 >0.05 
Lactobacillus rhamnosus 0.21 (0) 0.71 (0.21) 0.39 (0) 1.19 (0.18) 1.09 (0) 2.98 (0.25) 0.3631 0.0263 0.3631 
Oscillospira eae  605 (0) 5404 (6052) 1493 (1531) 1816 (1115) 2074 (311) 0 (0) >0.05 >0.05 >0.05 
Blautia coccoides  750 (198) 1629 (1388) 1043 (1137) 1147 (1018) 3056 (709) 4094 (1303) 0.0002 0.1684 0.6959 
Ruminococcus gnavus  647 (0) 2812 (2764) 0 (0) 29 (0) 6959 (0) 4087 (0) >0.05 >0.05 >0.05 
Bacteroides rodentium  1465 (52) 804 (98) 4661 (5427) 0 (0) 3268 (0) 2891 (0) >0.05 >0.05 >0.05 
Eggerthella sp. 59.23 (79.84) 247.35 (0.51) 71.49 (41.83) 64.72 (0.72) 84.19 (184.63) 89.12 (0.004) 0.0002 0.0006 0.0004 
The mean difference is significant at the p<0.05, bonferroni’s post hoc. # Comparison between groups, $ Comparison between time-points, & Group-time interaction. 
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A total of 603 species were classified and, of those, the 24 most prominent ones related 
to isoflavone metabolism appear in Table 3. For this analysis, were considered 48 fecal 
samples, being 19 samples to ISO, 18 samples to ISO+PROB and 11 samples to HT 
(figure 1), chosen by randomization and sequenced before and after the intervention, 
independent of the production status of equol. 
 
In table 5, were grouped the main equol-producing bacteria found only in women 
considered equol-producers. 
 
Table 5. Mainly intestinal bacteria capable of metabolizing daidzein to equol found in 
women equol-producers at the end of treatment, described as number of reads sequenced 
(Mean ± SD). 
 
 ISO ISO+PROB HT p-value* 
Akkermansia muciniphila 535 (1083) 266 (321) 112 (35) 0.647 
Adlercreutzia equolifaciens 70 (109) 15 (17) 90 (24) 0.224 
Faecalibacterium 
prausnitzii 
4771 (4238) 1507 (1079) 5290 (1902) 0.073 
Prevotella copri 834 (779) 936 (820) 4504 (1863) <0.001 
Slackia isoflavoniconvertens 35 (73) 15 (20) 64 (32) 0.378 
Bifidobacterium 
adolescentis 
682 (1071) 755 (950) 937 (1550) 0.942 
Blautia coccoides 1168 (1025) 470 (298) 2264 
(1191) 
0.064 
Eggerthella sp 27 (17) 23 (21) 177 (67) <0.001 
The mean difference is significant at the p<0.05, tukey’s post hoc. 
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4. Discussion 
In this study, it was investigated the influence of soy isoflavones administration, 
associated or not with probiotics, on equol production and the gut microbiota profile in 
menopausal women, compared to hormone therapy. The soy isoflavones quantification 
in urine and their conjugate metabolites show large variations in metabolism and 
excretion of these compounds between menopausal women. We found that isoflavones 
urinary concentration were directly associated with modification in composition and 
activity of the intestinal microbial community; equol-producing status was modulated by 
the consumption of isoflavones and mainly by the association of probiotics. 
Our finding are attributed to bidirectional relation between polyphenols and microbiota. 
The gut microbiota biotransforms polyphenols into more bioavailable metabolites, while 
unabsorbed polyphenols are involved in maintaining intestinal environment favorable to 
probiotics, indicating that the concept of prebiotics is not limited to non-digestible 
carbohydrates [18-20]. In this study, the decrease in daidzein excretion and increased 
production of equol and ODMA intermediates in the ISO+PROB group, demonstrated 
that the association of probiotic strains with isoflavones favored the breakdown of 
daidzein in intermediary compounds, such as dihydrodaizein, and the formation of active 
metabolites, as observed in urine analysis of this study (table 1) and other publications 
[10,11]. 
Clavel and Mapesa [21] identify as one of the possible bacterial routes for the conversion 
of dietary phenolics, reduction and ring fission by microorganisms as Coriobacteriaceae 
spp. e Eubacterium ramulus, as seen below in figure 8, which act in steps 1 and 2 
respectively, are able to biotransform up to 60% of dietary daidzein in equol, suggesting 
that specific probiotics isolated strains can be used to mimic physiological roles of 
phenolic-converting natural microbiota. 
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Figure 8. Proposed metabolic pathway of soy isoflavone daidzein. 
The chemical forms in which isoflavones are offered in a dietary or supplementation are 
determinant for its bioavailability and biological activity, once aglycones are absorbed 
more efficiently than isoflavone glucosides [22,23]. In our study, consumption of 
isoflavone supplement influenced urinary isoflavone excretion (Figure 5, Table 1), where 
it is possible to observe the presence of soy aglycones (daidzein, genistein and glycitein) 
and the metabolite equol identification. As show in figure 3, MS spectrum of equol 
recovered in the urine is identical to authentic equol (analytical standard), indicating that 
the method of analysis is reliable for quantification of the urinary equol contents. 
Although several methods have been proposed to evaluate equol production profile and 
determine whether a population is equol producer or non-producer, the cut-off point for 
the equol status remains arbitrary, conditioned to the population and evaluation type 
performed (plasmatic or urinary) [24,25]. In this study, for the production status of equol 
was defined a median of equol production (2.70 ug/ml), considering all subject over time 
where the equol was identified in some quantity different from zero, and based on this 
cut-off producers and non-produces were identified. About 60-95% of population around 
the world may produce ODMA, while approximately 25–60% of individuals are capable 
of produce equol; the major frequency between of equol-producers in adults from Japan, 
Korea, or China or in Western adult vegetarians [26-28]. Our findings agrees with the 
established values, over 50% in the groups that used isoflavones plus probiotics and 
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remaining in 32% among individuals who used hormone therapy, agreeing with the 
expected prevalence of equol producers in the western population (30-35%) [29]. In the 
HT group 2 participants were natural equol-producers, while in ISO and ISO+PROB 
group were found 4 and 5 natural equol-producers, respectively. The association of 
isoflavones with probiotics has led to a greater number of non-producers becoming 
producers. At the end of the 4 months of study (T120) twelve women of ISO group (71%) 
had equol in some concentration in the urine, against eighteen women of ISO+PROB 
group (95%), corroborating the greater biotransformation capacity of daidzein to equol 
when associated to probiotic strains [11]. 
Some evidences suggest that equol-producer phenotype proved to be stable over long 
time [30-32], although also there are suggest a profile variable over short time periods 
[34]. In figure 6, the findings showed a phenotype quickly changed (16-weeks), with 
isoflavone-probiotics association able to modify gut microbiota composition and promote 
equol-producer phenotype in non-producer subjects. 
The isoflavones aglycones excretion (daidzein, genistein and glycitein) was continued 
increased in supplementation with probiotics strains. When these results are compared to 
alone isoflavone, and mainly to control, hormone therapy (figure 6), its possible observe 
that isoflavones affect and are affected by members of the dominant gut microbiota 
because their bifidogenic action and possible prebiotic effect, [21,35,36], especially when 
studied in the biotransformation of soybean extracts, making it a promising nutraceutical 
to treat or improve menopausal symptoms [37,38]. 
Isoflavones may favor gut environment to promote specific gut microbial species and 
provide health benefits to host. In this study, the isoflavones and isoflavones with 
probiotics ingestion altered the abundance at several taxonomic hierarchies, with 
Firmicutes phyla, by far the most abundant and diverse group, increase in all treatments 
(p=0.0012) and Bacteroidetes decrease in presence of isoflavones, associated or no to 
probiotics (p=0.0128).  
In our study equol-producer status and the microbial diversity showed a positive 
correlation with the increase in the phylum Firmicutes, particularly lactic acid bacteria. 
Similarly, Guadamuro et al. [39] in an in vitro anaerobic culture model with faecal 
cultures from equol producing and non-producing women, find major part of sequences 
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attributed to phylum Firmicutes (mean 55%), followed by sequence less abundant from 
Bacteroidetes (27%), Actinobacteria (9%) and Proteobacteria (7%). 
At the genus level, increases were recorded for Faecalibacterium and Ruminococcus, 
butyrate producers as primary metabolic end products, while decrease for Prevotella 
member of Bacteroidetes, acetate and propionate producers [40,41]. In specie level, was 
observed an increase of anti-inflammatory bacterium Faecalibacterium prausnitzii, 
butyrate-producing Roseburia faecis, beside that equol-producing Alkaliphilus 
crotonatoxidans and Blautia coccoide in ISO+PROB group. In PCA analysis by phyla 
(figure 7), its possible observe that final ISO+PROB intervention profile was similar to 
HT group, suggesting a more bioavailable fraction of hormone to bind to receptors and 
tissue uptake in the presence of probiotics and the importance of the conversion of 
phenolics compounds from the diet of the individuals in the HT group. 
Adequate estrogen levels are important for a wilderness of functions outside of 
reproductive target tissues. Specific to the microbiome, estrogen and estrogen-like 
compounds (isoflavones) prevent the dysbiosis and promote growth and proliferation of 
beneficial bacteria [42]. Daidzein-converting bacterias to equol and ODMA, a less 
estrogenic metabolite, were found in all groups of study. Soy isoflavones genistein and 
glycitin, by increasing the concentration of Bifidobacterium, while suppressing 
Clostridiaceae, also collaborates to significantly change the structure and the composition 
of the gut bacterial community in postmenopausal women, demonstrating that microbial 
diversity could play a key role in equol production [35].  
In this study, isoflavones modified the colonic microbiota by increase specific microbial 
strains capable to biotransform glycosylated forms to aglycons. Bacteria Slackia 
isoflavoniconvertens (p=0.0296) and Eggerthella spp. (p<0.001), belonging to the 
Coriobacteriacea family, residents of distal portion of the gut and important participants 
in the conversion of the isoflavonoids into equol, were significantly increased in ISO 
group, but not in women who used isoflavone associated to probiotics. When only the 
women equol-producers are observed, Prevotella copri and Eggerthella sp. strains are 
significantly increased in hormone therapy group (table 5), demonstrating the importance 
of estrogen to gut barrier integrity [43]. Dysbiosis can impair the process of deconjugating 
estrogen, resulting in reduced circulating free estrogen levels [42]. 
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Unfavorable alterations in the composition of the fecal microbial community when 
combined with low estrogen levels, sedentary life style and fat-sugar rich diet, may favor 
a range of metabolic disorders. Postmenopausal women may become more susceptible to 
weight gain, hypertension, insulin resistance or abnormal fat distribution. Moreno-Indias 
et al. [44] highlighted in his study the increase of Bifidobacterias, Lactobacillus, 
Faecalibacterium prausnitzii and Roseburia, intestinal barrier protectors, when extracts 
rich in red-wine polyphenols were used in metabolic-syndrome-obese patients. 
Isoflavones can modulate the intestinal microbiota to avoid metabolic disorder. 
The main limitation of the study was the period of collection of urine. Isoflavones have a 
maximum excretion peak at 6 to 12 hours after ingestion; since the half-life of such 
phenolics is short [12]. Participants in the studies were instructed to take the medication 
at night and collect first urine, but some were unable to collect as directed.  
Based on MRS-equol correlation, analysis result of GEE test in the trust level 95% 
statistically show the significant correlation between equol level with menopause 
symptom based on MRS in postmenopausal women urine with p <0.001 over time, 
although this significant interaction is not seen for groups. In general, when evaluating 
the difference between the use of hormone therapy or isoflavone with probiotics in equol-
producing women, it is observed that time, but not intervention, attenuate the symptoms 
in total MRS and the somatic, psychological and urogenital subscales.  
The findings of the study indicate that isoflavone, associated or no to probiotics, provide 
an important change in fecal microbiota being able to induce non equol producers to 
become producers, and may bring some relief from climacteric symptoms over time, 
which may influence positively the postmenopausal metabolism. The ability to produce 
equol might not depend only the quantity, but mainly on the quality and feasibility of 
these bacteria and their optimal function within the host microbiome. Superior results 
could be achieved with a long-term intervention, with higher probiotics concentration and 
controlled diet. 
 
 
 
169 
 
 
 
 
Conclusion 
A high ratio of urinary equol-producers was observed in the postmenopausal Brazilian 
women participants of this study, that used isoflavone, and mainly isoflavones associated 
to probiotics. In the study population, about 50% of women using isoflavone associated 
or not with probiotics were equol-producers, whereas among HT users, only 30% 
converted daidzein to equol. The prevalence of the ODMA-producer phenotypes has been 
47% for ISO or ISO+PROB group and 11% to HT. 
The composition of the faecal bacterial communities was modified by the presence of 
phenolic compounds, including increases in equol-producing taxa associated to this 
microbial community. Even if, women with an equol-producer phenotype were primary 
benefited, equol non-producer also developed the ability to produce this compound after 
the intervention. Our findings corroborate that the ability to convert daidzein to equol can 
be induced in nonproducers, through the modulation of the gut microbiota. 
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5.DISCUSSÃO GERAL 
A sintomatologia climatérica, de ordem vasomotora, psicológica e urogenital, causada 
pelas flutuações hormonais são extremamente comuns na transição menopausal, sendo os 
sintomas vasomotores a manifestação mais comum, uma vez que 75% das mulheres pós-
menopausadas relatam incomodo por ondas de calor e suores noturnos que afetam 
diretamente sua qualidade de vida (1). Pedro et al. (2), destacou em um estudo de base 
populacional que a prevalência de ondas de calor na mulher Brasileira peri ou pós-
menopausada é de aproximadamente 70%, o que leva 80% destas mulheres a procurarem 
tratamento na rede de saúde. 
A terapia hormonal (TH) é a abordagem de primeira escolha para o tratamento dos 
sintomas vasomotores, da síndrome genitourinária e para a prevenção da perda de massa 
óssea e fraturas associadas (3). A relação risco-benefício do uso da terapia hormonal é 
favorável para mulheres com menos de 60 anos de idade ou dentro da “janela de 
oportunidade” (10 primeiros anos de menopausa) sem contraindicações diretas, como 
histórico pessoal de câncer de mama ou útero. A recomendação atual é de prescrição da 
menor dose efetiva para o menor período de duração da terapia, individualizando-se o 
tratamento (4,5). Para mulheres com mais de 60 anos, ou aquelas que optaram por iniciar 
a TH após 10 anos ou mais desde a menopausa há maiores riscos absolutos de doença 
coronarianas, acidente vascular cerebral, tromboembolismo venoso e demência (5). O 
impacto dos sintomas da menopausa na qualidade de vida é decisório para a escolha de 
se usar ou não a TH, sendo importante que a mulher seja plenamente informada e apoiada 
pela equipe de saúde que a acompanha sobre o adequado tipo, dose, formulação e duração 
da terapia hormonal para que efeitos adversos sejam reduzidos e os benefícios superem 
os riscos da intervenção (6). 
Os sintomas vasomotores geralmente se resolvem dentro de 4-5 anos para a maioria das 
mulheres, embora haja 10-15% de mulheres extremamente sintomáticas que continuam a 
se queixarem de ondas de calor por 7 a 10 anos após a menopausa (1,7). Mulheres pós 
menopausadas que não desejam utilizar a terapia hormonal sistêmica tradicional, por 
contraindicações médicas ou restrições pessoais, podem beneficiar-se de terapias 
complementares e alternativas, como prática de atividade física, terapia comportamental, 
uso off-label de antidepressivos, além de medicações fitoterápicas, como as isoflavonas 
da soja (8,9). Segundo Gold et al. (10), os tratamentos alternativos são parte da rotina de 
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aproximadamente 53% da população climatérica, sendo as isoflavonas da soja mais 
comumente utilizadas por mulheres pós-menopausadas que não fizeram uso de TH 
(p=0.013), mas que possuem alta prevalência de sintomas vasomotores (p=0.005). 
No nosso estudo, as mulheres que utilizaram isoflavonas da soja reportaram importante 
melhora na sintomatologia climatérica. O escore total do MRS e as subescalas somática, 
psicológica e urogenital apresentaram melhora para os três grupos de intervenção, com 
diferença estatística significativa entre os tempos avaliados. O tratamento com 
isoflavonas acrescidas de probióticos foi superior a isoflavona isolada, embora não tenha 
alcançado a efetividade da terapia hormonal, considerada padrão-ouro no manejo dos 
sintomas climatéricos, não sendo observadas diferenças entre produção de equol e 
subescalas do MRS (4,11). Isoflavonas, com propriedades fitoestrogênicas, vem sendo 
largamente estudadas para auxiliar no combate dos sintomas indesejáveis da menopausa, 
porém os resultados não são uniformes, o que dificulta estabelecer um esquema 
terapêutico ideal. 
A eficácia terapêutica dos suplementos de soja pode variar pela administração dos 
compostos nas formas glicosiladas ou agliconas, isoladas ou em conjunto (daidzeína, 
genisteína e gliciteína) e pela proporção e quantidade absoluta de agliconas utilizadas na 
formulação. Além disso, a capacidade individual de metabolizar esses compostos, o que 
inclui uma microbiota intestinal com cepas capazes de biotransformar isoflavonas a 
metabólitos e derivados mais bioativos, também influenciando no efeito farmacológico 
final (9). Uma revisão sistemática (19 ensaios) e metanálise (17 ensaios) avaliou a eficácia 
de isoflavonas de soja (em média 54 mg de agliconas), extraídas do grão ou quimicamente 
sintetizadas, no alívio de ondas de calor em mulheres na peri ou pós-menopausa, e 
encontrou redução de 20,6% a 26,2% (p<0,001) na frequência e severidade das ondas de 
calor para mulheres que usaram fitoestrógenos comparado ao placebo, independente da 
fonte do composto (12).  
Similarmente, a revisão sistemática e metanálise de Chen et al. (13), sobre 15 ensaios 
clínicos randomizados, demonstrou que embora o consumo de isoflavonas não tenha 
reduzido significativamente o índice de Kupperman (p=0,110), índice menopausal que 
classifica intensidade dos sintomas climatéricos, o consumo desses fitoestrógenos 
resultaram em uma redução significativamente maior na frequência de ondas de calor 
(p<0,005), sem efeitos colaterais graves (p=0,175), em comparação ao placebo. 
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Contrapondo-se a estes resultados, a literatura aponta estudos de revisão sistemática e 
metanálise não conclusivos a respeito do alívio de sintomas vasomotores pelo uso de 
isoflavonas (14,15). 
Em nosso trabalho, tanto as isoflavonas isoladas, quanto associadas a cepas probióticas 
resultaram em redução dos sintomas climatéricos, sem promover alterações significativas 
no metabolismo de lipídios e carboidratos. Em acordo com nossos achados, Ricci et al. 
(16) em uma metanálise com 794 participantes, destacou que o uso de isoflavonas não foi 
associado a redução significativa da glicemia em mulheres não asiáticas na peri e pós-
menopausa. Por sua vez, a meta-análise de Zhang, Wu, Fei (2016) sugeriu que o consumo 
de probióticos pode melhorar o metabolismo da glicose em um grau modesto, com um 
efeito potencialmente maior quando a duração da intervenção for superior a 8 semanas, 
ou quando várias espécies de probióticos são consumidas simultaneamente. 
No metabolismo de lipídios, após 16 semanas de intervenção, os níveis de colesterol total 
(p=0,0045) e LDL-c (p=0,0185) foram significativamente menores nas mulheres que 
utilizaram terapia hormonal, mas não sofreram alternação significativa nos grupos em uso 
de fitoestrógenos, associado ou não a probióticos. Embora as isoflavonas não trouxeram 
benefícios ao perfil lipídico, houve relevante interferência em mulheres que receberam a 
terapia hormonal. Lee et al. (17) avaliaram 154 mulheres coreanas pós-menopausadas 
saudáveis em um estudo de coorte retrospectivo, das quais 65 utilizaram estrógeno (39 
oral e 6 transdérmico) e 89 utilizaram estrógeno em combinação com progesterona 
micronizada (40 oral e 40 transdérmico). Após 6 meses de intervenção, LDL-c (p<0,001) 
e lipoproteína-a (p=0,025) diminuíram, e triglicérides (p=0,007) e HDL-c (p=0,001) 
aumentaram significativamente, não sendo influenciados pela adição de progesterona 
micronizada. Os resultados encontrados para isoflavonas são semelhantes aos relatos de 
estudos anteriores (18,19,20). 
Há evidências de que nem todos os indivíduos são capazes de metabolizar as isoflavonas 
a equol, sendo essa variabilidade atribuída às diferenças na composição da microbiota 
intestinal, hábitos alimentares, fatores genéticos, dentre outros (21). A capacidade de um 
indivíduo converter isoflavonas em equol e ODMA, metabólitos de maior atividade 
biológica, gerou a terminologia “produtor” e “não produtor”. Após ingestão de 
isoflavonas da soja a produção de ODMA ocorre em 80-90% da população, enquanto 
cerca de 20 a 30% da população ocidental metaboliza daidzeína a equol, porcentagem 
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baixa se comparada à frequência de aproximadamente 50% da população asiática ou 
vegetariana. A concentração de equol no soro de não produtores é aproximadamente ≤40 
nmol/L, enquanto os produtores apresentam pelo menos o dobro do composto no sangue 
(níveis ≥83 nmol/L) (22-24). 
Rowland et al. (25) definiu como produtor todo indivíduo com excreção 
urinária de equol superior a 1000 nM. A população do nosso estudo apresentou alta 
capacidade de produção de equol, razão pela qual preferiu-se estabelecer um ponto de 
corte próprio, uma vez que o metabolismo de isoflavonas na população avaliada foi 
superior ao encontrado em estudos semelhantes (26). Em nosso trabalho, muitas espécies 
bacterianas responsáveis pelo metabolismo de isoflavonas foram encontradas nas 
amostras de fezes das mulheres menopausadas, dentre elas destacaram-se 
Faecalibacterium prausnitzii, Adlercreutzia equolifaciens, Slackia isoflavoniconvertens, 
Bifidobacterium adolescentis e Eggerthella sp, apontadas como participantes do 
metabolismo da daidzeína (27-29). 
Considerando-se o mecanismo etiopatogênico da menopausa, o emprego de 
probióticos associados a isoflavonas pode apresenta-se como opção segura e com 
expressivo potencial terapêutico adjuvante no alívio de sintomas climatéricos, por meio 
da melhor absorção das isoflavonas e produção de seus metabólitos ativos. Os resultados 
obtidos são bastante instigantes e nos motivam a traçar estudos sobre o sinergismo entre 
isoflavonas e probióticos, a fim de se obter um produto nutracêutico padronizado quanto 
as cepas e suas concentrações, capaz de proporcionar a produção de equol em indivíduos 
não produtores. Além disso, espera-se investigar a relação da produção de equol a outros 
aspectos de satisfação e qualidade de vida da usuária, como influencia na massa óssea e 
associações ao perfil cardio-metabólico e imuno-inflamatório de mulheres na pós-
menopausa. 
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6. CONCLUSÃO GERAL 
 
• O uso de isoflavonas associadas a probióticos mostrou eficácia superior a 
isoflavona isolada, mas ainda inferior a terapia hormonal, na melhora dos 
sintomas climatéricos, sem exercer ação estrogênica no trato urogenital, com boa 
aceitabilidade e poucos efeitos colaterais; 
• Apenas o grupo que utilizou a terapia hormonal apresentou diminuição 
significativa no perfil lipídico (redução de colesterol total e LDL). Não houve 
efeito favorável significativo dos fitoestrógenos nos marcadores do metabolismo 
de lipídios ou carboidratos. 
• A produção de intermediários de equol é significativamente maior no grupo em 
que as isoflavonas são associadas a probióticos. A análise da microbiota intestinal 
demonstrou uma comunidade bacteriana fecal diversificada, com cepas 
responsáveis pela biotransformação de daidzeína a equol. 
• Sintomas menopausais foram reduzidos ao longo do tempo, para todos os grupos, 
independente do status de produção de equol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
 
 
 
7. REFERÊNCIAS 
 
A.B.V. Pinheiro, E.M.A. Lacerda, E.H. Benzecry, M.C.S. Gomes, V.M. Costa, Tabela 
para avaliação de consumo alimentar em medidas caseiras, 4a, Ed. Atheneu, São Paulo, 
2008. 
A.M. Da Fonseca, V.R. Bagnoli, M.A. Souza, R.S. Azevedo, E. De Barros Couto Júnior, 
J.M.S. Júnior, E.C. Baracat, Impact of age and body mass on the intensity of menopausal 
symptoms in 5968 Brazilian women, Gynecol. Endocrinol. 29 (2013) 116–118. 
doi:10.3109/09513590.2012.730570. 
A. Miura, C. Sugiyama, H. Sakakibara, K. Simoi, T. Goda, Bioavailability of isoflavones 
from soy products in equol producers and non-producers in Japanese women, J. Nutr. 
Intermed. Metab. 6 (2016) 41–47. doi:10.1016/j.jnim.2016.08.001. 
A. Uifălean, A. Farcaş, M. Ilieş, S.C. Hegheş, C. Ionescu, C.A. Iuga, Assessment of 
Isoflavone Aglycones Variability in Soy Food Supplements Using a Validated Hplc-Uv 
Method, Clujul Med. 88 (2015) 373. doi:10.15386/cjmed-468. 
A.A. Franke, J.F. Lai, I. Pagano, Y. Morimoto, G. Maskarinec, Equol production changes 
over time in pre-menopausal women., Br. J. Nutr. 107 (2012) 1201–1206. 
doi:10.1017/S0007114511004223. 
A.R.A. de Ávila, L.D. de Queirós, D.B. Lopes, C.G. Barin, T.M. Ueta, A.L.T.G. Ruiz, 
G.A. Macedo, J.A. Macedo, Enhanced estrogenic effects of biotransformed soy extracts, 
J. Funct. Foods. 48 (2018) 117–124. doi:10.1016/j.jff.2018.06.026. 
Ahsan M, Mallick AK. The effect of soy isoflavones on the menopause rating scale 
scoring in perimenopausal and postmenopausal women: A pilot study. J Clin Diagnostic 
Res. 2017;11(9):FC13-FC16.  
Avis NE, Carolina N, Crawford SL. Duration of Menopausal Vasomotor Symptoms Over 
the Menopause Transition. JAMA Intern Med. 2015;175(4):531–9.  
Ahuja, V., Miura, K., Vishnu, A., Fujiyoshi, A., Evans, R., Zaid, M., … Hisamatsu, T. 
(2017). Significant Inverse Association of Equol-Producer Status With Coronary Artery 
Calcification but Not Dietary Isoflavones in Healthy Japanese Men. British Journal of 
Nutrition, 117(2), 260–266. 
https://doi.org/https://doi.org/10.1017/S000711451600458X. 
Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of 
dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91(1):6-11. 
Anderson, J., & Garner, S. (1997). Phytoestrogens and Human Function. Nutrition Today, 
32(6), 232–239. 
Atteritano M, Mazzaferro S, Bitto A, et al. Genistein effects on quality of life and 
depression symptoms in osteopenic postmenopausal women: A 2-year randomized, 
double-blind, controlled study. Osteoporos Int. 2014;25(3):1123-1129. 
doi:10.1007/s00198-013-2512-5. 
B. Morio, A. Fardet, P. Legrand, J.M. Lecerf, Involvement of dietary saturated fats, from 
183 
 
 
 
 
all sources or of dairy origin only, in insulin resistance and type 2 diabetes, Nutr. Rev. 74 
(2016) 33–47. doi:10.1093/nutrit/nuv043. 
B. Sears, C. Ricordi, Anti-inflammatory nutrition as a pharmacological approach to treat 
obesity, J. Obes. 2011 (2011). doi:10.1155/2011/431985. 
Bolanos R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of 
climacteric vasomotor symptoms: Systematic review and meta-analysis. Menopause 
[Internet]. 2010;17(3):660–6. Available from: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&
AN=2010276221%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&
D=medl&NEWS=N&AN=20464785 
Baber, R., Panay, N., & Fenton, A. (2016). 2016 IMS Recommendations on women’s 
midlife health and menopause hormone therapy. Climacteric., 19(2), 109–50. 
https://doi.org/10.3109/13697137.2015.1129166. 
Barnes, S., Prasain, J., D’Alessandro, T., Arabshahi, A., Botting, N., Lila, M. A., … 
Weaver, C. M. (2011). The metabolism and analysis of isoflavones and other dietary 
polyphenols in foods and biological systems. Food & Function, 2(5), 235–44. 
https://doi.org/10.1039/c1fo10025d. 
Benvenuti, C., & Setnikar, I. (2011). Effect of Lactobacillus sporogenes on oral 
isoflavones bioavailability: single dose pharmacokinetic study in menopausal women. 
Phyto-Oestrogens, 61(11), 605–609. 
Beaufrère B, Morio B. Fat and protein redistribution with aging: Metabolic 
considerations. Eur J Clin Nutr. 2000;54:S48-S53. doi:10.1038/sj.ejcn.1601025. 
Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. 
J Steroid Biochem Mol Biol. 2014;139:225-236. doi:10.1016/j.jsbmb.2012.12.004. 
Beral, V. (2003). Breast cancer and hormone-replacement therapy in the Million Women 
Study. Lancet, 362(9382), 419–427. https://doi.org/10.1016/S0140-6736(03)14065-2. 
Bolanos, R., Del Castillo, A., & Francia, J. (2010). Soy isoflavones versus placebo in the 
treatment of climacteric vasomotor symptoms: Systematic review and meta-analysis. 
Menopause, 17(3), 660–666. https://doi.org/10.1097/gme.0b013e3181cb4fb5. 
Brahe, L. K., Le Chatelier, E., Prifti, E., Pons, N., Kennedy, S., Blædel, T., … Larsen, L. 
H. (2015). Dietary modulation of the gut microbiota – a randomised controlled trial in 
obese postmenopausal women. British Journal of Nutrition, 114(3), 406–417. 
https://doi.org/10.1017/S0007114515001786. 
Burkard, M., Leischner, C., Lauer, U. M., Busch, C., Venturelli, S., & Frank, J. (2017). 
Dietary flavonoids and modulation of natural killer cells: implications in malignant and 
viral diseases. The Journal of Nutritional Biochemistry, 46, 1–12. 
https://doi.org/10.1016/j.jnutbio.2017.01.006. 
C. Atkinson, K.M. Newton, E.J. Aiello Bowles, M. Yong, J.W. Lampe, Demographic, 
anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-
metabolizing phenotypes among premenopausal women in the United States, Am. J. Clin. 
184 
 
 
 
 
Nutr. 87 (2008) 679–687. doi:87/3/679 [pii]. 
C.H. Nakatsu, A. Armstrong, A.P. Clavijo, B.R. Martin, S. Barnes, C.M. Weaver, Fecal 
bacterial community changes associated with isoflavone metabolites in postmenopausal 
women after soy bar consumption, PLoS One. 9 (2014). 
doi:10.1371/journal.pone.0108924. 
C.L. Frankenfeld, C. Atkinson, W.K. Thomas, A. Gonzalez, T. Jokela, K. Wähälä, S.M. 
Schwartz, S.S. Li, J.W. Lampe, High concordance of daidzein-metabolizing phenotypes 
in individuals measured 1 to 3 years apart., Br. J. Nutr. 94 (2005) 873–876. 
doi:10.1079/BJN20051565. 
C.L. Frankenfeld, O -Desmethylangolensin : The Importance of Equol ’ s Lesser Known 
Cousin to Human Health, Adv. Nutr. 2 (2011) 317–324. 
doi:10.3945/an.111.000539.Figure. 
C.W. Gallon, M.C.O. Wender, Estado nutricional e qualidade de vida da mulher 
climatérica, Rev. Bras. Ginecol. Obs. 34 (2012) 175–183. 
http://www.scielo.br/pdf/rbgo/v34n4/07.pdf. 
Chen KL, Madak-Erdogan Z. Estrogen and Microbiota Crosstalk: Should We Pay 
Attention? Trends Endocrinol Metab [Internet]. Elsevier Ltd; 2016;27(11):752–5. 
Available from: http://dx.doi.org/10.1016/j.tem.2016.08.001 
Clavel T, Mapesa OJ. Phenolics in Human Nutrition: Importance of the Intestinal 
Microbiome for Isoflavone and Lignan Bioavailability. In: Ramawat KG, Mérillon J-M, 
editors. Handbook of Natural Products. Amsterdam: Springer Berlin Heidelberg; 2013. 
p. 2433–63.  
Cairns, J. R. K., & Esen, A. (2010). b-Glucosidases. Cellular and Molecular Life 
Sciences, 67(20), 3389–3405. https://doi.org/10.1007/s00018-010-0399-2. 
Cao, H., Chen, X., Jassbi, A. R., & Xiao, J. (2015). Microbial biotransformation of 
bioactive flavonoids. Biotechnology Advances, 33(1), 214–223. 
https://doi.org/10.1016/j.biotechadv.2014.10.012. 
Carmignani, L. O., Pedro, A. O., Costa-Paiva, L. H. S. da, & Pinto-Neto, A. M. (2014). 
The effect of soy dietary supplement and low dose of hormone therapy on main 
cardiovascular health biomarkers: a randomized controlled trial. Revista Brasileira de 
Ginecologia E Obstetrícia, 36(6), 251–258. https://doi.org/10.1590/S0100-
720320140004976. 
Carmignani LO, Pedro AO, Costa-Paiva LH, Pinto-Neto AM. The effect of dietary soy 
supplementation compared to estrogen and placebo on menopausal symptoms: A 
randomized controlled trial. Maturitas. 2010;67(3):262-269. 
doi:10.1016/j.maturitas.2010.07.007. 
Carmignani LO, Pedro AO, Montemor EB, Arias VA, Costa-Paiva LH, Pinto-Neto AM. 
Effects of a soy-based dietary supplement compared with low-dose hormone therapy on 
the urogenital system: A randomized, double-blind, controlled clinical trial. Menopause. 
2015;22(7):741-749. doi:10.1097/GME.0000000000000380. 
185 
 
 
 
 
Caruso, S., Cianci, S., Cariola, M., Fava, V., Rapisarda, A. M. C., & Cianci, A. (2017). 
Effects of nutraceuticals on quality of life and sexual function of perimenopausal women. 
Journal of Endocrinological Investigation, 40(1), 27–32. https://doi.org/10.1007/s40618-
016-05002. 
Cassidy, A. (2003). Potential Risks and Benefits of Phytoestrogen-Rich Diets. 
International Journal for Vitamin and Nutrition Research, 73, 120–126. 
https://doi.org/https://doi.org/10.1024/0300-9831.73.2.120. 
Cermak, R., Landgraf, S., & Wolffram, S. (2003). The bioavailability of quercetin in pigs 
depends on the glycoside moiety and on dietary factors. The Journal of Nutrition, 133(9), 
2802–7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12949368. 
Chandrasekara, A., & Shahidi, F. (2012). Bioaccessibility and antioxidant potential of 
millet grain phenolics as affected by simulated in vitro digestion and microbial 
fermentation. Journal of Functional Foods, 4(1), 226–237. 
https://doi.org/10.1016/j.jff.2011.11.001. 
Chang, Y., & Choue, R. (2013). Plasma pharmacokinetics and urinary excretion of 
isoflavones after ingestion of soy products with different aglycone/glucoside ratios in 
South Korean women. Nutrition Research and Practice, 7(5), 393–399. 
https://doi.org/10.4162/nrp.2013.7.5.393. 
Chen, K. I., Erh, M. H., Su, N. W., Liu, W. H., Chou, C. C., & Cheng, K. C. (2012). 
Soyfoods and soybean products: From traditional use to modern applications. Applied 
Microbiology and Biotechnology, 96(1), 9–22. https://doi.org/10.1007/s00253-012-4330-
7. 
Chen FP, Chang CJ, Chao AS, et al. Efficacy of Femarelle for the treatment of climacteric 
syndrome in postmenopausal women: An open label trial. Taiwan J Obstet Gynecol. 
2016;55(3):336-340. doi:10.1016/j.tjog.2016.04.008. 
Cheng M-H, Lee S-J, Wang S-J, Wang P-H, Fuh J-L. Does menopausal transition affect 
the quality of life? A longitudinal study of middle-aged women in Kinmen. Menopause. 
2007;14(5):885-890. doi:10.1097/gme.0b013e3180333a58. 
Cheng, K. C., Wu, J. Y., Lin, J. T., & Liu, W. H. (2013). Enhancements of isoflavone 
aglycones, total phenolic content, and antioxidant activity of black soybean by solid-state 
fermentation with Rhizopus spp. European Food Research and Technology, 236(6), 
1107–1113. https://doi.org/10.1007/s00217-013-1936-7. 
Chien, H. L., Huang, H. Y., & Chou, C. C. (2006). Transformation of isoflavone 
phytoestrogens during the fermentation of soymilk with lactic acid bacteria and 
bifidobacteria. Food Microbiology, 23(8), 772–778. 
https://doi.org/10.1016/j.fm.2006.01.002. 
Chlebowski, R., & Anderson, G. (2015). Menopausal hormone therapy and breast cancer 
mortality: clinical implicationso Title. Therapeutic Advances in Drug Safety, 6(2), 45–
56. https://doi.org/10.1177/ 2042098614568300. 
186 
 
 
 
 
Chun, O. K., Chung, S. J., & Song, W. O. (2009). Urinary Isoflavones and Their 
Metabolites Validate the Dietary Isoflavone Intakes in US Adults. Journal of the 
American Dietetic Association, 109(2), 245–254. 
https://doi.org/https://doi.org/10.1016/j.jada.2008.10.055. 
Clarkson, T. B., Freedman, R. R., Fughberman, A. J., Loprinzi, C. L., Reame, N. K., & 
Society, N. A. M. (2004). Treatment of menopause-associated vasomotor symptoms: 
position statement of the North American Menopause Society. Menopause., 11(1), 11–
33. https://doi.org/10.1097/01.GME.0000108177.85442.71. 
Clavel, T., Fallani, M., Lepage, P., Levenez, F., Mathey, J., Rochet, V., … Coxam, V. 
(2005). Isoflavones and functional foods alter the dominant intestinal microbiota in 
postmenopausal women. The Journal of Nutrition, 135(12), 2786–92. 
https://doi.org/135/12/2786 [pii]. 
Clavel, T., & Mapesa, O. J. (2013). Phenolics in Human Nutrition: Importance of the 
Intestinal Microbiome for Isoflavone and Lignan Bioavailability. In K. G. Ramawat & J.-
M. Mérillon (Eds.), Handbook of Natural Products (pp. 2433–2463). Amsterdam: 
Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-22144-6_94. 
Colditz, G. A., Kaphingst, K. A., Hankinson, S. E., & Rosner, B. (2012). Family history 
and risk of breast cancer: Nurses’ health study. Breast Cancer Research and Treatment, 
133(3), 1097–1104. https://doi.org/10.1007/s10549-012-1985-9. 
Crawford SL, Jackson EA, Churchill L, Lampe J, Leung K, Ockene JK. The impact of 
dose, frequency of administration, and equol production on efficacy of isoflavones for 
menopausal hot flashes: A pilot randomized trial. Menopause. 2013;20(9):911-921. 
doi:10.1097/GME.0b013e3182829413.THE. 
Cremoux, P. de, This, P., Leclercq, G., & Jacquot, Y. (2010). Controversies concerning 
the use of phytoestrogens in menopause management: Bioavailability and metabolism. 
Maturitas, 65(4), 334–339. 
https://doi.org/http://dx.doi.org/10.1016/j.maturitas.2009.12.019. 
Currie, H., Abernethy, K., & Gray, S. (2017). British Menopause Society vision for 
menopause care in the UK (subject to consultation). Post Reproductive Health, 23(3), 
205336911771720. https://doi.org/10.1177/2053369117717207. 
D. Ramdath, E. Padhi, S. Sarfaraz, S. Renwick, A. Duncan, Beyond the Cholesterol-
Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its 
Constituents on Risk Factors for Cardiovascular Disease, Nutrients. 9 (2017) 324. 
doi:10.3390/nu9040324. 
D.B. Lopes, L.D. Queiros, A. de Avila, N.E.S. Monteiro, G.A. Macedo, Bioconversions 
of Isoflavones in Bioactive Compounds, in: A. Grumezescu, A.M. Holban (Eds.), Food 
Bioconversion, 1st Editio, 2017: pp. 55–93. 
D.P.R. Herlemann, M. Labrenz, K. Jürgens, S. Bertilsson, J.J. Waniek, A.F. Andersson, 
Transitions in bacterial communities along the 2000 km salinity gradient of the Baltic 
Sea, ISME J. 5 (2011) 1571–1579. doi:10.1038/ismej.2011.41. 
D.R.S. De Lorenzi, E. Basso, P. de O. Fagundes, B. Saciloto, Prevalência de sobrepeso e 
187 
 
 
 
 
obesidade no climatério, Rev. Bras. Ginecol. E Obs. 27 (2005) 479–484. 
doi:10.1590/S0100-72032005000800008. 
D.R. Matthews, J.P. Hosker,  a S. Rudenski, B. a Naylor, D.F. Treacher, R.C. Turner, 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man., Diabetologia. 28 (1985) 412–419. 
doi:10.1007/BF00280883. 
Dalal P, Agarwal M. Postmenopausal syndrome. Indian J Psychiatry. 2015;57(6):222. 
doi:10.4103/0019-5545.161483. 
Davinelli, S., Scapagnini, G., Marzatico, F., Nobile, V., Ferrara, N., & Corbi, G. (2017). 
Influence of equol and resveratrol supplementation on health-related quality of life in 
menopausal women: A randomized, placebo-controlled study. Maturitas, 96, 77–83. 
https://doi.org/10.1016/j.maturitas.2016.11.016. 
Davis, S. (2015). Menopause. Nature Reviews Disease Primers, 1, 15004. 
https://doi.org/https://doi.org/10.1038/nrdp.2015.4. 
de Queirós, L. D., Macedo, J. A., & Macedo, G. A. (2016). A new biotechnological 
process to enhance the soymilk bioactivity. Food Science and Biotechnology, 25(3), 763–
770. https://doi.org/10.1007/s10068-016-0130-7. 
Deng F, Zito SW. Development and validation of a gas chromatographic-mass 
spectrometric method for simultaneous identification and quantification of marker 
compounds including bilobalide, ginkgolides and flavonoids in Ginkgo biloba L. extract 
and pharmaceutical preparatio. J Chromatogr A. 2003;986(1):121-127. 
doi:10.1016/S0021-9673(02)01921-0. 
Decroos, K., Vanhemmens, S., Cattoir, S., Boon, N., & Verstraete, W. (2005). Isolation 
and characterisation of an equol-producing mixed microbial culture from a human faecal 
sample and its activity under gastrointestinal conditions. Archives of Microbiology, 
183(1), 45–55. https://doi.org/10.1007/s00203-004-0747-4. 
Donkor, O. N., & Shah, N. P. (2008). Production of b-glucosidase and hydrolysis of 
isoflavone phytoestrogens by Lactobacillus acidophilus, Bifidobacterium lactis, and 
Lactobacillus casei in soymilk. Journal of Food Science, 73(1), 15–20. 
https://doi.org/10.1111/j.1750-3841.2007.00547.x. 
Duda-Chodak, A., Tarko, T., Satora, P., & Sroka, P. (2015). Interaction of dietary 
compounds, especially polyphenols, with the intestinal microbiota: a review. European 
Journal of Nutrition, 54(3), 325–341. https://doi.org/10.1007/s00394-015-0852-y. 
E.Y. Ki, S.Y. Hur, J.S. Park, K. Do Han, Y.G. Park, Differences in the lipid profile and 
hormone replacement therapy use in Korean postmenopausal women: the Korea National 
Health and Nutrition Examination Survey (KNHANES) 2010–2012, Arch. Gynecol. 
Obstet. 294 (2016) 165–173. doi:10.1007/s00404-015-3982-9. 
E.A.P. Nahás, J. Nahás Neto, L.A. De Luca, P. Traiman, A. Pontes, I. Dalben, Efeitos da 
isoflavona sobre os sintomas climatéricos e o perfil lipídico na mulher em menopausa, 
Rev. Bras. Ginecol. E Obs. 25 (2003) 337–343. doi:10.1590/S0100-
72032003000500006. 
188 
 
 
 
 
Ensrud, K. E., Joffe, H., Guthrie, K. A., Larson, J. C., Reed, S. D., Newton, K. M., … 
Freeman, E. W. (2012). Effect of escitalopram on insomnia symptoms and subjective 
sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a 
randomized controlled trial. Menopause (New York, N.Y.), 19(8), 848–55. 
https://doi.org/10.1097/gme.0b013e3182476099. 
F. Cardona, C. Andrés-Lacueva, S. Tulipani, F.J. Tinahones, M.I. Queipo-Ortuño, 
Benefits of polyphenols on gut microbiota and implications in human health, J. Nutr. 
Biochem. 24 (2013) 1415–1422. doi:10.1016/j.jnutbio.2013.05.001. 
F. Tomás-Barberán, M. Selma, J. Espín, Interactions of gut microbiota with dietary 
polyphenols and consequences to human health, Curr Opin Clin Nutr Metab Care. 19 
(2016) 471–476. 
F.B. Riserus, Ulf, Willett, Walter C., Hu, Dietary fats and prevention of type 2 diabetes, 
Progress. Lipid Res. 48 (2010) 44–51. doi:10.1016/j.plipres.2008.10.002.Dietary. 
F. Corrado, R. D’Anna, F. Caputo, M.L. Cannata, M.G. Zoccali, F. Cancellieri, 
Compliance with hormone replacement therapy in postmenopausal Sicilian women, Eur. 
J. Obstet. Gynecol. Reprod. Biol. 118 (2005) 225–228. doi:10.1016/j.ejogrb.2004.06.041. 
Finley, J. W., Sandlin, C., Holliday, D. L., Keenan, M. J., Prinyawiwatkul, W., & Zheng, 
J. (2013). Legumes reduced intestinal fat deposition in the Caenorhabditis elegans model 
system. Journal of Functional Foods, 5(3), 1487–1493. 
https://doi.org/10.1016/j.jff.2013.03.007. 
Frankenfeld, C. L. (2017). Cardiometabolic risk and gut microbial phytoestrogen 
metabolite phenotypes. Molecular Nutrition and Food Research, 61(1), 1–15. 
https://doi.org/10.1002/mnfr.201500900. 
Freeman E, Ensrud KE, Larson JC, Guthrie KA. Placebo Improvement in Pharmacologic 
Treatment of Menopausal Hot Flashes: Time Course, Duration, and Predictors. 
Psychosom Med. 2015;77(2):167–175. doi:doi:10.1097/PSY.0000000000000143. 
G. den Besten, K. van Eunen, A.K. Groen, K. Venema, D.-J. Reijngoud, B.M. Bakker, 
The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host 
energy metabolism, J. Lipid Res. 54 (2013) 2325–2340. doi:10.1194/jlr.R036012. 
Gold EB, Bair Y, Zhang G, Utts J, Greendale G a, Upchurch D, et al. Cross-sectional 
analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic 
group and menopausal status: the Study of Women’s Health Across the Nation (SWAN). 
Menopause [Internet]. 2007;14(4):612–23. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17327812 
Grady D. Clinical practice - Management of menopausal symptoms. N Engl J Med. 
2006;355(22):2338–47.  
Gaudard AMIS, Silva de Souza S, Puga MES, Marjoribanks J, da Silva EMK, Torloni 
MR. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database 
Syst Rev. 2016;2016(8). doi:10.1002/14651858.CD010407.pub2. 
189 
 
 
 
 
Gold, E. B. (2011). The Timing of the Age at Which Natural Menopause Occurs. 
Obstetrics and Gynecology Clinics of North America, 38(3), 425–440. 
https://doi.org/10.1016/j.ogc.2011.05.002. 
Gold, E. B., Bair, Y., Zhang, G., Utts, J., Greendale, G. a, Upchurch, D., … Adler, S. 
(2007). Cross-sectional analysis of specific complementary and alternative medicine 
(CAM) use by racial/ethnic group and menopausal status: the Study of Women’s Health 
Across the Nation (SWAN). Menopause (New York, N.Y.), 14(4), 612–23. 
https://doi.org/10.1097/gme.0b013e31802d975f. 
Guadamuro, L., Delgado, S., Redruello, B., Fl??rez, A. B., Su??rez, A., Mart??nez-
Camblor, P., & Mayo, B. (2015). Equol status and changes in fecal microbiota in 
menopausal women receiving long-term treatment for menopause symptoms with a soy-
isoflavone concentrate. Frontiers in Microbiology, 6(AUG), 1–10. 
https://doi.org/10.3389/fmicb.2015.00777. 
Guadamuro, L., Dohrmann, A. B., Tebbe, C. C., Mayo, B., & Delgado, S. (2017). 
Bacterial communities and metabolic activity of faecal cultures from equol producer and 
non-producer menopausal women under treatment with soy isoflavones. BMC 
Microbiology, 17(1), 93. https://doi.org/10.1186/s12866-017-1001-y. 
Handley A, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of 
vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pr. 
2015;27(1):54–61.  
Ho SC, Chan ASY, Ho YP, So EKF, Sham A, Zee B, et al. Effects of soy isoflavone 
supplementation on cognitive function in Chinese postmenopausal women. Menopause 
[Internet]. 2007;PAP(3):489–99. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=0004219
2-900000000-99855 
Hanson L, VandeVusse L, Jermé M, Abad CL, Safdar N. Probiotics for Treatment and 
Prevention of Urogenital Infections in Women: A Systematic Review. J Midwifery 
Womens Health. 2016;61(3):339-355. doi:10.1111/jmwh.12472. 
Hati, S., Vij, S., Singh, B. P., & Mandal, S. (2015). b-Glucosidase activity and 
bioconversion of isoflavones during fermentation of soymilk. Journal of the Science of 
Food and Agriculture, 95(1), 216–220. https://doi.org/10.1002/jsfa.6743. 
Heinemann LAJ, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HPG. The 
Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A 
validation study. Health Qual Life Outcomes. 2004;2:1-7. doi:10.1186/1477-7525-2-67. 
Hirose A, Terauchi M, Akiyoshi M, Owa Y, Kato K, Kubota T. Low-dose isoflavone 
aglycone alleviates psychological symptoms of menopause in Japanese women: a 
randomized, double-blind, placebo-controlled study. Arch Gynecol Obstet. 
2016;293(3):609-615. doi:10.1007/s00404-015-3849-0. 
Hirose A, Terauchi M, Akiyoshi M, Owa Y, Kato K, Kubota T. Low-dose isoflavone 
aglycone alleviates psychological symptoms of menopause in Japanese women: a 
randomized, double-blind, placebo-controlled study. Arch Gynecol Obstet. 2016; 
293(3):609–615. doi:10.1007/s00404-015-3849-0. 
190 
 
 
 
 
Hodis, H. N., Mack, W. J., Kono, N., Azen, S. P., ShoupeJ, D., Hwang-Levine, J., … 
Selzer, R. H. (2012). Isoflavone Soy Protein Supplementation and Atherosclerosis in 
Healthy Postmenopausal Women: A Randomized Controlled Trial. Stroke, 42(11), 3168–
3175. https://doi.org/10.1161/STROKEAHA.111.620831.Isoflavone. 
Hollman, P. C. H. (2004). Absorption, Bioavailability, and Metabolism of Flavonoids. 
Journal Pharmaceutical Biology, 42(1), Pages 74-83. 
https://doi.org/http://dx.doi.org/10.3109/13880200490893492. 
Hur, S. J., Lim, B. O., Decker, E. A., & McClements, D. J. (2011). In vitro human 
digestion models for food applications. Food Chemistry, 125(1), 1–12. 
https://doi.org/10.1016/j.foodchem.2010.08.036. 
I. Ferrer, M. Thurman, M. Churley, H. Prest, P. Stremple, Analysis of Phytoestrogens in 
Soy Milk by GC / MS / MS with the Agilent 7000 Series Triple Quadrupole GC / MS, 
Agil. Technol. (2009) 1–8. 
I. Fistonic, D. Franic, J. Popic, N. Fistonic, A. Maletic, Adherence with hormone 
replacement therapy in menopause, Climacteric. 13 (2010) 570–577. 
doi:10.3109/13697130903491018. 
I. Moreno-Indias, L. Sánchez-Alcoholado, P. Pérez-Martínez, C. Andrés-Lacueva, F. 
Cardona, F. Tinahones, M.I. Queipo-Ortuño, Red wine polyphenols modulate fecal 
microbiota and reduce markers of the metabolic syndrome in obese patients, Food Funct. 
7 (2016) 1775–1787. doi:10.1039/C5FO00886G. 
I. Vian, P. Zielinsky, A.M. Zilio, A. Mello, B. Lazzeri, A. Oliveira, K.V. Lampert, A. 
Piccoli, L.H. Nicoloso, G.B. Bubols, S.C. Garcia, Development and validation of a food 
frequency questionnaire for consumption of polyphenol-rich foods in pregnant women, 
Matern. Child Nutr. 11 (2015) 511–524. doi:10.1111/mcn.12025. 
IBGE. Instituto Brasileiro de Geografia e Estatística, Coordenação de Trabalho e 
Rendimento, Pesquisa de Orçamentos Familiares: 2008-2009. Análise do Consumo 
Alimentar Pessoal no Brasil, 2011. doi:ISSN 0101-4234. 
Igase, M., Igase, K., Tabara, Y., Ohyagi, Y., & Kohara, K. (2017). Cross-sectional study 
of equol producer status and cognitive impairment in older adults. Geriatrics & 
Gerontology International, (January), 1–6. https://doi.org/10.1111/ggi.13029. 
Ishiwata, N., Melby, M. K., Mizuno, S., & Watanabe, S. (2009). New equol supplement 
for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese 
women. Menopause (New York, N.Y.), 16(1), 141–8. 
https://doi.org/10.1097/gme.0b013e31818379fa. 
J. Kim, H. Lee, O. Lee, K.H. Lee, Y.B. Lee, K.D. Young, Y.H. Jeong, R. Choue, 
Isoflavone supplementation influenced levels of triglyceride and luteunizing hormone in 
Korean postmenopausal women, Arch. Pharm. Res. 36 (2013) 306–313. 
doi:10.1007/s12272-013-0059-9. 
J. Rossouw, G. Anderson, R. Prentice, A. LaCroix, C. Kooperberg, M. Stefanick, R. 
Jackson, S. Beresford, B. Howard, K. Johnson, Risks and Benefits of Estrogen Plus 
Progestin in Healthy Postmenopausal Women, JAMA. 288 (2002) 321–333. 
191 
 
 
 
 
J.C. Espín, A. González-Sarrías, F.A. Tomás-Barberán, The gut microbiota: A key factor 
in the therapeutic effects of (poly)phenols, Biochem. Pharmacol. 139 (2017) 82–93. 
doi:10.1016/j.bcp.2017.04.033. 
J.G. Caporaso, C.L. Lauber, W.A. Walters, D. Berg-Lyons, C.A. Lozupone, P.J. 
Turnbaugh, N. Fierer, R. Knight, Global patterns of 16S rRNA diversity at a depth of 
millions of sequences per sample, Proc. Natl. Acad. Sci. 108 (2011) 4516–4522. 
doi:10.1073/pnas.1000080107. 
J.M. Baker, L. Al-Nakkash, M.M. Herbst-Kralovetz, Estrogen–gut microbiome axis: 
Physiological and clinical implications, Maturitas. 103 (2017) 45–53. 
doi:10.1016/j.maturitas.2017.06.025. 
J.M. Landete, J. Arqués, M. Medina, P. Gaya, B. De La Rivas, R. Muñoz, Bioactivation 
of Phytoestrogens: Intestinal Bacteria and Health, Crit. Rev. Food Sci. Nutr. 8398 (2016) 
00–00. doi:10.1080/10408398.2013.789823. 
J.M. Sánchez-Calvo, M.A. Rodríguez-Iglesias, J.M.G. Molinillo, F.A. Macías, Soy 
isoflavones and their relationship with microflora: Beneficial effects on human health in 
equol producers, Phytochem. Rev. 12 (2013) 979–1000. doi:10.1007/s11101-013-9329-
x. 
J.K. Park, Y.-H. Lim, K.-S. Kim, S.G. Kim, J.H. Kim, H.G. Lim, J. Shin, Body Fat 
Distribution After Menopause and Cardiovascular Disease Risk Factors: Korean National 
Health and Nutrition Examination Survey 2010, J. Women’s Heal. 22 (2013) 587–594. 
doi:10.1089/jwh.2012.4035. 
J.T.T. Gonçalves, M.F. Silveira, M.C.C. Campos, L.H.R. Costa, Sobrepeso e obesidade 
e fatores associados ao climatério, Cien. Saude Colet. 21 (2016) 1145–1156. 
doi:10.1590/1413-81232015214.16552015. 
Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones 
in relieving vasomotor menopausal symptoms - A systematic review. Mol Nutr Food Res. 
2009;53(9):1084-1097. doi:10.1002/mnfr.200800552. 
Jin, J. S., Kitahara, M., Sakamoto, M., Hattori, M., & Benno, Y. (2010). Slackia 
equolifaciens sp. nov., a human intestinal bacterium capable of producing equol. 
International Journal of Systematic and Evolutionary Microbiology, 60(8), 1721–1724. 
https://doi.org/10.1099/ijs.0.016774-0. 
Jin, J. S., Nishihata, T., Kakiuchi, N., & Hattori, M. (2008). Biotransformation of C-
Glucosylisoflavone Puerarin to Estrogenic (3S)-Equol in Co-culture of Two Human 
Intestinal Bacteria. Biol.Pharm.Bull., 31(8), 1621–1625. https://doi.org/Doi 
10.1248/Bpb.31.1621. 
Jou HJ, Wu SC, Chang FW, Ling PY, Chu KS, Wu WH. Effect of intestinal production 
of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynecol 
Obstet. 2008;102(1):44-49. doi:10.1016/j.ijgo.2008.01.028. 
Juan, M. Y., & Chou, C. C. (2010). Enhancement of antioxidant activity, total phenolic 
and flavonoid content of black soybeans by solid state fermentation with Bacillus subtilis 
BCRC 14715. Food Microbiology, 27(5), 586–591. 
https://doi.org/10.1016/j.fm.2009.11.002. 
192 
 
 
 
 
K. Duval, D. Prud’Homme, R. Rabasa-Lhoret, I. Strychar, M. Brochu, J.M. Lavoie, É. 
Doucet, Effects of the menopausal transition on dietary intake and appetite: A MONET 
Group Study, Eur. J. Clin. Nutr. 68 (2014) 271–276. doi:10.1038/ejcn.2013.171. 
K. Setchell, J. Brown, S. Summer, E. King, J. Heubi, C. Sidnei, T. Guy, B. Hokin, Dietary 
Factors Influence Production of the Soy IsoflavoneMetaboliteS-(-)Equol in Healthy 
Adults, J. Nutr. 143 (2013) : 1950–1958. doi:10.3945/jn.113.179564.contributes. 
K. Setchell, N.M. Brown, E. Lydeking-olsen, The Clinical Importance of the Metabolite 
Equol — A Clue to the Effectiveness of Soy and Its Isoflavones, Am. J. Clin. Nutr. 132 
(2002) 3577–84. 
K.D.R. Setchell, C. Clerici, Equol : History , Chemistry , and Formation, J. Nutr. 3 (2010) 
1355–1362. doi:10.3945/jn.109.119776.1355S. 
K.D.R. Setchell, S.J. Cole, Method of Defining Equol-Producer Status and Its Frequency 
among Vegetarians, J. Nutr. 136 (2006) 2188–2193. doi:10.1093/jn/136.8.2188. 
K.L. Chen, Z. Madak-Erdogan, Estrogen and Microbiota Crosstalk: Should We Pay 
Attention?, Trends Endocrinol. Metab. 27 (2016) 752–755. 
doi:10.1016/j.tem.2016.08.001. 
Ko TF, Tsai HS, Lin SM, Liu CD, Learn SP, Chiou RY. GC-MS Determined Distribution 
of Urinary Equol Producers as Affected by Age, Gender, and Repeated Ingestions of 
Soymilk. J Food Sci. 2010;75(9):306–10.  
Kalaiselvan V, Kalaivani M, Vijayakumar A, Sureshkumar K, Venkateskumar K. Current 
knowledge and future direction of research on soy isoflavones as a therapeutic agents. 
Pharmacogn Rev. 2010;4(8):111. doi:10.4103/0973-7847.70900. 
Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially 
effective in reducing hot flashes in menopausal women. Menopause. 2007;PAP(1):125-
132. doi:10.1097/gme.0b013e31805c035b. 
Kawada, Y., Yokoyama, S., Yanase, E., Niwa, T., & Suzuki, T. (2016). The production 
of S-equol from daidzein is associated with a cluster of three genes in Eggerthella sp. 
YY7918. Bioscience of Microbiota, Food and Health, 35(3), 113–121. 
https://doi.org/10.12938/bmfh.2015-023. 
Kemperman, R. A., Bolca, S., Roger, L. C., & Vaughan, E. E. (2010). Novel approaches 
for analysing gut microbes and dietary polyphenols: Challenges and opportunities. 
Microbiology, 156(11), 3224–3231. https://doi.org/10.1099/mic.0.042127-0. 
Khaodhiar, L., Ricciotti, H. A., Li, L., Pan, W., Schickel, M., Zhou, J., & Blackburn, G. 
L. (2007). Daidzein-rich isoflavone aglycones are potentially effective in reducing hot 
flashes in menopausal women. Menopause, PAP(1), 125–132. 
https://doi.org/10.1097/gme.0b013e31805c035b. 
Kim, H., Kang, S., Chung, Y., Kim, J., & Kim, M. (2015). The Recent Review of the 
Genitourinary Syndrome of Menopause, 65–71. 
Kim, M., Kim, S. Il, Han, J., Wang, X. L., Song, D. G., & Kim, S. U. (2009). 
Stereospecific biotransformation of dihydrodaidzein into (3S)-equol by the human 
193 
 
 
 
 
intestinal bacterium Eggerthella strain julong 732. Applied and Environmental 
Microbiology, 75(10), 3062–3068. https://doi.org/10.1128/AEM.02058-08. 
Kim, Lee, J., & Han, J. (2015). Deglycosylation of isoflavone C-glycosides by newly 
isolated human intestinal bacteria. Journal of the Science of Food and Agriculture, 95(9), 
1925–1931. https://doi.org/10.1002/jsfa.6900. 
Kladna, A., Berczynski, P., Kruk, I., Piechowska, T., & Aboul-Enein, H. Y. (2016). 
Studies on the antioxidant properties of some phytoestrogens. Luminescence, (January), 
1201–1206. https://doi.org/10.1002/bio.3091. 
Ko, K. (2014). Isoflavones : Chemistry , Analysis , Functions and Effects on Health and 
Cancer. Asian Pacific Journal of Cancer Prevention, 15, 7001–7010. 
https://doi.org/http://dx.doi.org/10.7314/APJCP.2014.15.17.7001. 
Kucuk, O. (2017). Soy foods, isoflavones, and breast cancer. Cancer, 123(11), 1901–
1903. https://doi.org/10.1002/cncr.30614. 
L. De Koning, A.T. Merchant, J. Pogue, S.S. Anand, Waist circumference and waist-to-
hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective 
studies, Eur. Heart J. 28 (2007) 850–856. doi:10.1093/eurheartj/ehm026. 
L. Guadamuro, A.B. Dohrmann, C.C. Tebbe, B. Mayo, S. Delgado, Bacterial 
communities and metabolic activity of faecal cultures from equol producer and non-
producer menopausal women under treatment with soy isoflavones, BMC Microbiol. 17 
(2017) 93. doi:10.1186/s12866-017-1001-y. 
L. Guadamuro, S. Delgado, B. Redruello, A.B. Florez, A. Suarez, P. Martinez-Camblor, 
B. Mayo, Equol status and changes in fecal microbiota in menopausal women receiving 
long-term treatment for menopause symptoms with a soy-isoflavone concentrate, Front. 
Microbiol. 6 (2015) 1–10. doi:10.3389/fmicb.2015.00777. 
L. Khaodhiar, H.A. Ricciotti, L. Li, W. Pan, M. Schickel, J. Zhou, G.L. Blackburn, 
Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in 
menopausal women, Menopause. 15 (2008) 125–132. 
doi:10.1097/gme.0b013e31805c035b. 
L.A.J. Heinemann, T. DoMinh, F. Strelow, S. Gerbsch, J. Schnitker, H.P.G. Schneider, 
The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A 
validation study, Health Qual. Life Outcomes. 2 (2004) 1–7. doi:10.1186/1477-7525-2-
67. 
L.D. de Queirós, J.A. Macedo, G.A. Macedo, A new biotechnological process to enhance 
the soymilk bioactivity, Food Sci. Biotechnol. 25 (2016) 763–770. doi:10.1007/s10068-
016-0130-7. 
L. Pilsaková, I. Riecanský, F. Jagla, The physiological actions of isoflavone 
phytoestrogens, Physiol. Res. 59 (2010) 651–664. doi:931902 [pii]. 
Lee J, Hyun HS, Park H, Seo JH, Lee EY, Lee JS, et al. Effects of Hormone Therapy on 
Serum Lipid Levels in Postmenopausal Korean Women. J Menopausal Med [Internet]. 
2015;21:104–11. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=0004219
194 
 
 
 
 
2-201017050-00031 
Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens 
for menopausal vasomotor symptoms. Cochrane Database Syst Rev [Internet]. 2013;(12). 
Available from: http://doi.wiley.com/10.1002/14651858.CD001395.pub4 
Liu B, Qin L, Liu A, Uchiyama S, Ueno T, Li X, et al. Prevalence of the Equol-Producer 
Phenotype and Its Relationship with Dietary Isoflavone and Serum Lipids in Healthy 
Chinese Adults. J Epidemiol [Internet]. 2010;20(38):377–84. Available from: 
http://joi.jlc.jst.go.jp/JST.JSTAGE/jea/JE20090185?from=CrossRef 
Lopes DB, de Queirós LD, de ávila ARA, Monteiro NES, Macedo GA. The Importance 
of Microbial and Enzymatic Bioconversions of Isoflavones in Bioactive Compounds. 
Vol. 2, Food Bioconversion. 2017.  
Lambert, M. N. T., Hu, L. M., & Jeppesen, P. B. (2017). A systematic review and meta-
analysis of the effects of isoflavone formulations against estrogen-deficient bone 
resorption in peri- and postmenopausal women. American Journal of Clinical Nutrition, 
106(3), 801–811. https://doi.org/10.3945/ajcn.116.151464. 
Landete, J. M., Arqués, J., Medina, M., Gaya, P., De La Rivas, B., & Muñoz, R. (2016). 
Bioactivation of Phytoestrogens: Intestinal Bacteria and Health. Critical Reviews in Food 
Science and Nutrition, 8398(June 2015), 00–00. 
https://doi.org/10.1080/10408398.2013.789823. 
Langer, R. (2017). The evidence base for HRT: what can we believe? Climacteric, 20(2), 
91–96. https://doi.org/https://doi.org/10.1080/13697137.2017.1280251. 
Lee, M., Hong, G. E., Zhang, H., Yang, C. Y., Han, K. H., Mandal, P. K., & Lee, C. H. 
(2015). Production of the isoflavone aglycone and antioxidant activities in black soymilk 
using fermentation with Streptococcus thermophilus S10. Food Science and 
Biotechnology, 24(2), 537–544. https://doi.org/10.1007/s10068-015-0070-7. 
Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for vasomotor 
menopausal symptoms (Review) Phytoestrogens for vasomotor menopausal symptoms. 
Menopause J North Am Menopause Soc. 2010;(11):11-13. 
doi:10.1002/14651858.CD001395.pub3.Copyright. 
Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens 
for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12). 
doi:10.1002/14651858.CD001395.pub4. 
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., 
… Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate healthcare interventions: explanation and elaboration. 
BMJ, 339(jul21 1), b2700–b2700. https://doi.org/10.1136/bmj.b2700. 
Li L, Lv Y, Xu L, Zheng Q. Quantitative efficacy of soy isoflavones on menopausal hot 
flashes. Br J Clin Pharmacol. 2015;79(4):593-604. doi:10.1111/bcp.12533. 
Liu, B., Qin, L., Liu, A., Uchiyama, S., Ueno, T., Li, X., & Wang, P. (2010). Prevalence 
of the Equol-Producer Phenotype and Its Relationship with Dietary Isoflavone and Serum 
195 
 
 
 
 
Lipids in Healthy Chinese Adults. Journal of Epidemiology, 20(38), 377–384. 
https://doi.org/10.2188/jea.JE20090185. 
Liu, J., Yuan, F., Gao, J., Shan, B., Ren, Y., Wang, H., & Gao, Y. (2016). Oral isoflavone 
supplementation on endometrial thickness: a meta-analysis of randomized placebo-
controlled trials. Oncotarget, 7(14), 17369–17379. 
https://doi.org/10.18632/oncotarget.7959. 
Lobo, R. A. (2013). Where Are We 10 Years After the Women’s Health Initiative? The 
Journal of Clinical Endocrinology & Metabolism, 98(5), 1771–1780. 
https://doi.org/10.1210/jc.2012-4070. 
Lobo, R. A., Pickar, J. H., Stevenson, J. C., Mack, W. J., & Hodis, H. N. (2016). Back to 
the future: Hormone replacement therapy as part of a prevention strategy for women at 
the onset of menopause. Atherosclerosis, 254, 282–290. 
https://doi.org/10.1016/j.atherosclerosis.2016.10.005. 
Lopes, D. B., Queiros, L. D., de Avila, A., Monteiro, N. E. S., & Macedo, G. A. (2017). 
Bioconversions of Isoflavones in Bioactive Compounds. In A. Grumezescu & A. M. 
Holban (Eds.), Food Bioconversion (1st Editio, pp. 55–93). 
Lopes, D., de Avila, A., de Queiros, L., Macedo, J., & Macedo, G. (2016). Bioconversion 
of Isoflavones into Bioactive Equol: State of the Art. Recent Patents Food Nutrition 
Agriculture, 8(2), 91–98. https://doi.org/10.2174/2212798408666160620090519. 
L. Schierbeck, Primary prevention of cardiovascular disease with hormone replacement 
therapy, Climacteric. 18 (2015) 492–497. doi:10.3109/13697137.2015.1034098. 
M. Burkard, C. Leischner, U.M. Lauer, C. Busch, S. Venturelli, J. Frank, Dietary 
flavonoids and modulation of natural killer cells: implications in malignant and viral 
diseases, J. Nutr. Biochem. 46 (2017) 1–12. doi:10.1016/j.jnutbio.2017.01.006. 
M.G. Modena, Hypertension in postmenopausal women: How to approach hypertension 
in menopause, High Blood Press. Cardiovasc. Prev. 21 (2014) 201–204. 
doi:10.1007/s40292-014-0057-0. 
M. Messina, Soy and Health Update: Evaluation of the Clinical and Epidemiologic 
Literature, Nutrients. 8 (2016). doi:10.3390/nu8120754. 
M.R. Soules, S. Sherman, E. Parrott, R. Rebar, N. Santoro, W. Utian, Executive summary: 
Stages of Reproductive Aging Workshop (STRAW), Climacteric. 4 (2001) 267–272. 
doi:https://doi.org/10.1080/cmt.4.4.267.272. 
Murota K, Nakamura Y, Uehara M. Flavonoid metabolism: The interaction of metabolites 
and gut microbiota. Biosci Biotechnol Biochem [Internet]. Taylor & Francis; 
2018;82(4):600–10. Available from: http://doi.org/10.1080/09168451.2018.1444467 
M.A. Islam, A. Punt, B. Spenkelink, A.J. Murk, F.X. Rolaf van Leeuwen, I.M.C.M. 
Rietjens, Conversion of major soy isoflavone glucosides and aglycones in in vitro 
intestinal models, Mol. Nutr. Food Res. 58 (2014) 503–515. 
doi:10.1002/mnfr.201300390. 
M. Gambacciani, M. Levancini, Featured Editorial Hormone replacement therapy and the 
196 
 
 
 
 
prevention of postmenopausal osteoporosis, Menopausal Rev. 4 (2014) 213–220. 
doi:10.5114/pm.2014.44996. 
Ma, D.-F., Qin, L.-Q., Wang, P.-Y., & Katoh, R. (2008). Soy isoflavone intake increases 
bone mineral density in the spine of menopausal women: meta-analysis of randomized 
controlled trials. Clinical Nutrition (Edinburgh, Scotland), 27(1), 57–64. 
https://doi.org/10.1016/j.clnu.2007.10.012. 
Maclennan, A., Broadbent, J., Lester, S., & Moore, V. (2004). Oral oestrogen and 
combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane 
Database of Systematic Reviews (Online), 18(4), CD002978. 
https://doi.org/10.1002/14651858.CD002978.pub2. 
Manach, C., Williamson, G., Morand, C., Scalbert, A., & Rémésy, C. (2005). 
Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability 
studies. The American Journal of Clinical Nutrition, 81(1), 230S–242S. 
Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, 
A. Z., … Wactawski-Wende, J. (2017). Menopausal Hormone Therapy and Long-term 
All-Cause and Cause-Specific Mortality. Jama, 318(10), 927. 
https://doi.org/10.1001/jama.2017.11217. 
Marazza, J. A., Garro, M. S., & Savoy de Giori, G. (2009). Aglycone production by 
Lactobacillus rhamnosus CRL981 during soymilk fermentation. Food Microbiology, 
26(3), 333–339. https://doi.org/10.1016/j.fm.2008.11.004. 
Marazza, J. A., Nazareno, M. A., de Giori, G. S., & Garro, M. S. (2012). Enhancement 
of the antioxidant capacity of soymilk by fermentation with Lactobacillus rhamnosus. 
Journal of Functional Foods, 4(3), 594–601. https://doi.org/10.1016/j.jff.2012.03.005. 
Marko, K. I., & Simon, J. A. (2017). Clinical trials in menopause. Menopause, 25(2), 1. 
https://doi.org/10.1097/GME.0000000000000978. 
Maruo, T., Sakamoto, M., Ito, C., Toda, T., & Benno, Y. (2008). Adlercreutzia 
equolifaciens gen. nov., sp. nov., an equol-producing bacterium isolated from human 
faeces, and emended description of the genus Eggerthella. International Journal of 
Systematic and Evolutionary Microbiology, 58(5), 1221–1227. 
https://doi.org/10.1099/ijs.0.65404-0. 
Matthies, A., Blaut, M., & Braune, A. (2009). Isolation of a human intestinal bacterium 
capable of daidzein and genistein conversion. Applied and Environmental Microbiology, 
75(6), 1740–1744. https://doi.org/10.1128/AEM.01795-08. 
McCabe, L., Britton, R., & Parameswaran, N. (2015). Prebiotic and Probiotic Regulation 
of Bone Health: Role of the Intestine and its Microbiome. Current Osteoporosis Reports, 
13(6), 363–371. https://doi.org/doi:10.1007/s11914-015-0292-x. 
M.J. Butel, Probiotics, gut microbiota and health, Med. Mal. Infect. 44 (2014) 1–8. 
doi:10.1016/j.medmal.2013.10.002. 
Messina M. Soy and Health Update: Evaluation of the Clinical and Epidemiologic 
197 
 
 
 
 
Literature. Nutrients. 2016;8(12). doi:10.3390/nu8120754. 
Mittal N, Hota D, Dutta P, et al. Evaluation of effect of isoflavone on thyroid economy 
& autoimmunity in oophorectomised women: A randomised, double-blind, placebo-
controlled trial. Indian J Med Res. 2011;133(6):633-640. 
Monteiro NES, Queirós LD, Lopes DB, Pedro AO, Macedo GA. Impact of microbiota on 
the use and effects of isoflavones in the relief of climacteric symptoms in menopausal 
women – A review. J Funct Foods. 2018;41(August 2017):100-111. 
doi:10.1016/j.jff.2017.12.043. 
Moehrer, B., Hextall, A., & Jackson, S. (2003). Oestrogens for urinary incontinence in 
women (Review). Cochrane Database of Systematic Reviews (Online), 2(CD001405). 
https://doi.org/10.1002/14651858. CD001405. 
Mohammed, K., Moain, A., Dabrh, A., Benkhadra, K., Nofal, A. Al, Leon, B. G. C., … 
Murad, M. H. (2017). Oral vs Transdermal Estrogen Therapy and Vascular Events : A 
Systematic Review and Meta-Analysis. J Clin Endocrinol Metab., 100(November 2015), 
4012–4020. https://doi.org/10.1210/jc.2015-2237. 
Moilanen, J., Aalto, A. M., Hemminki, E., Aro, A. R., Raitanen, J., & Luoto, R. (2010). 
Prevalence of menopause symptoms and their association with lifestyle among Finnish 
middle-aged women. Maturitas, 67(4), 368–374. 
https://doi.org/10.1016/j.maturitas.2010.08.007. 
Mørch, L. S., Kjær, S. K., Keiding, N., Løkkegaard, E., & Lidegaard, Ø. (2016). The 
influence of hormone therapies on type i and II endometrial cancer: A nationwide cohort 
study. International Journal of Cancer, 138(6), 1506–1515. 
https://doi.org/10.1002/ijc.29878. 
Moreira, A. C., Silva, A. M., Santos, M. S., & Sardão, V. A. (2014). Phytoestrogens as 
alternative hormone replacement therapy in menopause: What is real, what is unknown. 
Journal of Steroid Biochemistry and Molecular Biology, 143, 61–71. 
https://doi.org/10.1016/j.jsbmb.2014.01.016. 
Nahas EAP, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira MLCS, Dias R. Efficacy 
and safety of a soy isoflavone extract in postmenopausal women: A randomized, double-
blind, and placebo-controlled study. Maturitas. 2007;58(3):249–58.  
NAMS, Nonhormonal management of menopause-associated vasomotor symptoms: 
2015 position statement of The North American Menopause Society, Menopause J. North 
Am. Menopause Soc. 22 (2015) 1–18. doi:10.1097/GME.0000000000000546. 
NAMS, The 2017 hormone therapy position statement of The North American 
Menopause Society, Menopause J. North Am. Menopause Soc. 24 (2017) 728–753. 
doi:10.1097/gme.0b013e31824b970a. 
NAMS. Nonhormonal management of menopause-associated vasomotor symptoms: 
2015 position statement of The North American Menopause Society. Menopause J North 
Am Menopause Soc. 2015;22(11):1–18.  
NAMS. The 2012 Hormone Therapy Position Statement of The North American 
Menopause Society (NAMS). Menopause J North Am Menopause Soc. 2012;19(3):257–
198 
 
 
 
 
71.  
National Institute for Health and Care Excellence, Menopause: Full Guideline - NICE 
Guideline, Natl. Collab. Cent. Women’s Child. Heal. (UK). 23 (2015). 
Nachtigall, L. E. (2001). Isoflavones in the management of menopause. The Journal of 
the British Menopause Society, S1, 8–11. 
NAMS. (2011). The role of soy isoflavones in menopausal health. Menopause: The 
Journal of The North American Menopause Society, 18(7), 732–753. 
https://doi.org/10.1097/gme.0b013e31821fc8e0. 
NAMS. (2012). The 2012 Hormone Therapy Position Statement of The North American 
Menopause Society (NAMS). Menopause: The Journal of The North American 
Menopause Society, 19(3), 257–271. https://doi.org/10.1097/gme.0b013e31824b970a. 
NAMS. (2015). Nonhormonal management of menopause-associated vasomotor 
symptoms: 2015 position statement of The North American Menopause Society. 
Menopause: The Journal of The North American Menopause Society, 22(11), 1–18. 
https://doi.org/10.1097/GME.0000000000000546. 
NAMS. (2017). The 2017 hormone therapy position statement of The North American 
Menopause Society. Menopause: The Journal of The North American Menopause 
Society, 24(7), 728–753. https://doi.org/10.1097/gme.0b013e31824b970a. 
National Collaborating Centre for Women’s and Children’s Health. (2015). Menopause: 
Full Guideline. National Institute for Health and Care Excellence: Clinical Guidelines., 
(November). Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/26598775. 
Nedrow, A., Miller, J., Walker, M., Nygren, P., Huffman, L., & Nelson, H. (2006). 
Complementary and Alternative Therapies for the Management of Menopause-Related 
Symptoms-A Systematic Evidence Review. Archives of Internal Medicine, 166(14), 
1453–65. 
Németh, K., Plumb, G. W., Berrin, J. G., Juge, N., Jacob, R., Naim, H. Y., … Kroon, P. 
A. (2003). Deglycosylation by small intestinal epithelial cell β-glucosidases is a critical 
step in the absorption and metabolism of dietary flavonoid glycosides in humans. 
European Journal of Nutrition, 42(1), 29–42. https://doi.org/10.1007/s00394-003-0397-
3. 
N. Karmakar, S. Majumdar, A. Dasgupta, Quality of life among menopausal women: A 
community-based study in a rural area of West Bengal Nabarun, J. Midlife. Health. 8 
(2017) 21–27. doi:10.4103/jmh.JMH. 
N.M.P. Daan, B.C.J.M. Fauser, Menopause prediction and potential implications, 
Maturitas. 82 (2015) 257–265. doi:10.1016/j.maturitas.2015.07.019. 
Nachtigall LE. Isoflavones in the management of menopause. J Br Menopause Soc. 
2001;S1:8-11. 
NAMS. The role of soy isoflavones in menopausal health. Menopause J North Am 
Menopause Soc. 2011;18(7):732-753. doi:10.1097/gme.0b013e31821fc8e0. 
199 
 
 
 
 
National Institute for Health and Care Excellence, Menopause: Full Guideline - NICE 
Guideline, Natl. Collab. Cent. Women’s Child. Heal. (UK). 23 (2015). 
Nelson H, Haney E, Humphrey L, Miller J. Management of menopause-related 
symptoms. Evid Rep Technol Assess (Full Rep). 2005;120:1–6. 
Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The reciprocal 
interactions between polyphenols and gut microbiota and effects on bioaccessibility. 
Nutrients. 2016;8(2):1-36. doi:10.3390/nu8020078. 
O.A. Tokede, T.A. Onabanjo, A. Yansane, J.M. Gaziano, L. Djoussé, Soya products and 
serum lipids: A meta-Analysis of randomised controlled trials, Br. J. Nutr. 114 (2015) 
831–843. doi:10.1017/S0007114515002603. 
P. Louis, H.J. Flint, Formation of propionate and butyrate by the human colonic 
microbiota, Environ. Microbiol. 19 (2017) 29–41. doi:10.1111/1462-2920.13589. 
Pedro AO, Pinto-Neto AM, Costa-Paiva LHS, Duarte Osis MJ, Hardy EE. Síndrome do 
climatério: Inquérito populacional domiciliar em Campinas, SP. Rev Saude Publica. 
2003;37(6):735–42.  
Pinkerton J V. Hormone Therapy: Key Points from NAMS 2017 Position Statement. Clin 
Obstet Gynecol. 2018;61(3):447–53.  
Palacios, S., Rojo, I. A., Cancelo, M. J., Neyro, J. L., & Castelo-Branco, C. (2008). 
Women’s perception of the efficacy of a soy extract with probiotic: the M3 study. 
Gynecological Endocrinology : The Official Journal of the International Society of 
Gynecological Endocrinology, 24(4), 178–83. 
https://doi.org/10.1080/09513590801954687. 
Pawlowski, J. W., Martin, B. R., McCabe, G. P., McCabe, L., Jackson, G. S., Peacock, 
M., … Weaver, C. M. (2015). Impact of equol-producing capacity and soy-isoflavone 
profiles of supplements on bone calcium retention in postmenopausal women: A 
randomized crossover trial1,2. American Journal of Clinical Nutrition, 102(3), 695–703. 
https://doi.org/10.3945/ajcn.114.093906. 
Piazza, C., Privitera, M. G., Melilli, B., Incognito, T., Marano, M. R., Leggio, G. M., … 
Drago, F. (2007). Influence of inulin on plasma isoflavone concentrations in healthy 
postmenopausal women. American Journal of Clinical Nutrition, 86(3), 775–780. 
Pentico DW. On the determination and use of optimal sample sizes for estimating the 
difference in means. Am Statistic; 1981;35 (1):40-43. 
doi:10.1080/00031305.1981.10479301. 
Q. Zhang, Y. Wu, X. Fei, Effect of probiotics on glucose metabolism in patients with type 
2 diabetes mellitus: A meta-analysis of randomized controlled trials, Med. 52 (2016) 28–
34. doi:10.1016/j.medici.2015.11.008. 
Quaas AM, Kono N, Mack WJ, et al. the Effect of Isoflavone Soy Protein Postmenopausal 
Women: a Randomized Controlled. Natl Inst od Heal. 2014;20(8):840-844. 
doi:10.1097/GME.0b013e3182804353. 
200 
 
 
 
 
Raimondi, S., Roncaglia, L., De Lucia, M., Amaretti, A., Leonardi, A., Pagnoni, U. M., 
& Rossi, M. (2009). Bioconversion of soy isoflavones daidzin and daidzein by 
Bifidobacterium strains. Applied Microbiology and Biotechnology, 81(5), 943–950. 
https://doi.org/10.1007/s00253-008-1719-4. 
Rapkin, A. J. (2007). Vasomotor symptoms in menopause: physiologic condition and 
central nervous system approaches to treatment. American Journal of Obstetrics and 
Gynecology, 196(2), 97–106. https://doi.org/10.1016/j.ajog.2006.05.056. 
Rekha, C. R., & Vijayalakshmi, G. (2011). Isoflavone phytoestrogens in soymilk 
fermented with β-glucosidase producing probiotic lactic acid bacteria. International 
Journal of Food Sciences and Nutrition, 62(2), 111–120. 
https://doi.org/10.3109/09637486.2010.513680. 
Ricci, E., Cipriani, S., Chiaffarino, F., Malvezzi, M., & Parazzini, F. (2010). Effects of 
soy isoflavones and genistein on glucose metabolism in perimenopausal and 
postmenopausal non-Asian women: a meta-analysis of randomized controlled trials. 
Menopause (New York, N.Y.), 17(5), 1080–1086. 
https://doi.org/10.1097/gme.0b013e3181dd05a9. 
Rowland I, Wiseman H, Sanders T, Adlercreutz H, Bowey E. Interindividual Variation 
in Metabolism of Soy Isoflavones and Lignans: Influence of Habitual Diet on Equol 
Production by the Gut Microflora Ian. Nutr Cancer. 2000;36(1):27–32.  
Rodríguez-Roque, M. J., Rojas-Graü, M. A., Elez-Martínez, P., & Martín-Belloso, O. 
(2013). Soymilk phenolic compounds, isoflavones and antioxidant activity as affected by 
in vitro gastrointestinal digestion. Food Chemistry, 136(1), 206–212. 
https://doi.org/10.1016/j.foodchem.2012.07.115. 
Rosic S, Kendic S, Rosic M. Phytoestrogens impact on menopausal symptomatology. 
Mater Sociomed. 2013;25(2):98-100. doi:10.5455/msm.2013.25.98-100. 
Roussouw, J. E. et al. (2002). Risks and benefits of estrogen plus progestin in healthy 
post-menopausal women. Journal of the American Medical Association, 288(3), 321–
333. https://doi.org/10.1001/jama.288.3.321. 
Rozenberg, S., Vandromme, J., & Antoine, C. (2013). Postmenopausal hormone therapy: 
risks and benefits. Nature Reviews. Endocrinology, 9(4), 216–27. 
https://doi.org/10.1038/nrendo.2013.17. 
Rozenfeld, S. (2007). Terapia hormonal para a menopausa (TH): múltiplos interesses a 
considerar. Ciência & Saúde Coletiva, 12(2), 437–42. https://doi.org/10.1590/S1413-
81232007000200020. 
Sánchez-Calvo, J. M., Rodríguez-Iglesias, M. A., Molinillo, J. M. G., & Macías, F. A. 
(2013). Soy isoflavones and their relationship with microflora: Beneficial effects on 
human health in equol producers. Phytochemistry Reviews, 12(4), 979–1000. 
https://doi.org/10.1007/s11101-013-9329-x. 
201 
 
 
 
 
Santoro, N., Epperson, C. N., & Mathews, S. B. (2015). Menopausal Symptoms and Their 
Management. Endocrinology and Metabolism Clinics of North America, 44(3), 497–515. 
https://doi.org/10.1016/j.ecl.2015.05.001. 
Sapre, S., & Thakur, R. (2014). Lifestyle and dietary factors determine age at natural 
menopause. Journal of Mid-Life Health, 5(1), 3–5. https://doi.org/10.4103/0976-
7800.127779. 
Sare, G. M., Gray, L. J., & Bath, P. M. W. (2008). Association between hormone 
replacement therapy and subsequent arterial and venous vascular events: A meta-analysis. 
European Heart Journal, 29(16), 2031–2041. https://doi.org/10.1093/eurheartj/ehn299. 
Sarri, G., Pedder, H., Dias, S., Guo, Y., & Lumsden, M. A. (2017). Vasomotor symptoms 
resulting from natural menopause: a systematic review and network meta-analysis of 
treatment effects from the National Institute of Health and Care Excellence guideline on 
menopause. BJOG : An International Journal of Obstetrics and Gynaecology, 1–10. 
https://doi.org/10.1111/1471-0528.14619. 
Schoenaker, D. A. J. M., Jackson, C. A., Rowlands, J. V., & Mishra, G. D. (2014). 
Socioeconomic position, lifestyle factors and age at natural menopause: A systematic 
review and meta-analyses of studies across six continents. International Journal of 
Epidemiology, 43(5), 1542–1562. https://doi.org/10.1093/ije/dyu094. 
Selma, M. V., Espín, J. C., & Tomás-Barberán, F. A. (2009). Interaction between 
phenolics and gut microbiota: Role in human health. Journal of Agricultural and Food 
Chemistry, 57(15), 6485–6501. https://doi.org/10.1021/jf902107d. 
Setchell K, Brown J, Summer S, King E, Heubi J, Sidnei C, et al. Dietary Factors 
Influence Production of the Soy IsoflavoneMetaboliteS-(-)EquolinHealthyAdults. J Nutr. 
2013;143:: 1950–1958.  
Setchell KDR, Clerici C. Equol : History , Chemistry , and Formation. J Nutr. 
2010;3(29):1355–62.  
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Dietary 
Reference Intakes, 1997. doi:10.1016/S0002-8223(02)90346-9. 
Setchell, K. (1998). Phytoestrogens: the biochemistry, physiology, and implications for 
human health of soy isoflavones. The American Journal of Clinical Nutrition, 134(6), 
1333–1343S. 
Setchell, K., Brown, J., Summer, S., King, E., Heubi, J., Sidnei, C., … Hokin, B. (2013). 
Dietary Factors Influence Production of the Soy IsoflavoneMetaboliteS-(-
)EquolinHealthyAdults. J. Nutr., 143, : 1950–1958. 
https://doi.org/10.3945/jn.113.179564.contributes. 
Setchell, K., Brown, N. M., & Lydeking-olsen, E. (2002). The Clinical Importance of the 
Metabolite Equol — A Clue to the Effectiveness of Soy and Its Isoflavones. The American 
Journal of Clinical Nutrition, 132(12), 3577–84. 
Setchell, K., Brown, N. M., Zimmer-nechemias, L., Brashear, W. T., Wolfe, B. E., 
Kirschner, A. S., & Heubi, J. E. (2002). Evidence for lack of absorption of soy isoflavone 
202 
 
 
 
 
glycosides in humans , supporting the crucial role of intestinal metabolism for. The 
American Journal of Clinical Nutrition, 76(2), 447–53. 
Setchell, K. D. R., & Clerici, C. (2010). Equol : History , Chemistry , and Formation. The 
Journal of Nutrition, 3(29), 1355–1362. https://doi.org/10.3945/jn.109.119776.1355S. 
Singleton VL, Orthofer R, Lamuela-Raventós RM. Analysis of total phenols and other 
oxidation substrates and antioxidants by means of folin-ciocalteu reagent. Methods 
Enzymol. 1998;299(1974):152-178. doi:10.1016/S0076-6879(99)99017-1. 
Singleton VL.; Rossi JA. Colorimetry of total phenolic with 
phosphomolybdicphosphotungstic acid reagents. American Journal of Enology and 
Viticulture, 1965;16(3):144-158. 
Shimada, Y., Yasuda, S., Takahashi, M., Hayashi, T., Miyazawa, N., Sato, I., … 
Hishigaki, H. (2010). Cloning and expression of a novel NADP(H)-dependent daidzein 
reductase, an enzyme involved in the metabolism of daidzein, from equol-producing 
Lactococcus strain 20-92. Applied and Environmental Microbiology, 76(17), 5892–5901. 
https://doi.org/10.1128/AEM.01101-10. 
Shimizu, M. (2017). Multifunctions of dietary polyphenols in the regulation of intestinal 
inflammation. Journal of Food and Drug Analysis, 25(1), 93–99. 
https://doi.org/10.1016/j.jfda.2016.12.003. 
Singh, H. B., Singh, B. N., Singh, S. P., & Nautiyal, C. S. (2010). Solid-state cultivation 
of Trichoderma harzianum NBRI-1055 for modulating natural antioxidants in soybean 
seed matrix. Bioresource Technology, 101(16), 6444–6453. 
https://doi.org/10.1016/j.biortech.2010.03.057. 
Singhal, S., & Shullai, W. (2016). Comparative study of gabapentin and isoflavone in 
menopausal vasomotor symptoms. Journal of Mid-Life Health, 7(3), 132. 
https://doi.org/10.4103/0976-7800.191017. 
S.I. Richardson, L.M. Steffen, K. Swett, C. Smith, L. Burke, X. Zhou, J.M. Shikany, C.J. 
Rodriguez, Dietary Total Isoflavone Intake Is Associated With Lower Systolic Blood 
Pressure: The Coronary Artery Risk Development in Young Adults (CARDIA) Study, J. 
Clin. Hypertens. 18 (2016) 778–783. doi:10.1111/jch.12760. 
S.M. Charandabi, R. Nazanin, S. Hakimi, A. Montazeri, T. Safoura, H. Taghinejad, K. 
Sayehmiri, Quality of Life of Postmenopausal Women and Their Spouses: A Community-
Based Study, Iran. Red Crescent Med. J. 17 (2015). doi:10.5812/ircmj.21599. 
S.S. Faubion, C.L. Kuhle, L.T. Shuster, A. Rocca, H. Clinic, M. Clinic, M. Clinic, 
Menopause and Considerations for Management, Climacteric. 18 (2015) 483–491. 
doi:10.3109/13697137.2015.1020484.Long-term. 
Sood, R., Faubion, S. S., Kuhle, C. L., Thielen, J. M., & Shuster, L. T. (2014). Prescribing 
menopausal hormone therapy: An evidence-based approach. International Journal of 
Women’s Health, 6(1), 47–57. https://doi.org/10.2147/IJWH.S38342. 
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. 
A. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An endocrine 
203 
 
 
 
 
society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 
100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236. 
Taku, K., Melby, M. K., Nishi, N., Omori, T., & Kurzer, M. S. (2011). Soy isoflavones 
for osteoporosis: An evidence-based approach. Maturitas, 70(4), 333–338. 
https://doi.org/10.1016/j.maturitas.2011.09.001. 
Taylor, M. (2015). Complementary and Alternative Approaches to Menopause. 
Endocrinology and Metabolism Clinics of North America, 44(3), 619–48. 
https://doi.org/10.1016/j.ecl.2015.05.008. 
T. Clavel, M. Fallani, P. Lepage, F. Levenez, J. Mathey, V. Rochet, M. Sérézat, M. 
Sutren, G. Henderson, C. Bennetau-Pelissero, F. Tondu, M. Blaut, J. Doré, V. Coxam, 
Isoflavones and Functional Foods Alter the Dominant Intestinal Microbiota in 
Postmenopausal Women, J. Nutr. 135 (2005) 2786–2792. doi:10.1093/jn/135.12.2786. 
T. Clavel, O.J. Mapesa, Phenolics in Human Nutrition: Importance of the Intestinal 
Microbiome for Isoflavone and Lignan Bioavailability, in: K.G. Ramawat, J.-M. Mérillon 
(Eds.), Handb. Nat. Prod., Springer Berlin Heidelberg, Amsterdam, 2013: pp. 2433–2463. 
doi:10.1007/978-3-642-22144-6_94. 
T. Izumi, M.K. Piskula, S. Osawa, A. Obata, K. Tobe, M. Saito, S. Kataoka, Y. Kubota, 
M. Kikuchi, Human Nutrition and Metabolism Soy Isoflavone Aglycones Are Absorbed 
Faster and in Higher Amounts than Their Glucosides in Humans, J. Nutr. 130 (2000) 
1695–1699. doi:10.1093/jn/130.7.1695. 
T.F. Ko, H.S. Tsai, S.M. Lin, C.D. Liu, S.P. Learn, R.Y. Chiou, GC-MS Determined 
Distribution of Urinary Equol Producers as Affected by Age, Gender, and Repeated 
Ingestions of Soymilk, J. Food Sci. 75 (2010) 306–310. doi:10.1111/j.1750-
3841.2010.01860.x. 
T.M. Wallace, J.C. Levy, D.R. Matthews, Use and abuse of HOMA modeling, Diabetes 
Care. 27 (2004) 1487–1495. doi:10.2337/diacare.27.6.1487. 
Taku K, Melby M, Kronenberg F  et al. Extracted or synthesized soybean isoflavones 
reduce menopausal hot flash frequency and severity: systematic review and meta-analysis 
of randomized controlled trials. Vol. 19, Menopause. 2012. p. 776–90.  
Teekachunhatean S, Mattawanon N, Khunamornpong S. Short-Term Isoflavone 
Intervention in the Treatment of Severe Vasomotor Symptoms after Surgical Menopause: 
A Case Report and Literature Review. Case Rep Obstet Gynecol. 2015;2015:1-7. 
doi:10.1155/2015/962740. 
Timan, P., Rojanasthien, N., Manorot, M., Sangdee, C., & Teekachunhatean, S. (2014). 
Effect of synbiotic fermented milk on oral bioavailability of isoflavones in 
postmenopausal women. International Journal of Food Sciences and Nutrition, 65(6), 
761–7. https://doi.org/10.3109/09637486.2014.908169. 
Tousen, Y., Matsumoto, Y., Matsumoto, C., Nishide, Y., Nagahata, Y., Kobayashi, I., & 
Ishimi, Y. (2016). The combined effects of soya isoflavones and resistant starch on equol 
production and trabecular bone loss in ovariectomised mice. British Journal of Nutrition, 
116(2), 247–257. https://doi.org/10.1017/S0007114516001537. 
204 
 
 
 
 
Trimarco, V., Rozza, F., Leo, V. De, Cappelli, V., Riccardi, C., & Carlo, C. Di. (2016). 
Effects of a new combination of nutraceuticals on postmenopausal symptoms and 
metabolic profile : a crossover , randomized , double-blind trial. International Journal of 
Women’s Health, 8, 581–587. 
Tsangalis, D., Ashton, J. F., McGill, A. E. J., & Shah, N. P. (2002). Enzymic 
Transformation of Isoflavone Phytoestrogens in Soymilk by β-Glucosidase-Producing 
Bifidobacteria. Journal of Food Science, 67(8), 3104–3113. 
https://doi.org/10.1111/j.1365-2621.2002.tb08866.x. 
Tsangalis, D., Ashton, J. F., McGill, A. E. J., & Shah, N. P. (2003). Biotransformation of 
Isoflavones by Bifidobacteria in Fermented Soymilk Supplemented with D-Glucose and 
L-Cysteine. Journal of Food Science, 68(2), 623–631. 
Uchiyama, S., Ueno, T., Masaki, K., Shimizu, S., Aso, T., & Shirota, T. (2007). The cross-
sectional study of the relationship between soy isoflavones, equol and the menopausal 
symptoms in Japanese women. J Jpn. Menopause Soc., 15(1), 28–37. 
Uifălean A, Farcaş A, Ilieş M, Hegheş SC, Ionescu C, Iuga CA. Assessment of Isoflavone 
Aglycones Variability in Soy Food Supplements Using a Validated Hplc-Uv Method. 
Clujul Med. 2015;88(3):373. doi:10.15386/cjmed-468. 
Ueno, T., & Uchiyama, S. (2002). Identification of the specific intestinal bacteria capable 
of metabolizing soy isoflavone to equol. Annals of Nutrition and Metabolism, 45(114). 
Utian, W. H., Jones, M., & Setchell, K. D. R. (2015). S-equol: A Potential Nonhormonal 
Agent for Menopause-Related Symptom Relief. Journal of Women’s Health, 24(3), 200–
208. https://doi.org/10.1089/jwh.2014.5006. 
United States Department of Agriculture, United States Department of Agriculture, 
USDA Database Flavonoid Content Sel. Foods Release Available 
Http//Www.Nal.Usda.Gov/Fnic/ Foodcomp/Data/Flav/Flav02-1.Pdf. (2007). 
Valdés, L., Cuervo, A., Salazar, N., Ruas-Madiedo, P., Gueimonde, M., & González, S. 
(2015). The relationship between phenolic compounds from diet and microbiota: impact 
on human health. Food & Function, 6(8), 2424–2439. 
https://doi.org/10.1039/c5fo00322a. 
Villa, P., Costantini, B., Suriano, R., Perri, C., Macrì, F., Ricciardi, L., … Lanzone, A. 
(2009). The differential effect of the phytoestrogen genistein on cardiovascular risk 
factors in postmenopausal women: relationship with the metabolic status. The Journal of 
Clinical Endocrinology and Metabolism, 94(2), 552–558. 
https://doi.org/10.1210/jc.2008-0735. 
X.-G. Zhuo, M.K. Melby, S. Watanabe, Soy isoflavone intake lowers serum LDL 
cholesterol: a meta-analysis of 8 randomized controlled trials in humans., J. Nutr. 134 
(2004) 2395–400. doi:10.1093/jn/134.9.2395. 
X.X. Liu, S.H. Li, J.Z. Chen, K. Sun, X.J. Wang, X.G. Wang, R.T. Hui, Effect of soy 
isoflavones on blood pressure: A meta-analysis of randomized controlled trials, Nutr. 
Metab. Cardiovasc. Dis. 22 (2012) 463–470. doi:10.1016/j.numecd.2010.09.006. 
205 
 
 
 
 
Wang, H., & Murphy, P. a. (1994). Isoflavone Content in Commercial Soybean Foods. 
Journal of Agricultural and Food Chemistry, 42(8), 1666–1673. 
https://doi.org/10.1021/jf00044a016. 
Watanabe, S., Uesugi, S., & Kikuchi, Y. (2002). Isoflavones for prevention of cancer, 
cardiovascular diseases, gynecological problems and possible immune potentiation. 
Biomedicine & Pharmacotherapy, 56(6), 302–312. 
Wei, P., Liu, M., Chen, Y., & Chen, D. C. (2012). Systematic review of soy isoflavone 
supplements on osteoporosis in women. Asian Pacific Journal of Tropical Medicine, 5(3), 
243–248. https://doi.org/10.1016/S1995-7645(12)60033-9. 
Wender, M. C., Pompei, L., & Fernandes, C. (2014). Consenso Brasileiro de Terapêutica 
Hormonal da Menopausa. Ssociação Brasileira de Climatério, 148. 
WHO. (1996). Research on the menopause in the 1990s. Report of a WHO Scientific 
Group. World Health Organization Technical Report Series, 866, 1–107. 
Wolffram, S., Blöck, M., & Ader, P. (2002). Quercetin-3-glucoside is transported by the 
glucose carrier SGLT1 across the brush border membrane of rat small intestine. The 
Journal of Nutrition, 132(4), 630–635. 
Xiao, Y., Wang, L., Rui, X., Li, W., Chen, X., Jiang, M., & Dong, M. (2015). 
Enhancement of the antioxidant capacity of soy whey by fermentation with Lactobacillus 
plantarum B1–6. Journal of Functional Foods, 12, 33–44. 
https://doi.org/10.1016/j.jff.2014.10.033. 
Xue, Y., Yu, J., & Song, X. (2009). Hydrolysis of soy isoflavone glycosides by 
recombinant b-glucosidase from hyperthermophile Thermotoga maritima. Journal of 
Industrial Microbiology and Biotechnology, 36(11), 1401–1408. 
https://doi.org/10.1007/s10295-009-0626-8. 
Yeo, S.-K., & Liong, M.-T. (2010). Angiotensin I-converting enzyme inhibitory activity 
and bioconversion of isoflavones by probiotics in soymilk supplemented with prebiotics. 
International Journal of Food Sciences and Nutrition, 61(March), 161–181. 
https://doi.org/10.3109/09637480903348122. 
Yeom, S. J., Kim, B. N., Kim, Y. S., & Oh, D. K. (2012). Hydrolysis of isoflavone 
glycosides by a thermostable b-glucosidase from pyrococcus furiosus. Journal of 
Agricultural and Food Chemistry, 60(6), 1535–1541. https://doi.org/10.1021/jf204432g. 
Yokoyama, S. ichiro, Oshima, K., Nomura, I., Hattori, M., & Suzuki, T. (2011). Complete 
genomic sequence of the equol-producing bacterium Eggerthella sp. Strain YY7918, 
isolated from adult human intestine. Journal of Bacteriology, 193(19), 5570–5571. 
https://doi.org/10.1128/JB.05626-11. 
Yokoyama, S., & Suzuki, T. (2008). Isolation and characterization of a novel equol-
producing bacterium from human feces. Bioscience, Biotechnology, and Biochemistry, 
72(10), 2660–2666. https://doi.org/10.1271/bbb.80329. 
206 
 
 
 
 
Yoshikata, R., Myint, K. Z., & Ohta, H. (2017). Relationship between equol producer 
status and metabolic parameters in 743 Japanese women: equol producer status is 
associated with antiatherosclerotic conditions in women around menopause and early 
postmenopause. Menopause (New York, N.Y.), 24(2), 216–224. https://doi.org/doi: 
10.1097/GME.0000000000000743. 
Yuan, J. P., Wang, J. H., & Liu, X. (2007). Metabolism of dietary soy isoflavones to equol 
by human intestinal microflora - Implications for health. Molecular Nutrition and Food 
Research, 51(7), 765–781. https://doi.org/10.1002/mnfr.200600262. 
Zhang, F. F., Haslam, D. E., Terry, M. B., Knight, J. A., Andrulis, I. L., Daly, M. B., … 
John, E. M. (2017). Dietary isoflavone intake and all-cause mortality in breast cancer 
survivors: The Breast Cancer Family Registry. Cancer, 123(11), 2070–2079. 
https://doi.org/10.1002/cncr.30615. 
Zhang, S. T., Shi, Y., Zhang, S. L., Shang, W., Gao, X. Q., & Wang, H. K. (2014). Whole 
soybean as probiotic lactic acid bacteria carrier food in solid-state fermentation. Food 
Control, 41(1), 1–6. https://doi.org/10.1016/j.foodcont.2013.12.026. 
Z. Liu, Y. Chen, S.C. Ho, Effects of soy intake on glycemic control : a meta-analysis of 
randomized controlled trials, Am J Clin Nutr. 93 (2011) 1092–1101. 
doi:10.3945/ajcn.110.007187.1. 
WHO, Research on the menopause in the 1990s. Report of a WHO Scientific Group, 
World Health Organ. Tech. Rep. Ser. 866 (1996) 1–107. 
Y. Ruan, J. Sun, J. He, F. Chen, R. Chen, H. Chen, Effect of probiotics on glycemic 
control: A systematic review and meta-analysis of randomized, controlled trials, PLoS 
One. 10 (2015) 1–15. doi:10.1371/journal.pone.0132121. 
Y. Tokudome, N. Imaeda, T. Nagaya, M. Ikeda, N. Fujiwara, J. Sato, K. Kuriki, S. 
Kikuchi, S. Maki, S. Tokudome, Daily, weekly, seasonal, within- and between-individual 
variation in nutrient intake according to four season consecutive 7 day weighed diet 
records in Japanese female dietitians., J. Epidemiol. 12 (2002) 85–92. 
doi:10.2188/jea.12.85. 
Y.-B. Ye, A.-L. Chen, W. Lu, S.-Y. Zhuo, J. Liu, J.-H. Guan, W.-P. Deng, S. Fang, Y.-
B. Li, Y.-M. Chen, Daidzein and genistein fail to improve glycemic control and insulin 
sensitivity in Chinese women with impaired glucose regulation: A double-blind, 
randomized, placebo-controlled trial, Mol. Nutr. Food Res. 59 (2015) 240–249. 
doi:10.1002/mnfr.201400390. 
 
 
  
 
 
 
207 
 
 
 
 
8. APÊNDICES 
 
8.1. Termo de Consentimento Livre e Esclarecido (TCLE) 
 
 
 
Você está sendo convidada a participar como voluntária de uma pesquisa que terá a 
duração de 4 meses. Este documento, chamado Termo de Consentimento Livre e 
Esclarecido, visa assegurar seus direitos como participante e é elaborado em duas vias, 
uma que deverá ficar com você e outra com o pesquisador. Por favor, leia com atenção e 
calma, aproveitando para esclarecer suas dúvidas. Se houver perguntas antes ou mesmo 
depois de assiná-lo, você poderá esclarecê-las com a pesquisadora. Se preferir, pode levar 
este Termo para casa e consultar seus familiares ou outras pessoas antes de decidir 
participar. Não haverá nenhum tipo de penalização ou prejuízo se você não aceitar 
participar ou retirar sua autorização em qualquer momento. Justificativa e objetivos: A 
menopausa é uma fase natural da vida da mulher, muitas mulheres passam pela 
menopausa sem queixas ou necessidade de tratamento, porém algumas apresentam 
sintomas como ondas de calor, suor intenso, insônia, depressão, ansiedade, infecções 
urinárias recorrentes, dentre diversos outros problemas que fazem necessário uso de 
medicamentos sintéticos ou terapias alternativas, como alimentos ou medicamentos 
extraídos de plantas para aquelas mulheres que não podem ou não desejam realizar a 
reposição hormonal. Este estudo tem o objetivo de avaliar se o tratamento alternativo 
constituído de isoflavonas, que são substâncias benéficas da soja, ao serem acrescidas ou 
não de probióticos, que são bactérias benéficas que vivem no seu corpo e ajudam a manter 
sua saúde e evitar doenças, contribuem na melhora dos sintomas da menopausa em 
comparação a terapia padrão de reposição hormonal.  
Lembre-se: *Probióticos: São bactérias do bem **Isoflavonas: São substâncias benéficas 
da soja que dentro do nosso organismo trabalham imitando hormônios, por isso na falta 
Avaliação da Influência de probióticos na absorção e produção de metabólitos 
de isoflavonas da soja em mulheres menopausadas com sintomatologia 
climatérica. 
 
Pesquisadores responsáveis: Nutricionista Naice Eleidiane Santana Monteiro, Dra Ana 
Elisa Ribeiro, Prof Dra Adriana Orcesi Pedro, Prof Dra Gabriela Alves Macedo,  
 
Número do CAAE: 56751216.7.0000.5404 
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de um hormônio as isoflavonas são reconhecidas pelo organismo como um substituto, 
provocando a ação necessária.  
Procedimentos: Ao participar deste estudo você deverá vir ao Ambulatório de 
menopausa do CAISM/UNICAMP em três consultas agendadas pela pesquisadora, além 
de receber dois telefonemas em momentos intermediários do estudo, para informar a 
equipe da pesquisa como você vem se sentindo com o uso do medicamento. Durante as 
consultas no Ambulatório de menopausa você deverá:  
• Vir 3 vezes ao Ambulatório de menopausa do CAISM, cada consulta deve demorar 
aproximadamente 40 minutos; 
 • Responder questionários aplicados pela pesquisadora, sobre informações pessoais e 
sintomas da menopausa;  
• Realizar coleta de sangue na primeira e na terceira consulta, na quantidade de 10 ml por 
amostra; 
 • Trazer em cada consulta uma amostra de urina e uma amostra de fezes, separadas em 
dois potes coletores que você receberá antecipadamente. Você deve coletar urina e fezes 
o suficiente para preencher pouco mais da metade do pote coletor;  
• Realizar exame de densitometria óssea;  
• Realizar exame ginecológico de rotina nas três consultas, esse exame será realizado por 
uma médica ginecologista e deve durar aproximadamente 15 minutos.  
Participando deste estudo você poderá ser alocada no grupo isoflavona, no grupo 
isoflavona com probióticos ou no grupo hormônios tradicionais, essa alocação será por 
meio de sorteio. Durante os 4 meses da pesquisa você não poderá consumir soja ou 
produtos derivados de soja.  
Desconfortos e riscos: Você não deve participar deste estudo se apresentar alergia ou 
intolerância a probióticos, se possui contra-indicação a uso de terapia de reposição 
hormonal, em caso de apresentar câncer de mama, doença do fígado ou dos rins, 
problemas vasculares, hipertensão arterial severa e diabetes descompensado. Os possíveis 
desconfortos do estudo são coleta de sangue, realização de exame ginecológico, trazer 
amostras de urina e fezes em cada consulta e disponibilizar tempo para responder aos 
questionamentos da pesquisa durante as consultas e por telefone. Neste estudo existem 
riscos associados ao uso de terapia hormonal em mulheres com histórico familiar de 
doenças cardiovasculares e possibilidade de sangramento vaginal, naquelas que vierem a 
usar isoflavonas isoladas não há riscos previsíveis, mas pode haver possível desconforto 
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gastrointestinal (flatulência e aumento na frequência de evacuações) no grupo que receber 
isoflavonas acrescidas de probióticos. Para minimizar surgimento de desconfortos e 
riscos existirá acompanhamento dos exames de sangue e exames ginecológicos com 
contato frequente entre participantes e pesquisador. 
Você tem a garantia de que sua identidade será mantida em sigilo e nenhuma informação 
será dada a outras pessoas que não façam parte da equipe de pesquisadores. Na divulgação 
dos resultados desse estudo seu nome não será citado. Os resultados dos seus exames de 
sangue e ginecológicos farão parte do prontuário para que seu médico tenha acesso 
durante as consultas. Você tem o direito de desistir de participar em qualquer momento 
do estudo, sendo que os seus dados coletados até o momento da sua desistência poderão 
ser utilizados para compor a pesquisa. A decisão por interromper a participação em nada 
prejudica o seu atendimento no hospital da UNICAMP.  
ATENÇÃO: Caso você não possa comparecer a alguma consulta marcada deve 
reagendar com a pesquisadora o mais rápido possível para que não comprometa seu 
próprio tratamento e os resultados da pesquisa.  
Ressarcimento e Indenização: Você tem direito a trazer um acompanhante nas consultas 
e durante o período do estudo você e seu/sua acompanhante receberão auxílio para custear 
o transporte na forma de vale transporte e alimentação na forma de vale alimentação. 
Você terá a garantia ao direito à indenização diante de eventuais danos decorrentes da 
pesquisa.  
Armazenamento de material biológico: As amostras de urina e fezes que você trará em 
cada consulta serão armazenadas em Biofreezer no Laboratório de Bioprocessos da 
Faculdade de Engenharia de Alimentos da UNICAMP, durante o período do estudo e 
mais 5 anos após a conclusão do ensaio, para caso haja necessidade de repetir alguma 
análise. Toda nova pesquisa a ser realizada com o material armazenado será submetida 
para aprovação do Comitê de Ética em Pesquisa (CEP) e, quando for o caso, da Comissão 
Nacional de Ética em Pesquisa (CONEP).  
 Quanto à coleta, o depósito, o armazenamento e a utilização do meu material biológico: 
( ) Concordo em participar do presente estudo, porém NÃO AUTORIZO o 
armazenamento do meu material biológico, devendo o mesmo ser descartado ao final 
desta pesquisa.  
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( ) Concordo em participar do presente estudo e AUTORIZO o armazenamento do meu 
material biológico, sendo necessário meu consentimento a cada nova pesquisa, que 
deverá ser aprovada pelo CEP institucional e, se for o caso, pela CONEP.  
Você, ou seu representante legal, a qualquer tempo e sem quaisquer ônus ou prejuízos, 
pode retirar o consentimento da guarda e utilização do seu material biológico armazenado. 
O descarte do material armazenado será autorizado nas seguintes situações:  
Exigência do doador da amostra ou em caso de falecimento. Em situações de condição 
incapacitante do doador, os direitos sobre o material armazenado deverão ser dados 
a:______________________________________Telefone:_______________________. 
(pedir para o participante indicar o nome de uma pessoa a ser contatada).  
Contato: Em caso de dúvidas sobre a pesquisa, você poderá entrar em contato com os 
pesquisadores: Naice Eleidiane Santana Monteiro, Laboratório de Bioprocessos 
Faculdade de Engenharia de Alimentos (FEA-UNICAMP), email naice.esm@gmail.com 
ou telefone (19) 3521-4079, ou com a Dra Adriana Orcesi Pedro, Departamento de 
Tocoginecologia, CAISM- Unicamp, email aopedro@uol.com.br ou telefone (19) 9601-
2321.  
Em caso de denúncias ou reclamações sobre sua participação e sobre questões éticas do 
estudo, você poderá entrar em contato com a secretaria do Comitê de Ética em Pesquisa 
(CEP) da UNICAMP das 08:30hs às 11:30hs e das 13:00hs as 17:00hs na Rua: Tessália 
Vieira de Camargo, 126; CEP 13083-887 Campinas – SP; telefone (19) 3521-8936 ou 
(19) 3521-7187; e-mail: cep@fcm.unicamp.br. O Comitê de Ética em Pesquisa (CEP). O 
papel do CEP é avaliar e acompanhar os aspectos éticos de todas as pesquisas envolvendo 
seres humanos.  
A Comissão Nacional de Ética em Pesquisa (CONEP), tem por objetivo desenvolver a 
regulamentação sobre proteção dos seres humanos envolvidos nas pesquisas. 
Desempenha um papel coordenador da rede de Comitês de Ética em Pesquisa (CEPs) das 
instituições, além de assumir a função de órgão consultor na área de ética em pesquisas. 
Consentimento livre e esclarecido: Após ter recebido esclarecimentos sobre a natureza 
da pesquisa, seus objetivos, métodos, benefícios previstos, potenciais riscos e o incômodo 
que esta possa acarretar, aceito participar e declaro estar recebendo uma via original deste 
documento assinada pelo pesquisador e por mim, tendo todas as folhas por nós rubricadas:  
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Nome do(a) participante: 
______________________________________________________________________ 
Contato telefônico_____________________ e-mail (opcional):____________________ 
Data: ____/_____/______.  
______________________________________________________________________ 
(Assinatura da participante)  
 
Responsabilidade do Pesquisador: Asseguro ter cumprido as exigências da resolução 
466/2012 CNS/MS e complementares na elaboração do protocolo e na obtenção deste 
Termo de Consentimento Livre e Esclarecido. Asseguro, também, ter explicado e 
fornecido uma via deste documento ao participante. Informo que o estudo foi aprovado 
pelo CEP perante o qual o projeto foi apresentado e pela CONEP, quando pertinente. 
Comprometo-me a utilizar o material e os dados obtidos nesta pesquisa exclusivamente 
para as finalidades previstas neste documento ou conforme o consentimento dado pelo 
participante. _______________________________________Data: ____/_____/______ 
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8.2. Termo de Biorrepositório 
 
Universidade Estadual de Campinas 
Departamento de Alimentos e Nutrição – Faculdade de Engenharia de Alimentos 
Regulamento do Biorrepositório vinculado à projeto de pesquisa 
Título da Pesquisa: Avaliação da Influência de probióticos na absorção e produção de 
metabólitos de isoflavonas da soja em mulheres menopausadas com sintomatologia 
climatérica 
1. Armazenamento e uso do material biológico: 
a) O material biológico será armazenado em natura. As amostras serão armazenadas em 
equipamentos de congelação (freezer -80oC) específico com compartimentos utilizado 
somente para este fim, presente no laboratório de Bioprocessos, coordenado pela Prof. 
Dra. Gabriela Alves Macedo. As amostras serão codificadas apenas por números e a 
chave de ligação entre números e nomes de pacientes será armazenada em programa de 
computador protegido por senha. Somente 2 pessoas terão acesso a esta chave de código 
(pela posse da senha): Profa. Dra. Gabriela Alves Macedo (matrícula UNICAMP 283837) 
e a aluna de doutorado, pesquisadora principal do projeto, Me. Naice Eleidiane Santana 
Monteiro, RA 143983. 
b) A guarda e a autorização do uso do referido material estará sob a responsabilidade 
exclusiva da Profa. Dra. Gabriela Alves Macedo (matrícula UNICAMP 283837), Docente 
do Departamento de Alimentos e Nutrição, FEA-UNICAMP. 
c) Será assegurado a todos os participantes da pesquisa, consentidores do material, a 
garantia de que resultados obtidos e que sejam de seu interesse lhes seja comunicada (e/ou 
ao médico responsável por seu tratamento, quando for o caso). Para tanto, informações 
sobre endereço para contato e telefone serão armazenadas em um programa de 
computador protegido por senha, e utilizado como descrito no item a. 
2. Com relação ao funcionamento do Biorrepositório: 
a) O participante da pesquisa, ou seu representante legal, a qualquer tempo e sem 
quaisquer ônus ou prejuízos, pode retirar o consentimento de guarda e utilização do 
material biológico armazenado no Biorrepositório, valendo a desistência a partir da data 
de formalização desta. 
a1) A retirada do consentimento será formalizada por manifestação, por escrito e 
assinada, pelo sujeito da pesquisa ou seu representante legal, cabendo-lhe a devolução 
das amostras existentes. 
b) O prazo de armazenamento do material biológico humano no Biorrepositório consta 
no cronograma da pesquisa correspondente e será por 5 anos (2016 a 2020), considerando 
a data de término do projeto (2018) e 2 anos como tempo adicional para publicação. 
c) Renovações da autorização de armazenamento serão permitidas após autorização do 
CEP/FCM/Unicamp. 
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d) Ao final do período de realização da pesquisa, o material biológico humano 
armazenado deverá ser transferido formalmente para outro Biorrepositório, mediante 
aprovação do CEP. Ou descartado caso seja o interesse dos pesquisadores. 
3. Sob a utilização das amostras do Biorrepositório em outros projetos concomitantes: 
a) as amostras armazenadas podem ser utilizadas em novas pesquisas aprovadas pelo CEP 
e, quando for o caso, pela CONEP; 
b) Poderá haver um TCLE específico para a nova pesquisa ou a solicitação de sua 
dispensa, conforme disposto no TCLE de formação do Biorrepositório. 
c) Quando fundamentada a impossibilidade de obtenção do consentimento específico para 
a nova pesquisa, mediante opção do sujeito em ser consultado a cada pesquisa, cabe ao 
CEP autorizar, ou não, a utilização do material biológico humano armazenado no 
Biorrepositório. 
4. As amostras, vinculadas ao presente projeto de pesquisa, permanecerão durante todo o 
período do projeto sob a guarda e a responsabilidade da pesquisadora responsável pelo 
Biorrepositório, não haverá Transferência de Material para outro local dentro ou fora do 
Brasil. 
5. O consentimento livre e esclarecido referente à coleta, depósito, armazenamento do 
material biológico humano é formalizado através de TCLE, por meio do qual é informado 
no item “de acordo como projeto de pesquisa”: “As amostras serão coletadas e 
enviadas apropriadamente para análise ao laboratório de Bioprocessos, Faculdade de 
Engenharia de Alimentos - UNICAMP. As amostras serão armazenadas em 
biorrepositórios. Estas amostras serão utilizadas para o presente projeto específico. A 
utilização futura da amostra armazenada em novos projetos está condicionada a: 
apresentação de novo projeto de pesquisa para ser analisado e aprovado pelo Sistema 
CEP/CONEP, e obrigatoriamente, ao reconsentimento do participante da pesquisa por 
meio de um TCLE específico, referente ao novo projeto de pesquisa. Do contrário, ao 
final do presente projeto, as amostras serão destruídas.” Obedecendo ao artigo (item) 5º 
da Resolução CNS nº441 de 2011. 
Profa. Dra. Gabriela Alves Macedo 
Responsável pelo Biorrepositório 
FEA-UNICAMP 
............................................................................................................................. 
Me. Naice Eleidiane Santana Monteiro 
Doutoranda em Alimentos e Nutrição (pesquisadora principal) 
FEA-UNICAMP 
............................................................................................................................. 
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8.3. Ficha de triagem 
 SIM NÃO 
Idade entre 40 a 60 anos           
Data da última menstruação espontânea >12 meses   
FSH >40 mUI/mL (prontuário)   
Estradiol <30 pg/mL (prontuário)   
Presença de sintomas climatéricos   
Presença de sintomas urogenitais   
Sem antecedentes pessoais de: 
Diabetes tipo 2 
  
Doenças cardiovasculares   
Doenças gastrointestinais   
Histerectomia   
Cirurgia bariátrica   
Sem contraindicação de: 
Uso de terapia hormonal 
  
Uso de probiótico   
Sem uso nos últimos 6 meses e atual de: 
Contraceptivos orais 
  
Terapias hormonais   
Hipolipemiantes   
Antibióticos   
  
CHECK LIST DE TRIAGEM 
Nome:________________________________________________ Idade:_______ 
 
Apta                                 Não apta   
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8.4. Tabela de randomização aleatorizada 
CASOS A B C 
1 6 1 3 
2 7 2 4 
3 12 5 8 
4 13 9 11 
5 15 10 14 
6 16 22 21 
7 17 27 30 
8 18 28 31 
9 19 29 34 
10 20 32 36 
11 23 33 37 
12 24 40 38 
13 25 42 41 
14 26 47 43 
15 35 49 44 
16 39 51 45 
17 46 52 48 
18 53 54 50 
19 58 56 55 
20 59 60 57 
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8.5. Ficha de coleta de dados 
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8.6 Questionário de frequência alimentar para compostos fenólicos 
Alimento Quantas vezes consome Frequência Porção Usual 
Alface N     1     2     3     4     5   (    ) D     S     M    A Folhas: 
Couve manteiga N     1     2     3     4     5   (    ) D     S     M    A Folhas: 
Chicória N     1     2     3     4     5   (    ) D     S     M    A Folhas: 
Rúcula N     1     2     3     4     5   (    ) D     S     M    A Folhas: 
Espinafre N     1     2     3     4     5   (    ) D     S     M    A Folhas: 
Almeirão N     1     2     3     4     5   (    ) D     S     M    A Folhas: 
Repolho roxo N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Repolho branco N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Abóbora N     1     2     3     4     5   (    ) D     S     M    A Pedaços: 
Cenoura crua ralada N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Chuchu N     1     2     3     4     5   (    ) D     S     M    A Pedaços: 
Pepino N     1     2     3     4     5   (    ) D     S     M    A Fatias: 
Vagem N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Tomate cru N     1     2     3     4     5   (    ) D     S     M    A Fatias: 
Molho de tomate N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Batata doce N     1     2     3     4     5   (    ) D     S     M    A Pedaços: 
Batata N     1     2     3     4     5   (    ) D     S     M    A Pedaços: 
Mandioca N     1     2     3     4     5   (    ) D     S     M    A Pedaços: 
Abacaxi N     1     2     3     4     5   (    ) D     S     M    A Fatias:                                  P    M    G 
Açaí N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Morango N     1     2     3     4     5   (    ) D     S     M    A Unidade: 
Banana N     1     2     3     4     5   (    ) D     S     M    A Unidade:                              P    M    G 
Laranja N     1     2     3     4     5   (    ) D     S     M    A Unidade:                              P    M    G 
Limão N     1     2     3     4     5   (    ) D     S     M    A Unidade:                              P    M    G 
Ponkan / mexerica N     1     2     3     4     5   (    ) D     S     M    A Unidade:                              P    M    G 
Maçã com casca N     1     2     3     4     5   (    ) D     S     M    A Unidade:                  P     M    G 
Mamão N     1     2     3     4     5   (    ) D     S     M    A Fatias: P    M    G 
Manga N     1     2     3     4     5   (    ) D     S     M    A Unidade: P    M    G 
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Melancia N     1     2     3     4     5   (    ) D     S     M    A Fatia: P    M    G 
Melão N     1     2     3     4     5   (    ) D     S     M    A Fatia: P    M    G 
Uva vermelha N     1     2     3     4     5   (    ) D     S     M    A Unidade: 
Uva branca N     1     2     3     4     5   (    ) D     S     M    A Unidade: 
Coentro N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Salsinha e cebolinha N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Pimenta ou molho de 
pimenta 
N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Brócolis  N     1     2     3     4     5   (    ) D     S     M    A Ramos:  
Couve flor N     1     2     3     4     5   (    ) D     S     M    A Ramos: 
Beterraba N     1     2     3     4     5   (    ) D     S     M    A Pedaços: P    M    G 
Azeite de oliva N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Soja em grãos N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Amora N     1     2     3     4     5   (    ) D     S     M    A Unidade: P    M    G 
Ameixa N     1     2     3     4     5   (    ) D     S     M    A Unidade: P    M    G 
Caqui N     1     2     3     4     5   (    ) D     S     M    A Unidade: P    M    G 
Pêssego N     1     2     3     4     5   (    ) D     S     M    A Unidade: P    M    G 
Cebola branca picada N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Cebola roxa picada N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Alho N     1     2     3     4     5   (    ) D     S     M    A Dente: P    M    G 
Suco natural 
(qualquer fruta) 
N     1     2     3     4     5   (    ) D     S     M    A Copos: P    M    G 
Café preto N     1     2     3     4     5   (    ) D     S     M    A Xícara: P    M    G 
Chá preto ou branco N     1     2     3     4     5   (    ) D     S     M    A Xícara: P    M    G 
Chá mate N     1     2     3     4     5   (    ) D     S     M    A Xícara: P    M    G 
Chá verde N     1     2     3     4     5   (    ) D     S     M    A Xícara: P    M    G 
Chá de camomila N     1     2     3     4     5   (    ) D     S     M    A Xícara: P    M    G 
Chá de boldo N     1     2     3     4     5   (    ) D     S     M    A Xícara: P    M    G 
Chocolate em pó 
(nescau, toddy) 
N     1     2     3     4     5   (    ) D     S     M    A Col sopa: 
Chocolate meio 
amargo/amargo 
N     1     2     3     4     5   (    ) D     S     M    A Unidade: P    M    G 
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8.7 Parecer de aprovação do comitê de ética 
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8.8 Registro Brasileiro de Ensaios Clínicos  
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